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Chiral amines are industrially useful chemicals found in the pharmaceutical, chemical 
and agrochemical industries. While many excellent methods have been developed for 
their synthesis using abiotic catalysis, these are often reliant on precious metals the 
global supply of which is becoming increasingly scarce. Additionally, those catalysts 
often require harsh, non-environmentally friendly reaction conditions such as high 
temperatures and pressures. 
Biocatalytic imine reduction, which involves the asymmetric reduction of imines to 
form chiral amines using imine reductases (IREDs), offers an efficient and sustainable 
synthesis of chiral amines which overcomes many of the limitations encountered in 
abiotic catalysis. 
Two NADPH-dependent IREDs were expressed and purified; SkR-IRED from 
Streptomyces kanamyceticus and SS-IRED from Streptomyces sp. GF3546, which 
catalyse the reduction of the model imine 2-methylpyrroline to (R)- and (S)- amine 
products respectively. 
The SkR-IRED monomer consists of an N-terminal Rossman fold motif and a C-
terminal helical domain. SkR-IRED exists as a homodimer of two monomers which are 
linked by an unusual reciprocal domain sharing arrangement. The structure of SkR-
IRED was used as a basis to study mechanism using mutagenesis experiments which 
suggested that residue Asp187 may be important for catalysis.  
The structure of SS-IRED was solved to a resolution of 3.2 Å in its apo form and 
revealed that the enzyme shares the structural features of SkR-IRED. Mutagenesis 
experiments suggested that residue Tyr169 is necessary for catalysis.  
Last, a novel IRED from the moss Physcomitrella patens (Pp-IRED) was expressed and 
purified. Pp-IRED was active towards the amine N-methyl-1-quinolin-6-
ylmethanamine in the oxidative direction, the first IRED active towards this substrate. 
The structure of Pp-IRED was solved in both its apo form and in complex with NADPH 
(2.5 Å resolution). The structure was distinct from other IREDs as it did not display 
the reciprocal domain sharing arrangement seen in SkR-IRED and SS-IRED. 
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1.1.1 The history of biocatalysis 
Biocatalysis is the use of biological entities such as enzymes, either in their isolated 
form or as part of their host organism, to catalyse chemical reactions. Enzymes, which 
usually take the form of proteins, are biological catalysts that underpin a great 
majority of vital biological reaction processes within organisms, from the digestion of 
food sources to biosynthesis of tissues.  
The use of biological systems in the conversion of one chemical species to another is 
a process is known as a biotransformation, and is a process that has been 
biotechnologically exploited outside its natural physiological context for thousands of 
years. For instance, Saccharomyces cerevisiae, known as baker’s yeast, has been used 
in the fermentation of sugars to form carbon dioxide and ethanol in the production of 
bread products and alcoholic drinks.1 Enzymatic reactions also play an important role 
in the production of other food products such as the use of enzyme cocktail, rennet, in 
the production of cheese and the use of Lactobacillus in the controlled fermentation 
processes to produce yoghurt.1  
In more recent years, biotransformations have been exploited for a broader range of 
applications, including manufacture of bulk chemicals and pharmaceuticals. One of 
the first examples of this was the discovery of penicillin, the first antibiotic used as a 
pharmaceutical, by Dr Alexander Fleming in 1928.2 Microbes for its bulk manufacture 
were subsequently developed within the pharmaceutical industry.1  
This early interest in biotechnology for the production of pharmaceuticals drove a 
wave of research into the use of microorganisms in the production of chemicals, 
underpinning our knowledge of the large scale production of relevant 
microorganisms using fermentation equipment, and the biochemical behaviour of 
enzymes. In particular, the development of technologies such as PCR and 
heterologous expression of genes using convenient host organisms and improved 
DNA sequencing technologies have allowed for extremely rapid progress in 
Biocatalysis research  in recent decades.1  
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1.1.2 The advantages of biocatalysis 
The field of biocatalysis in organic synthesis has expanded rapidly in recent decades 
due to advancements in microbiology that have made the production of enzymes 
easier. There has been motivation to develop this field due to the distinct advantages 
offered by enzymes towards many of the challenges faced by the synthetic chemist. 
Biocatalysis is becoming increasingly realised as a solution to a number of issues 
facing the synthetic chemist. Firstly, they adhere strongly to the principles of green 
chemistry. Due to their inherently low toxicities, preference for mild reaction 
conditions (such as atmospheric temperature and pressure), and their ability to 
function optimally in water-based media without the requirement for organic 
solvents, they comply well with the principles of green chemistry (Figure 1.1). This is 
highly advantageous when they are being applied as catalysts on a large scale in an 
industrial setting.3  
 
Figure 1.1: The principles of green chemistry. The use of enzymes is particularly 
relevant for certain green chemistry criteria. Their use reduces the need for auxiliary 
substances (i.e. organic solvents). They are also energy efficient, operating optimally 




Moreover, enzymes are inherently highly selective. They have often evolved in nature 
to transform a substrate in a very specific manner, with tight binding pockets that 
allow chemical changes to be carried out in a certain region of a molecule and 
chemical environments within the protein conferring very specific reaction 
environments into their active sites, making them regio-, chemo- and 
enantioselective. While impressive advancements have been made in regioselective 
and asymmetric chemocatalysis, it is often more difficult to introduce the levels of 
selectivity into chemical catalysis that are present in their biological counterparts.   
With the increasing demand for pharmaceuticals and other fine chemicals to be 
dispensed in their enantiomerically pure forms, this high selectivity is an increasingly 
attractive feature in enzymes as catalysts.  
1.2 Chiral amines 
Optically pure chiral amines are highly valuable compounds due to their multitude of 
applications. They are applied in the pharmaceutical, chemical and agrochemical 
industries due to their uses as chiral auxiliaries, resolving agents and catalysts for 
asymmetric synthesis and account for many alkaloid natural products.3, 5-8 Chiral 
amine centres are particularly common in pharmaceutical molecules. This is 
unsurprising due to the biological potency of this chemical class arising from their 
structural influence delivered by their propensity to form hydrogen bonds to 
neighbouring chemical entities such as proteins. A number of important examples of 




Figure 1.2: An array of pharmaceutical products containing optically active amine 
functional groups including diabetes, Alzheimer’s and malaria treatments. The image 
illustrates the high demand for chiral amines in the pharmaceutical industry.8 
1.3 Chemical synthesis of chiral amines 
The synthesis of chiral amines in a regio-, stereo- and chemoselective manner is highly 
challenging. However, a number of chemical methods have been developed for their 
synthesis.8 
Synthetic efforts have been focussed primarily on α-chiral primary amines, as most 
amine-containing pharmaceuticals and natural products are α-chiral secondary or 
tertiary amines which can be easily derived from α-chiral primary amines by simple 
alkylation or amidation. Therefore, α-chiral primary amines are the most convenient 
chiral building blocks used by chemists for the synthesis of pharmaceuticals and 
alkaloid natural products. 
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Traditionally, the desired enantiomer was isolated using techniques such as classical 
revolution and preparative HPLC.9 However, such techniques are not green due to the 
necessity for additional reaction steps and wastage of the unwanted product 
enantiomer.8 
The most efficient method to produce chiral amines is by asymmetric synthesis, 
where the desired enantiomer can be produced with high optical purity. A number of 
chemical routes of this nature have been developed; most commonly the reduction of 
enamides, reductive amination and the reduction of imines. Each of these methods 
share the asymmetric addition of hydride as the stereochemistry-determining step.8 
1.3.1 Reduction of enamides 
The pathways for the synthesis of primary amines from enamides are pictured in 
Figure 1.3. The most common enamide substrate employed in the synthesis of chiral 
amines is an N-acetylenamide, such as that which is pictured in the centre right of 





Figure 1.3: Synthetic routes towards primary chiral amines from N-acetylenamides. 
Synthesis of the enamide occurs using either a nitrile or ketone starting material. The 
enamide is then asymmetrically reduced with hydride using a Rhodium catalyst.8 
While the asymmetric hydrogenation step generally provides 100 % conversion of 
enamide to the corresponding secondary amine product, the less reactive nature of 
the enamide substrate dictates that high hydrogen pressures (5 – 25 bar) are required 
for this reaction step.10, 11 Fortunately this use of higher pressures does not adversely 
affect ee, but temperature must be controlled to ensure that sufficiently high product 
ees are obtained.11, 12 While this reaction step can be performed in a number of 
solvents, the most favourable ees of the secondary amine product are obtained when 
CH2Cl2 or MeOH is employed as a solvent.12, 13 
1.3.2 Reductive amination 
Reductive amination is the one-pot conversion of a ketone and an amine starting 
material to the conjugated amine product,14 as opposed to the reduction of preformed 
imines, which will be discussed in section 1.3.3.   
An important example of an asymmetric reductive amination was reported in 1999 
by Blaser and co-workers as a route towards the synthesis of an active ingredient in 
commercial herbicides, (S)-metolachlor. The synthesis involved a transition metal 
catalyst; an Ir-xyliphos complex under high pressures (80 bar) at 50 °C. Xyliphos is an 
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iron-containing chiral diphosphine complex used for the substrate-specific 
enantioselective catalysis of this reaction.15  
 
Figure 1.4: The first example of an enantioselective reductive amination: a synthesis 
of an active ingredient in commercial herbicides, metolachlor. The reaction involves 
the conjugation of methoxyacetone with 2-methyl-6-ethylaniline to form an 
intermediary imine in situ, before reduction using H2 in the presence of an Ir-
complexed chiral catalyst, Xyliphos.15  
Ultimately, this reaction pathway was disfavoured for industrial application in light 
of a synthesis using a direct imine reduction which required decreased catalyst 
loadings (Section 1.3.3).16 
As well as using transition metal-based asymmetric catalysts including the above 
example, reductive amination has also been performed asymmetrically using 
asymmetric organocatalysts such as chiral phosphoric acids and chiral auxiliaries 
such as chiral ammonia.17, 18 Despite the need for removal of a chiral auxiliary using 
an additional deprotection step, this method is still feasible on an industrial scale 
provided the auxiliary is inexpensive.8 
Despite its convenience, asymmetric reductive amination is less thoroughly explored 
than direct imine reduction due to some limitations in its implantation. Firstly, ketone 
starting materials involved in this reaction type are incompatible with transition 
metal hydride catalysts used in asymmetric hydrogenation reactions due to the 
formation of alcohol by-products. Additionally, transition metal catalysts are 
inhibited by complexation with amines, which act as both starting materials and 
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products in reductive amination reactions.8, 16 However, recent developments in 
enzymatic asymmetric reductive amination brings a great deal of promise to the use 
of this pathway in an industrial context.8 
1.3.3 Reduction of imines 
The direct, asymmetric reduction of imines is a direct route towards the formation of 
chiral amines. The most common strategy employed for this synthetic route is 
homogeneous catalysis using a transition-metal based catalyst, however, the use of 
asymmetric organocatalysts is making an increasingly important contribution 
towards the field of asymmetric imine reduction.8  
One of the most successful examples of an asymmetric imine reduction in an 
industrial context is the asymmetric reduction step in the synthesis of (S)-
metolachlor, which is used in favour of alternative techniques using reductive 
amination due to the decreased catalytic load required as mentioned in Section 1.3.2 
(Figure 1.5).19 
Metolachlor is used as a herbicide in volumes in excess of 20,000 tonnes per year. The 
use of enantiomerically enriched (S)-metolachlor in place of a racemic mixture greatly 
reduces the necessary environmental load of the herbicide, greatly increasing the 
need for  its efficient asymmetric synthesis.19 
 
Figure 1.5: The synthesis of (S)-metolachlor using an asymmetric reduction step. 
Chirality is introduced by use of an asymmetric catalyst; the Ir-xyliphos (an iridium-
complexed iron-containing chiral phosphine complex). 
1.3.4 Limitations of chemical chiral amine synthesis 
A number of approaches to the synthesis of chiral amines using chemical methods 
have been discussed in this section. While many remarkable examples where 
impressive yields and rates of conversion to products of interest have been obtained, 
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there are a number of limitations in the implementation of these reactions on an 
industrial scale. 
Usually, asymmetric synthesis of chiral amines requires the use of transition metal 
catalysts or organocatalysts whose syntheses are complex in their own right. In the 
case of transition metal catalysts, many such metals are becoming increasingly 
expensive as global supply dwindles, and there is therefore a pressure to avoid their 
usage. Moreover, reduction reactions commonly necessitate high pressures and 
temperatures which further increase the environmental impact of these chemical 
processes. Deprotection steps are also sometimes necessary, particularly with the use 
of chiral auxiliaries, which further reduce the efficiency of such reactions by 
increasing the number of necessary steps and reducing atom economy.8, 15-19 
Due to these factors, there is a strong market for the use of biocatalytic routes towards 
the synthesis of chiral amines, as this offers an opportunity to develop sustainable 
routes towards the synthesis of chiral amines which circumvent some of the 
disadvantages of chemical routes listed above. 
1.4 Biocatalytic routes towards chiral amines 
Because enzymes offer many industrial advantages (Section 1.1.2) as well as being 
highly selective, they offer a desirable tool towards the synthesis of chiral amines. 
There have therefore been substantial efforts to establish biocatalytic methods for the 
synthesis of chiral amines, and a number of classes of enzymes have been employed 




Figure 1.6: Enzymatic routes for the production of chiral amines. Current methods 
include kinetic resolution of racemic amines by hydrolases, dynamic kinetic 
resolution (DKR) and deracemization of racemic amines by hydrolases and oxidases, 
asymmetric amination of ketones by transaminases, decarboxylation of carboxylic 




Lipases are enzymes of the hydrolase family which can catalyse the reversible 
hydrolysis and acylation of amides and esters (Figure 1.7).20-22 As a class of enzymes, 
they have been thoroughly explored in terms of their applications and present many 
advantages for use in industrial biotechnology. They can be produced produced in 
high yield in bacteria and fungi, possess extremely high levels of chemo-, regio- and 





Figure 1.7: A general illustration of the lipase-catalysed reversible acetylation of an 
amide substrate to form the corresponding enantiomerically pure amine alongside 
the amide with opposite chirality.20 
Lipases may be exploited for the synthesis of chiral amines using a kinetic resolution 
approach. The kinetic resolution approach limits the potential yield to only 50 % as 
only half of the starting material will be hydrolysed or acetylated. However, such 
limitations can be overcome using two different approaches. 
Firstly, a dynamic kinetic resolution technique may be employed where unconverted 
starting material is racemised in situ to facilitate a theoretical 100 % yield. An example 
of this was reported by Reetz and coworkers in 1996, where racemic 
phenylethylamine was converted to the enantiomerically pure N-acetylated product 
using a strongly selective lipase from C. antarctica with palladium on charcoal (Pd/C) 
as a racemization agent (Figure 1.8).26 
 
Figure 1.8: Dynamic kinetic resolution of a racemic amine by the selective acylation 
of the (R)-amine by a lipase and the racemisation of the unreacted (S)-amine using an 
achiral Pd/C catalyst.26 
Secondly, an approach may be used where both enantiomerically pure products can 
be formed and separated to maximise the utility of the racemic starting material. A 
reaction using this method was reported by Balkenhohl and coworkers in 1997 
(Figure 1.9). In the first reaction step a lipase in P. plantarii converts the (R)-amine to 
the corresponding amide, while enantiomerically pure, unreacted (S)-amine remains 
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in the reaction mixture. The amide is then separated from the reaction mixture by 
distillation or extraction and converted to the corresponding (R)-amine by basic 
hydrolysis.27  
 
Figure 1.9: The two-step separation of racemic phenylethylamine to both the (S)- and 
(R)-phenylethylamine in their enantiomerically pure forms. The (R)-amine is initially 
converted to the corresponding amide by a lipase from P. plantarii. The (R)-amide 
product is subsequently separated by distillation and converted back to the (R)-amine 
by basic hydrolysis. The optically pure unreacted (S)-amine remains in the reaction 
mixture after removal of the (R)-amide by distillation.27 
1.4.2 Transaminases 
Transaminases are enzymes that catalyse the transfer of an amino group from an 
amino donor to a ketone or aldehyde. Transaminases are dependent on a 
pyridoxamine cofactor, which is converted to pyridoxal phosphate following the 
amination of the carbonyl-containing substrate (Figure 1.10).  Transaminases can be 
broadly categorised into two classes; α-transaminases, which require a carboxylic 
acid moiety in the α-position relative to the aldehyde of ketone group and ω-
transaminases, which can potentially accept any aldehyde or ketone. The latter are 
considered more useful from a biotechnological standpoint due to their increased 
versatility due to a broader substrate range as well as their ability to also catalyse the 




Figure 1.10: The general scheme of a reaction catalysed by a transaminase. An amino 
group is transferred from the pyridoxamine cofactor which acts as an amino donor to 
a ketone or aldehyde substrate, which facilitates the formation of a chiral amine when 
performed asymmetrically.20 
When transaminases are enantioselective, they offer a route towards the synthesis of 
chiral amines. Historically, a number of limitations have inhibited their application as 
industrial biocatalysts; firstly, the presence of product inhibition due to the reversible 
nature of the enzymes and secondly, the limited substrate scope of wild-type 
enzymes.20 
Successful efforts have been made to overcome limitations with product inhibition. 
An example an effective approach reported by Shin and co-workers where the 
inhibitory ketone product was extracted from the aqueous phase in a membrane 
reactor during kinetic resolution.29 
An instance of a successful application in a commercial setting is where a 
transaminase was engineered for the synthesis of Januvia®, an anti-diabetic drug 
which lowers the blood sugar levels of patients (Figure 1.11).30, 31 The wild-type 
enzyme was an (R)-selective ω-transaminase, ATA-117, which initially displayed 
activity towards small substrates which exhibited similarity towards the target 
molecule. A rational mutagenesis approach was employed during a collaboration 
between Merck and Codexis to target the precise substrate of interest, followed by 
additional rounds of mutation to improve properties of the enzyme specifically for 




Figure 1.11: A biocatalytic route towards the synthesis of Januvia®, an antidiabetic 
drug used to lower the blood sugar level in patients, using a mutant rationally evolved 
from transaminase ATA-117. 
 
This is a very good example to illustrate the use of enzymes in the commercial 
synthesis, as the biocatalytic route towards Januvia® using a transaminase increased 
the overall yield by 10 % while eliminating the need to use precious metal catalysts 
compared to the original chemocatalytic route using a Rh-based catalyst.33 
1.4.3 Amine oxidases 
Amine oxidases are oxidoreductases, which are enzymes that catalyse redox 
reactions. This class of enzymes is largely made up of monoamine oxygenases (MAOs) 
which catalyse the oxidation of amines to imines with concurrent reduction of oxygen 
to hydrogen peroxide (Figure 1.12). Amine oxidases can be grouped into two 
categories; Type I and Type II. Type I amine oxidases are dependent on both copper 
and pyrroloquinolinequinone (PQQ) cofactors, and are involved in biological 
pathways such as the metabolism of amino acids and biosynthesis of alkaloid natural 
products in bacteria, fungi, plants and animals. Type II amine oxidases are flavin-
dependent enzymes found in mammals, fungi and bacteria which in humans are 
membrane bound-proteins which catalyse the inactivation of neurotransmitters such 




Figure 1.12: A general reaction catalysed by a flavin-dependent amine oxidase. An 
imine is reversible oxidised to an amine with concurrent reduction of oxygen to 
hydrogen peroxide.20 
The most commonly applied amine oxidase in a biotechnological setting is the MAO 
from Aspergillus niger (MAO-N). The organism contains both species of amine oxide 
(Type I and Type II). Type I amine oxygenases form covalently bound imine products, 
therefore their use for biocatalytic applications is limited. Type II amine oxygenases 
generate free imines which may be used as substrates in subsequent biocataytic 
reaction steps. Therefore, although A. niger contains both species of amine oxidase, 
only those of the Type II category are applied. 
MAO-N may be applied to obtain optically pure amines.34 A library of MAO-N variants 
has been developed by directed evolution experiments to enable the synthesis of a 
diverse range of chiral amines, as well as variants with increased levels of activity and 
selectivity.35-38 Such mutants have been applied in a novel deracemization process for 
the production of chiral amines where amines are enantioselectively oxidised by 
MAO-N variants in combination with an achiral chemical reduction of the prochiral 






Figure 1.13: The deracemization of primary, secondary or tertiary amines by MAO-N 
variants with concurrent achiral reduction of the imine product back to the racemized 
amine starting material. The amine enantiomer which is not converted by MAO-N 
accumulates in the reaction mixture with increasing levels of optical purity.39 
The extensive evolution efforts involving MAO-N have presented the enzyme as a 
promising catalyst for many industrially relevant reactions. An example of an 
application of the use of the deracemization chemistry of MAO-N in the context of 
pharmaceutical synthesis is the use a variant termed MAO-N D5 in the 
desymmetrisation of 3,4-substituded meso-pyrrolidines via the formation of the 
corresponding pyrroline imine.40 This reactivity was exploited in the synthesis of 






Figure 1.14: A biocatalytic step in the synthesis of Telaprevir, a Hepatitis C viral 
protease inhibitor, mediated by an engineered variant of MAO-N from Aspergillus 
niger.41  
 
1.4.4 Amine dehydrogenases 
Amine dehydrogenases (AmDHs) are NAD(P)H-dependent enzymes which catalyse 
the enantioselective reductive amination of ketones to produce the corresponding 
chiral amine via an imine intermediate. The majority of AmDHs have been engineered 
from wild-type amino acid dehydrogenases (AADHs), which catalyse the reductive 
amination of keto-acids using ammonia to form amino acids via an imino-acid 
intermediate (Figure 1.15). However, there also exist a small number of wild-type 
AmDHs including an AmDH from Streptomyces virginiae with limited selectivity.42 




Figure 1.15: The reactions catalysed by amino acid dehydrogenases (AADHs) (top) 
and amine dehydrogenases (AmDHs) (bottom).  AADHs catalyse the NADH-
dependent interconversion of keto-acids and amino acids while AmDHs catalyse the 
interconversion of ketones and amines. 
AmDHs were engineered to target substrates which are precursors to active 
pharmaceutical ingredients or speciality chemicals that contain chiral amines, and 
have primarily been evolved from leucine dehydrogenases, phenylalanine 
dehydrogenases and chimeric amino acid dehydrogenases possessing both of these 
activities.  
In 2015 Mutti and co-workers reported the use of AmDHs in the synthesis of chiral 
amines from primary and secondary alcohols as part of a cascade reaction. The 
reaction involves the concurrent use of an alcohol dehydrogenase (ADH) and an 
AmDH to afford the amination of a broad range of aliphatic and aromatic alcohols to 






Figure 1.16: A cascade reaction employing an ADH and AmDH to convert racemic 
alcohols to chiral amines using NAD(H) in a single reaction vessel. 
1.4.5 Imine reductases (IREDs) 
This section focuses on the use of biocatalytic imine reduction to produce chiral 
amines. This involves the conversion of a prochiral imine to a chiral amine using an 
IRED. The ability to convert a prochiral starting material to an optically pure amine 
with a theoretical yield of 100 % makes this a potentially very efficient route towards 
the synthesis of chiral amines, and it has therefore attracted a large amount of interest 
in the Industrial Biotechnology sector. 
Biocatalytic imine reduction offers a particularly attractive route for the synthesis of 
chiral amines. Imines are prochiral, so when their reduction is carried out 
asymmetrically, such as by using a selective IRED, this offers a means of directly 
introducing chirality into the achiral imine starting material, facilitating a theoretical 





Figure 1.17: Imine reduction as a route for the synthesis of amines. When done 
asymmetrically, such as by using an enzyme, the reduction of imines (which are 
readily obtainable from ketones) can be used to generate optically pure amines. 
Despite the desirability of IREDs as catalysts, this is a technology which had until 
recently not been well explored.  Because many imines are labile under aqueous 
conditions, few organisms have evolved to metabolise them, and therefore few 
naturally occurring IREDs are known. As a result, some doubt initially existed as to 
whether IREDs exist as an enzyme class. However, increasing numbers of examples of 
IREDs arose in the literature in recent years, and knowledge about this enzyme class 
continues to rapidly expand. 
A well-studied example of a naturally occurring imine reductase is dihydrofolate 
reductase (DHFR) from E. coli, the enzyme responsible for the reduction of 
dihydrofolate, a folic acid derivative, to form tetrahydrofolate, a key intermediate in 
the biosynthesis of DNA (Figure 1.18).44 While this enzyme has not been exploited for 
biotechnological purposes, aside from in the formation of its natural product (S)-
tetrahydrofolate,45 this is a very widely known example which proved the principle 




Figure 1.18: Reduction of imine moiety of dihydrofolate by DHFR to form 
tetrahydrofolate; an intermediary reaction in the biosynthesis of DNA.44, 45  
 
A further example of naturally occurring IRED activity arises in the biosynthetic 
pathways of pyrrolobenzodiazepines (PDBs), which are natural products that exhibit 
antibiotic and anti-tumour properties. Imine reducing activity in species which 
biosynthesise PDBs is dependent on an unusual deazaflavin cofactor F-420, which 
acts as a redox cofactor in biocatalytic reactions (Figure 1.19).46-48 
 
Figure 1.19: The reduction of the flavin moiety of the enzyme cofactor F420 to produce 




Two examples of F420-dependent IREDs are TomJ, an F420-dependent IRED in the 
biosynthesis of the PBD Tomaymycin from Streptomyces achromogenes and SibT, an 
F420-dependent IRED in the biosynthesis of the PBD Sibyromycin from 
Streptosporangium sibiricum, whose biosynthetic roles are outlined in Figure 1.20. 
 
Figure 1.20: The role of F420-dependent IREDs TomJ and SibT in the biosynthesis of 
PBDs Tomaymycin and Sibiromycin in Streptomyces achromogenes and 
Streptosporanium sibiricum respectively. TomJ and SibT are each responsible for the 
imine reduction step in these biosynthetic pathways. 
More recently, IREDs have been sought specifically for their biotechnological 
applications. Candida parapsilosis ATCC 7330, which is known for its ability to reduce 
α- and β-keto esters49, was found to also possess IRED activity towards aryl imines, 





Figure 1.21: Reduction of imine moiety of dihydrofolate by DHFR to form 
tetrahydrofolate; an intermediary reaction in the biosynthesis of DNA.50  
 
Later, multiple strains of Saccharomyces were screened for activity towards β-
carboline imines (Figure 1.22). Reduction was successfully carried out with moderate 
to high enantioselectivity in multiple strains of Saccharomyces, with S. bayanus 
proving the most effective whole cell biocatalyst of all the strains tested.51  
 
Figure 1.22: Reduction of imine moiety of beta-carboline imines by cell free extract 
of strains of Saccharomyces to form the corresponding (R)-amines.51  
 
The enantioselective reduction of β-carboline imines was also subsequently carried 
out successfully using cell free extract from E. foetida (earthworms) in the presence 





Figure 1.23: Reduction of imine moiety of beta-carboline imines by cell free extract 
of E. foetida to form the corresponding (R)-amines.52  
 
Most interestingly from a biotechnological standpoint, a broad-ranging screen of 
activity of organisms towards the imine 2-methyl-pyrroline (1a) by Mitsukura and 
co-workers led to the discovery of two enantiocomplementary strains of Streptomyces 
with IRED activity towards 1a; Streptomyces sp. GF3587 and Streptomyces sp. 
GF3546, which reduced 1a to enantioselectively form the corresponding amine (R)-
1b and (S)-1b with 99.2 % ee and 92.3 % ee respectively (Figure 1.24).53, 54 The 
sequences of these IREDs, which will be referred to as SR-IRED and SS-IRED 
respectively, were determined by the procurement of N-terminal amino acid 
sequence data from purified enzyme. They were found to exclusively exhibit NADPH 
cofactor dependence.53, 55  
The gene encoding SR-IRED was used to identify an additional homologue, an IRED 
from Streptomyces kanamyceticus (SkR-IRED), which was also found to (R)-selectively 
reduce 1 to form (R)-1b with 99.6 % ee.55 SR-IRED and SS-IRED have been 
recombinantly expressed in E. coli and purified to homogeneity by Mitsukura and co-
workers.53, 55 The expression, purification and characterization of SkR-IRED had thus 




Figure 1.24: Reduction of imine moiety of 2-methyl-1-pyrroline (R)-selectively and 
(S)-selectively by enantiocomplementary strains of Streptomyces. Reduction of 1a 
using produces amine (R)-1b with Streptomyces sp. GF3587 and (S)-1b using 
Streptomyces sp. GF3546 53-56 
1.5 Project aims 
The aim of this project will be to increase knowledge about NADPH-dependent IREDs 
as a class of enzymes. In order to do this, the structure and mechanism of a number of 
IREDs of this family will be studied.  
The practical aims of this project are the cloning, recombinant expression and 
purification of these enzymes with a view for obtaining crystal structures to inform 
mechanistic studies as well as engineering for improved catalytic properties and 
increased substrate range, as outlined in Figure 1.25. Analysis of the structure and 
function of a range of IREDs will also facilitate investigation into what directs the 




Figure 1.25: A schematic view of the aims of the first part of this project, which will 
involve the study of NADPH-dependent IREDs. 
As the cloning, expression and purification of SkR-IRED has not yet been reported, this 
IRED was investigated first. The crystal structure of this enzyme was solved in 
preparation for this project, and will now be used to inform mechanistic studies of 
this enzyme and, therefore, (R)-selective IREDs more broadly. 
The applications and substrate range of SS-IRED has been investigated.55, 57 However, 
an S-selective NADPH-dependent IRED had not yet been characterised structurally 
and mechanistically. This will therefore form the next part of the focus of this project 
in the context of NADPH-dependent IREDs.  
Studies of the structures and applications of SkR-IRED and SS-IRED, which exhibit 
opposite enantioselectivity, will facilitate investigation into the basis of selectivity in 
NADPH-dependent IREDs. Additionally, gaining an insight into the mechanism of 
NADPH-dependent IREDs may ultimately facilitate a sufficient understanding of this 
enzyme class that this can be used to inform rational mutagenesis experiments to 
improve their catalytic properties. 
1.6 Addendum to the Introduction 
The initial discovery of NADPH-dependent IREDs SR-IRED and SS-IRED by Mitsukura 
and co-workers attracted the further investigation of these enzymes by a large 
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number of groups worldwide over subsequent years as this finding newly unlocked 
the real potential for the use of IREDs in an industrial context. This is because, unlike 
in the examples outlined in Section 1.4.5, the enzymes responsible for these imine 
reductions have been successfully identified which therefore facilitates further study, 
while also operating on a simple, biotechnologically promising substrate.58 
As a result, this subsection of biocatalysis is a field which grew rapidly throughout the 
timespan of this PhD, and continual publication of new literature heavily influenced 
the direction of the project. It is therefore appropriate to include in this introduction 
literature which has been published since the start of this PhD project began. 
 The 5-membered cyclic imine 1a was used as a model substrate in the initial 
screening of organisms for imine reducing activity due to its stability in aqueous 
environments as well as its commercial availability. However, further investigations 
towards the applications of SR-IRED and SS-IRED carried out by the Turner group at 
the Manchester Institute of Biotechnology indicated that the substrate specifity of 
these enzymes is much broader, and includes both substituted and unsubstituted 6-
membered and 7-membered rings as well as quinoline derivatives and, in the case of 
SS-IRED, β-carboline derivatives. These findings demonstrated that IREDs of this class 
offer a broader substrate scope than initially realised, this further increasing their 
potential for industrial application.57, 59 
The structure of SkR-IRED, which shares high levels of homology with SS-IRED and, 
particularly, SR-IRED was solved in both its apo form and in complex with NADPH. 
This structural facilitated the beginnings of investigation towards an understanding 
of how this class of enzymes works.60 Subsequently, the structure of SS-IRED in 
complex with NADPH  was also determined by Huber and co-workers. The findings 
demonstrate that the structure of a monomeric subunit of this class of IREDs consists 
of an N-terminal helical domain and a C-terminal Rossman-fold motif connected by a 
long inter-domain helix. The active form of these enzymes consists of a closely formed 
dimeric complex of two monomers connected by a reciprocal domain sharing 
arrangement. Dimer formation results in the creation of a hydrophobic cleft which 
forms at the interface of the N-terminal domain of one subunit and the C-terminal 
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domain of the opposite subunit, which contains the active site region of the protein.61 
It is observed that the inter-domain cleft closes upon binding of the NADPH cofactor.58 
The identification of the genes coding for SR-IRED, SS-IRED and SkR-IRED has 
facilitated the identification of a substantial numbers of related genes available for 
sub-cloning, expression, purification and screening for IRED activity. This effort was 
championed by the Hauer group who developed a database of putative IRED 
sequences grouped into sub-families according to sequence homology.62  
A substantial number of these newly discovered genes have since been characterised. 
Examples include the isolation and characterization of IREDs from S. roseum, S. 
turgidiscabies  and Paenibacillus elgii by Hauer and co-workers. The former two IREDs 
exhibited (R)-selectivity towards 1a while the latter exhibited (S)-selectivity. Höhne 
and co-workers demonstrated that IREDs could also operate on acyclic imines when 
they isolated and characterized IREDs from P. elgii B69, S. ipomoeae 91-03 and 
Pseudomonas putida KT2440. Assays were performed in the oxidative direction and 
showed that these IREDs could oxidize the acyclic amine, N-methyl-2-pentanamine.63 
More recently, Xu and co-workers successfully exploited an IRED from Paenibacillus 
lactis to reduce indoline-based imines and iminium ions to the corresponding 
optically pure (S)-amines.64 
Grogan and co-workers subsequently cloned and expressed IREDs from Bacillus 
cereus (BcS-IRED) and Nocardiopsis halophilia (Nh-IRED). While Bc-SIRED was found 
to be predominantly (S)-selective towards the usual panel of imines, the investigation 
of NhIRED, in particular, demonstrated that the (R)- and (S)-selective nature of IREDs 
can be highly substrate dependent. Selectivity was found to change from (S)- to (R)- 
with more sterically demanding substrates. 
Furthermore, Iding and co-workers based at Roche characterized 20 IRED enzymes 
in terms of their substrate scope and selectivity. These findings confirmed that while 
many IREDs are uniformly selective, there are number of IREDs for which selectivity 
is substrate dependent. This provided an opportunity to examine the function of many 
sequences from the available database of theoretical IREDs and seek evidence as to 
what determines the enantioselectivity of an IRED.65 
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The first two chapters of this thesis are based on the findings of Mitsukura and co-
workers, building on their initial characterization of SS-IRED, SR-IRED and SkR-IRED. 
The literature presented in this addendum had an impact on the final two results 
chapters of this PhD thesis, as the research reported in these sections builds in the 
knowledge acquired from the characterization of additional IRED homologues 




2. Materials and Methods 
2.1 Materials 
2.1.1 Bacterial growth media 
Lysogeny broth (LB) growth medium was used as standard for the growth of E. coli 
cultures. LB components (Table 2.1) were solubilised in Milli-Q water. 
Table 2.1: Components required to make LB medium 
Component Concentration (g L-1) 
Sodium chloride 10 
Yeast extract 5 
Tryptone 10 
 
Where necessary, LB medium was supplemented with 30 μg mL-1 kanamycin (LB-
Kan). 
Where increased cell yield was required, the richer medium terrific broth (TB) was 
used. TB components (Table 2.2) were solubilised in Milli-Q water. 
Table 2.2: Components required to make TB medium 
Component Concentration 
Yeast extract 24 g L-1 
Tryptone 12 g L-1 
Glycerol 5 g L-1 
NaH2PO4 17 mM 
Na2HPO4 72 mM 
 
2.1.2 Buffers for protein purification and enzyme assays 




Table 2.3: Components required to make buffer A  
Component Final 
concentration 
Tris 50 mM 
NaCl 300 w/v 
Adjusted to pH 7.5 with conc. HCl 
Diluted to total volume in Milli-Q 
water 
 
Buffer B (Table 2.4) was used as a buffer for the resuspension of expression cells, and 
in nickel affinity chromatography. 
Table 2.4: Components required to make buffer B 
Component Final 
concentration 
Tris 50 mM 
NaCl 300 w/v 
Imidazole 30 mM 
Adjusted to pH 7.5 with conc. HCl 






Buffer C (Table 2.5) was used as an elution buffer in nickel affinity chromatography. 
Table 2.5: Components required to make 1 L buffer C 
Component Final 
concentration 
Tris 50 mM 
NaCl 300 w/v 
Imidazole 500 mM 
Adjusted to pH 7.5 with conc. HCl 
Diluted to 1 L total volume in Milli-Q 
water 
 
2.1.3 Gel electrophoresis buffers  
Agarose gel electrophoresis 
Table 2.7: Components required to make TAE buffer for agarose gel electrophoresis 
Component Concentration 
Tris 40 mM 
Acetic acid 20 mM 
EDTA 1 mM 
 
To prepare a single agarose gel, 0.6 g agarose was dissolved in 60 mL TAE buffer by 




Sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) buffers 
Table 2.8: Components required to make 4 x loading buffer for SDS-PAGE 
Component Concentration 
Tris 120 mM 
Glycerol 20 % w/v 
SDS 4 % w/v 
β-mercaptoethanol 20 % w/v 
Bromophenol blue 0.04 % w/v 
Adjusted to pH 8.0 with conc. HCl 
 
Table 2.9: Components required to make running buffer for SDS-PAGE 
Component Concentration 
Tris 25 mM 
Glycine 200 mM 
SDS 0.1% w/v 
 
Table 2.10: Components required to make sufficient resolving gel for SDS-PAGE for 
2 SDS-PAGE gels 
Component Concentration Volume 
Deionised water - 3.2 mL 
Acrylamide 40 % w/v 4.5 mL 
Resolving buffer 
(1.5 M Tris.HCl 
containing 0.1 % w/v 
SDS, pH 8.8) 
- 2.5 mL 
APS 10 % w/v 20 μL 




Table 2.11: Components required to make sufficient gel for SDS-PAGE for 2 SDS-
PAGE gels 
Component Concentration Volume 
Deionised water - 3.2 mL 
Acrylamide 40 % w/v 0.5 mL 
Stacking buffer (0.5 
M Tris.HCl 
containing 0.4 % w/v 
SDS, pH 6.8) 
- 1.3 mL 
APS 10 % w/v 20 μL 
TEMED - 8 μL 
 
Table 2.12: Components required for preparation of glycin-NaOH buffer (0.1 M, pH 
9.5) 
Component Concentration 
Glycine 100 mM 
Adjusted to pH 9.5 with 0.2 M NaOH 
Dissolved to 1 L total volumn in milliQ water 
 
Table 2.13: Components required for preparation of phosphate buffer (0.1 M, pH 7.5) 
Component Mass 
Na2HPO4 13.40 g L-1 
NaH2PO4 2.63 g -1 





2.1.4 Substrates and products 
Table 2.14: Imine, aldehyde and alcohol substrates employed in IRED reactions 
Abbreviation Molecular 
Formula 
























































    




Table 2.15: Products for IRED reactions. Products have not been included where the 
product compound is already included in the list of substrates 
Abbreviation Molecular 
Formula 














































2.2 Molecular cloning 
Target genes were subcloned into pET-YSBL-LIC3C (Figure 2.1).66 The vector confers 
kanamycin resistance onto E. coli cells, and a cleavable N-terminal 6His tag onto gene 
products. The vector is adapted from the pET system, which is designed to facilitate 
the production of large copy numbers of the target protein within the host cell. 
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Figure 2.1: The pET-YSBLIC3C expression vector, based on the widely used pET28a 
vector. pET28a carries an N-terminal 6His tag coding sequence, a kanamycin 
antibiotic resistance marker, a multiple cloning site, the T7 promoter sequence, the 
lac operator coding sequence and the lacI gene which codes for the lactose repressor 
protein, Additionally to the pET28a features, pET-YSBLIC3C contains  the coding 
sequence for a human rhinovirus 3C (HRV3C) protease cleavage site downstream of 
the 6His tag, allowing for the cleavage of the N-terminal 6His tag from expressed 
proteins. The pET-YSBLIC3C expression vector has also been modified to include a 




2.2.1 Polymerase chain reaction 
The polymerase chain reaction (PCR) is a temperature-controlled, molecular 
biological technique for generating large copy numbers of the desired template gene 
using a three-step process; denaturation, annealing and extension.  
Initially the two strands of parent DNA are reversibly separated at approximately 95 
°C in the denaturation step. Custom oligonucleotides designed to anneal to both 
termini of the target DNA sequence then bind to the sense and antisense strands at 
approximately 55 °C in the annealing step. The annealing temperature is dictated by 
the melting temperature (Tm) of the primers. In the extension step, a new strand of 
DNA is synthesised by a DNA polymerase by adding dNTPs complementary to the 
template from the 3’ end of each oligonucleotide using deoxynucleotide triphosphate 
monomeric units (dNTPs). The extension step is usually carried out at 72 °C, 
depending on the DNA polymerase used. This process is repeated over 25-35 cycles 
until many copies of the desired gene have been achieved. PCR is carried out using a 
thermal cycler, which facilitates the rapid temperature changes required by the 
reaction. A schematic diagram of the denaturing, annealing and extending step cycle 





Figure 2.2: The repeating cycle of denaturing the target DNA template, annealing of 
complementary oligonucleotide primers and extension of new DNA using DNA 





To a 500 µL PCR tube, the components listed in Table 2.16 were added. 
Table 2.16: The reaction components used in standard PCR for the amplification of 
target DNA sequences 
Component Stock concentration Volume 
Plasmid DNA template 100 ng µL-1 1 µL 
Forward primer 20 pmol µL-1 1 µL 
Reverse primer 20 pmol µL-1 1 µL 
dNTPs 2 mM (each 
nucleotide) 
5 µL 
MgSO4 25 mM 3 µL 
Merck KOD Hot Start DNA 
polymerase buffer 
10 x 5 µL 
Merck KOD Hot Start DNA 
polymerase 
1.0 U µL-1 1 µL 
Milli-Q water to 50 µL 
 
PCR cycling parameters 
The following parameters were employed as standard for PCR using a thermal cycler 




Table 2.17: Cycling parameters used as standard PCR protocol for the amplification 
of target DNA sequences in a thermal cycler. 
Step Temperature/ °C Time 
Initial 
denature 
94 180 s 
Denature 94 30 s 
Annealing 55 30 s 
Extension 72 60 s 
Final extension 72 180 s 
2.2.2 Ligation-independent cloning (LIC) 
Ligation-independent cloning is a method for molecular cloning without the use of 
restriction endonucleases or DNA ligases. This technique was used as standard for all 
instances of sub-cloning of target genes into the pET-YSBLIC3C expression vector. 
This technique exploits the 3’-5’ exonuclease activity of T4 DNA polymerase in order 
to generate lengthy (10-15 bp) overhangs in both the target gene and expression 
vector which facilitate the spontaneous annealing of gene and vector.  
Linearisation of expression vector 
To a 1.5 mL Eppendorf, pET-YSBLIC3C vector DNA (12.5 μg), BseRI (12.5 μL), NEB 10 
x Buffer 2 (25 μL) were added. The volume was diluted to 250 μL with the appropriate 
volume of Milli-Q water. The reaction was placed in an incubator (37 °C, 110 min). 
The digested vector DNA was loaded onto an agarose gel (1 % agarose TAE, 100 V, 90 
min) and the band corresponding to linearized DNA excised and purified using a 
Sigma gel extraction it according to the manufacturer’s instructions. DNA 




T4 DNA polymerase treatment of expression vector 
To a 1.5 mL Eppendorf, BseRI-linearised vector (1.0 pmol), Merck T4 DNA polymerase 
10 x buffer (10 μL), dTTP (25 mM, 10 μL) and DTT (100 mM, 5 μL). The reaction 
volume was diluted to 250 μL with the appropriate volume Milli-Q water. The reaction 
mixture was divided into multiple 50 μL aliquots in 500 μL PCR cups and incubated 
in a PCR thermocycler at 22 °C for 30 min followed by 75 °C for 20 min. The reaction 
was purified using a Qiagen PCR clean up kit according to manufacturer’s instructions, 
and eluted in autoclaved Milli-Q water. DNA concentration was measured using an 
Eppendorf Biophotometer with Milli-Q water as a blank. 
T4 DNA polymerase treatment of target gene 
To a 500 μL PCR tube, the PCR amplified target gene (0.2 pmol), T4 10 x DNA 
polymerase buffer (2 μL), dATP (25 mM, 2 μL), DTT (100 mM, 1 μL) and LIC qualified 
T4 DNA polymerase (2.5 U μL-1, 0.5 μL). The reaction mixture was diluted to 20 μL 
with the appropriate volume Milli-Q water and incubated in a PCR thermocycler at 22 
°C for 30 min followed by 75 °C for 20 min. 
2.1.2.4 Annealing 
To a 500 μL Eppendorf tube, 3 μL T4 DNA polymerase-treated gene insert and 2 μL 
T4 DNA polymerase-treated linearised pET-YSBLIC3C was added. The reaction was 
incubated at 22 °C for 10 min before EDTA (25 mM, 1 μL) was added. The reaction 
was then incubated for a further 10 min. 
2.1.2.5 Transformation 
To a 1.5 mL Eppendorf, chemically competent E. coli XL10 Gold cells (50 µL) and SDM 
DNA product (5 μL) containing the desired mutation was added. The mixture was 
incubated on ice for 20 min followed by heat shock  (42 °C, 45 s) before returning to 
ice for 2 min. To the heat shocked cells, SOC medium was added (150 µL) and the 
resulting mixture incubated in an orbital shaker (37 °C, 60 min, 180 rpm). The cells 





From each plate, two colonies were selected and cultured in LB-Kan medium (5 mL) 
and incubated in an orbital shaker (37 °C, 16 h, 180 rpm). Cells were harvested by 
centrifugation (13,000 g, 1 min), from which plasmid DNA was isolated using a Sigma 
miniprep kit according to manufacturer’s instructions. DNA was eluted in 50 μL Milli-
Q water. DNA concentration was measured using an Eppendorf biophotometer.  
Diagnostic restriction digest 
A restriction digest was carried out to determine the presence of an appropriately 
sized insert in the purified plasmid DNA. To a 1.5 mL Eppendorf, plasmid DNA (7 μL,  
80 - 100 ng μL-1), NdeI (1 μL), NcoI (1 μL) and 10 x NEB CutSmart buffer (1 μL) was 
added. The digestion reaction was incubated at 37 °C for 3 h. The sample was mixed 
with 6 x DNA loading dye (2 μL) and loaded onto an agarose gel (1 % agarose TAE, 
100 V, 25 min). DNA bands were visualised using a Blue Light transilluminator and 
assessed for the presence of an appropriately sized DNA insert. 
Sequencing 
Clones that appeared positive according to diagnostic restriction digest were diluted 
to 20 μL at 60 ng μL-1 and submitted to sequencing at GATC Biotech to verify the 




2.3 Protein production 
2.3.1 Transformation 
To a 1.5 mL Eppendorf, chemically competent E. coli BL21 (DE3) cells (25 µL) and 
pET-YSBLIC3C vector containing the target gene (100 ng) was added. The mixture 
was incubated on ice (20 min) and heat shocked (42 °C, 45 s) before returning to ice 
(2 min). To the heat shocked cells, SOC medium was added (150 µL) and the resulting 
mixture incubated in an orbital shaker (37 °C, 60 min, 180 rpm). The cells were 
subsequently plated out onto LB+Kan plates and incubated (37 °C, 16 h). 
2.3.2 Small scale expression tests 
For novel genes for which expression conditions had not previously been established, 
small scale expression tests were carried out.  
Inoculation of liquid cultures 
Cell material from a single colony was used to inoculate an LB-Kan preculture (10 
mL). The precultures were incubated in an orbital shaker (37 °C, 16 h, 180 rpm). Four 
aliqots of LB-Kan medium (10 mL) in 50 mL falcon tubes were inoculated with 
preculture (100 µL) and incubated in an orbital shaker (37 °C, 180 rpm) until an OD600 
of 0.8 was reached.  
Induction of protein expression 
At an OD600 of 0.8, three of the four cultures were induced with 200 µg mL-1 Isopropyl 
β-D-1-thiogalactopyranoside (IPTG) and one culture incubated in separate orbital 
shakers at 16 °C, 30 °C and 37 °C (180 rpm, 20 h). 
Harvesting of cells 
The induced cell cultures were harvested by centrifugation (15 min, 5000 g). The 
fourth culture was harvested at an OD600 of 0.8 by centrifugation without induction by 
IPTG (15 min, 5000 g).  
Cell lysis 
Cell pellets were resuspended in buffer A (1 mL) and disrupted by sonication (3 x 30 
s) with incubation on ice during and between pulses. Sonicated cells were subjected 
to centrifugation (30 min, 13,000 g, 4 °C). 
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Preparation of samples for SDS-PAGE analysis 
Soluble fractions were decanted into separate 2 mL Eppendorf tubes, and the 
insoluble pellets suspended in buffer A (1 mL). For both soluble and insoluble 
samples, samples were taken (10 µL) and mixed with 2 x SDS-PAGE (10 µL) loading 
buffer. All samples were then heat denatured (94 °, 5 min). 
SDS-PAGE analysis 
To prepare a 12 % acrylamide SDS-PAGE gel, the resolving gel components (Table 2.9) 
were mixed and loaded into a Mini-PROTEAN® Tetra Cell casting stand loaded with 
two 1.0 mm thickness BioRad Mini-PROTEAN® spacer plates and two short glass 
plates. The resolving gel was topped with butanol (100 μL). After the resolving gel had 
set (approx. 30 min), the butanol layer was removed with compressed air. The 
stacking gel components (Table 2.10) were mixed and loaded atop the resolving gel. 
A BioRad Mini-PROTEAN® comb (1.0 mM thickness, 10-15 well) was inserted into 
the stacking gel. After the stacking gel had set (approx. 45 min), the comb was 
removed. 
To run a 12 % acrylamide SDS-PAGE gel, the gels were transferred within their glass 
plates to a BioRad electrophoresis cell. Samples were loaded into sample wells and 
the gel was run (200 V, 50 min). 
Samples were run alongside a BioRad low range molecular weight marker. 
2.3.3 Large scale protein production 
Inoculation of liquid cultures 
Cell material from a single colony on an agar plate was used to inoculate 2 LB-Kan 
precultures (10 mL). Precultures were incubated in an orbital shaker (37 °C, 16 hours, 
180 rpm) and used to inoculate two LB-Kan cultures (1 L) in baffled 2 L Erlenmyer 
flasks. Flasks were incubated in an orbital shaker (37 °C, 180 rpm) until an OD600 of 
0.8 was reached.  
Induction of protein expression 
Cells were then induced with ITPG (200 µg mL-) and incubated in an orbital shaker 
(16 °C, 20 h, 180 rpm) at an OD600 of 0.8.  
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Harvesting of cells 
Cells were harvested by centrifugation in Beckman 1 L centrifuge bottles (10 min, 




2.4 Protein purification 
Target proteins were routinely purified from cell lysate in two steps; nickel affinity 
chromatography and size exclusion chromatography. 
2.4.1 Cell lysis 
Cell pellets were resuspended in buffer B (40 mL) and disrupted by sonication 
(13,000 amplitude microns, 6 x 30 s) with incubation on ice. Cell free extract was 
obtained in supernatant after centrifugation (16,000 g, 45 min, 4 °C). 
2.4.2 Nickel affinity chromatography 
Nickel affinity chromatography (figure 2.3) exploits the 6His tag conferred onto 
proteins by the pET-YSBLIC3C vector. The resin of the nickel affinity column is 
charged with Ni2+ ions, which chelate the 6His tag at the terminus of the protein while 
untagged host proteins from E. coli are not bound and elute through the column. 
Proteins are eluted in an increasing gradient of imidazole, for which the Ni2+ ions have 
a very high affinity. Imidazole displaces the bound 6His tagged proteins, allowing 





Figure 2.3: A schematic representation of a nickel affinity chromatography column. 
Target proteins tagged with the 6His tag have a high affinity for the Ni2+ resin, 
therefore binding to the column medium. The remaining proteins are eluted through 
the column without binding, allowing them to be removed from the mixture. The 6His-
tagged target protein is then displaced from the column by imidazole, which has a 
higher affinity for Ni2+, and is eluted from the column as pure protein. 
Lysate was loaded onto a HisTrap HP column (5 mL) charged with nickel sulfate using 
a bench-top peristaltic pump (5 mL min-1). Bound proteins were then eluted with an 
increasing imidazole gradient on an Äkta purifier (30 – 500 mM imidazole, 100 mL, 2 
mL min-1,, 2 mL fractions).  Fractions were analysed by SDS-PAGE, and those 
containing the target protein were pooled. 
2.4.3 Size exclusion chromatography (SEC) 
Size exclusion chromatography (SEC) (figure 2.4) is a technique used to separate 
proteins according to their molecular weight. It is particularly useful for obtaining 
proteins exclusively in their correct oligomeric state, as different oligomerisations 
will elute at distinct elution volumes. SEC columns contain a fine resin through which 
heavier proteins elute faster, as they are unable to pass through the narrower 
channels within the beads. Smaller proteins are able to pass through narrower pores 
in the resin of the column, and therefore traverse a longer route before eluting from 




Figure 2.4: A schematic representation of a SEC column. The resin contains small 
pores through which smaller proteins are able to flow, causing them to take a longer 
route through the column. Larger proteins do not fit through these pores and 
therefore bypass them, resulting in a faster route through the column. Larger proteins 
are therefore eluted more quickly than smaller ones. 
 
After purification by nickel affinity chromatography, the target protein was 
concentrated in a 30 kDa Amicon Ultra-15 centrifugal filter (5,000 g, 4 °C) to a volume 
of 2 mL. The protein was filtered using membrane syringe filter (0.45 μM) to remove 
particulate matter. The protein was loaded onto a SuperDex HiLoad 16/60 S75 size 
exclusion column via a 2 mL injection loop and eluted in buffer A (120 mL, 0.5 mL min-
1). Fractions were analysed by SDS-PAGE. Those containing pure protein in its correct 




2.4.4 Protein concentration 
Protein concentration was determined by measuring absorbance at 280 nm using an 
Eppendorf Biophotometer with buffer A as a blank. The concentration could be 
calculated using the Beer-Lambert law, 
𝐴 =  𝜀. 𝑐. 𝑙 
A = Measured absorbance 
ε = Exctinction coefficient 
l = Path length 
The absorption coefficient was ascertained using the ExPASy ProtParam tool, and the 
pathlength of the measurement cuvette was 1 cm. 
2.4.5 Protein storage 
For long term storage, protein was aliquoted flash frozen in liquid nitrogen and stored 
(-20 °C) until use. 
2.5 6His tag cleavage 
The pET-YSBLIC3C expression vector codes for a cleavage site (Leu-Glu-Val-Leu-Phe-
Gln/Gly-Pro-Ala) recognised by the human rhinovirus 3C protease (HRV 3C) 
downstream from the N-terminal 6His tag. It was therefore possible to cleave the 6His 
tag from proteins expressed in the pET-YSBLIC3C expression vector using HRV 3C. 
Proteins were diluted to a concentration of 1 mg mL-1, and 1 mg HRV 3C protease per 
100 mg protein substrate was added. The reaction was incubated (4 °C, 16 h). The 
cleaved protein was purified using nickel-affinity chromatography (section 2.3.2), 
where the cleaved protein was eluted before the imidazole gradient due to its lack of 




2.6 Analytical techniques 
2.6.1 Ultraviolet-visible (UV) spectrophotometry 
Ultraviolet-visible (UV-Vis) spectrophotometry is routinely used in analytical 
chemistry to characterise molecules that absorb light within the ultraviolet or visible 
regions. Many transition metal and unsaturated organic compounds are able to 
absorb UV or visible light as they contain π- or non-bonding electrons that can absorb 
energy from photons with wavelengths in the UV or visible regions that excite them 
into higher energy anti-bonding molecular orbitals.  
The UV-Vis spectrophotometer instrument operates by generating a beam of light at 
a given wavelength. Both the intensity of the incident beam before it reaches the 
sample (I0) and the intensity of the beam transmitted from the sample (I) are 
measured. The ratio I/I0 is known as the transmittance and can be used to calculate 
the absorbance, a quantitative measure of the amount of radiation absorbed by a 
sample: 




The Beer-Lambert states that the absorbance of a solution is directly proportional to 
the concentration of an absorbing species and the path length, allowing the 
absorbance to be directly converted into the concentration of the species of interest. 
𝐴 =  𝜀. 𝑐. 𝑙 
A = Measured absorbance 
I0 = Incident intensity of light at a given wavelength (λ) 
I = Transmitted intensity of light at a given wavelength (λ) 
l = Path length of the measurement vessel 
c = Concentration of sample 
ε = Extinction coefficient 
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UV-Vis spectrophotometry may also be used to follow the progression of a reaction 
using time course measurements, where absorbance and thus reactant or product 
concentration is measured at regular intervals. This technique can be used to 
determine reaction rates, and is therefore useful for determining kinetic parameters 
in enzyme reactions. 
2.6.2 HPLC 
HPLC is an analytical technique for the separation of chemicals in a mixture.  It is a 
form of liquid column chromatography achieved by pumping solvents through the 
column at high pressures, thus greatly increasing the speed of analysis.  
An HPLC system consists of a sampler, pumps and a detector (figure 2.5). The sampler 
introduces the sample mixture into the mobile phase (solvent). The sample is carried 
through the column via the mobile phase. The pump dictates the flow rate and 
composition of the mobile phase as it passes through the column. The detector detects 
peaks corresponding to molecules from the sample as they are eluted from the 
column, generating a signal that is proportional in size to the corresponding molecule.  
HPLC can be carried out using a normal phase or reversed phase setup. In the normal 
phase, the stationary phase (the column) is polar and the mobile phase (solvent) is 
non-polar. Non-polar molecules elute more slowly through the column due to 
increased Van der Waals interactions with the non-polar mobile phase. Reversed 
phase HPLC refers to a non-polar stationary phase and a polar mobile phase. Polar 
molecules in the liquid sample passing through the column display an increased 
affinity towards the polar mobile phase, leading to longer retention times relative to 
non-polar molecules. This principle allows for the separation of molecules according 











Figure 2.5: A schematic diagram of the experimental setup of an HPLC. The sample is 
injected into the column, through which a gradient of buffers is pumped. The speed at 
which analytes travel through the column is determined by the solubility of the 
compound in the solvent and the degree of interaction of the analyte to the stationary 
phase. Analytes eluted from the column are detected, producing a signal that is 





Gas chromatography (GC) is an analytical technique for the separation of chemicals in 
a mixture. The equipment consists of a sample injector, a column where separation 
occurs, a detector and a processing and display unit (figure 2.6). Small sample 
volumes are injected at the injector and analytes are carried through the column by a 
gaseous mobile phase. The stationary phase is situation within the column and is 
normally a high boiling point liquid absorbed onto a solid. The speed at which the 
analytes pass through the column is determined by how strongly they are attracted 
to the stationary phase. Compounds more strongly attracted to the stationary phase 
pass through the column more slowly as they more readily condense or dissolve in 
the liquid of the stationary phase.  
 
Figure 2.6: A schematic diagram of the experimental setup of a GC. The sample is 
injected and transported through the column via a carrier gas. The speed at which 
analytes are eluted from the column is determined by their boiling point and the 
degree of affinity to the stationary phase. Analytes eluted from the column are 
detected at the detector, producing a signal that are then visualised using a processing 














2.7 Enzyme kinetics 
All assays were carried out with purified enzyme unless otherwise specified.  
2.7.1 Michaelis-Menten kinetics 
The Michaelis-Menten model is widely used for describing ideal enzyme kinetic 
behaviour. An enzymatic reaction in equilibrium may be described by the equation: 
     
𝐸 + 𝑆 ⇌ 𝐸𝑆 → 𝐸 + 𝑃 
Where substrate, S, and enzyme, E, bind reversibly to form the enzyme-substrate 
complex, ES, and the reaction of the ES complex to form the product, P, is assumed to 
be irreversible under a large excess of concentration of S relative to P.  










Vmax = The maximum reaction velocity of the system 
KM = The Michaelis-Menten constant 
[S] = Substrate concentration 
kcat = Catalytic turnover number of enzyme 
[E]0 = Initial enzyme concentration 
The Vmax describes the maximum reaction velocity for the system at saturating 
substrate concentrations. 
The kcat may be calculated directly from the Vmax and the enzyme concentration. This 
is the turnover number of the enzyme, and describes the number of molecules turned 
over by one molecule of enzyme per second.  
The KM is the substrate concentration at which half the Vmax is achieved. This serves 
as a measure of the affinity of the substrate to an enzyme, where a lower KM indicates 
tighter binding of substrate and enzyme, and a higher KM indicates weaker binding, as 
more substrate is required to achieve the maximum reaction rate. 
A general measure of the efficiency of an enzyme can be measured using the specifity 
constant, kcat/KM. This value may be used to compare the efficiency of enzyme-
substrate systems. 
The kinetic parameters Vmax, kcat and KM can be determined using an experimental 
setup where reaction velocity is measured with constant concentration of enzyme at 
increasing substrate concentrations. The Michaelis-Menten model predicts that the 
enzyme will adopt the kinetic behaviour depicted graphically in Figure 2.7 where 










Figure 2.7: A representation of a typical Michaelis-Menten plot for enzyme kinetics. 
Reaction velocity is plotted against substrate concentration. A maximum velocity is 
reached as a certain substrate concentration where the enzyme becomes saturated. 
This velocity is termed Vmax. The substrate concentration at which an enzyme velocity 
of half the Vmax is achieved is termed the KM, and is a measure of enzyme affinity for 
the substrate. 
2.7.2 Substrate inhibition kinetics 
In some cases, as substrate concentration increases, reaction velocity does not 
converge to a maximum value as is the case in the Michaelis Menten model, but 
instead begins to decrease (figure 2.8). In such cases an inactive enzyme complex, ESS, 
is said to be formed at high concentrations of substrate, where two substrate 
molecules bind to the enzyme in the following manner. 
𝐸 + 𝑆 ⇌ 𝐸𝑆 → 𝐸 + 𝑃 
                                                              ⇅ +𝑆 
                                                                           𝐸𝑆𝑆 
From this, an equation describing the substrate inhibition model is derived, 
𝑣 =
𝑉𝑚𝑎𝑥 [𝑆]







The substrate inhibition equation shares the parameters Vmax and KM with the 
Michaelis Menten equation with the additional parameter, Ki, which represents the 
inhibition constant, corresponding to rate constant of formation of the inactive ESS 
complex. Ki acts as a measure of the potency of substrate inhibition, with higher values 








Figure 2.8: A representation of a substrate inhibition model reaction (dotted blue 
line) superposed onto a typical Michaelis-Menten model (red line). Reaction velocity 
is plotted against substrate concentration. Unlike in a Michaelis-Menten system, 
maximum velocity (Vmax) is not reached at higher substrate concentrations as the 
substrate begins to exhibit an inhibitory effect on the system. Vmax and KM are 
determined by fitting a curve using a model which includes an inhibition constant, KI, 
to account for substrate inhibition. 
2.7.3 NADPH concentration assays 
The cofactor NADPH is reversibly oxidised to NADP+ in enzymatically catalysed 
reduction reactions. Both NADPH and NADP+ absorb strongly in the UV region due to 
the presence of the adenine moiety, however their absorbance behaviours differ 
considerably. NADPH has a λmax of 340 nm, while NADP+ does not absorb at this 
wavelength. Therefore, the concentration of NADPH may be monitored by measuring 
the depletion in absorbance at 340 nm. This allows for the indirect monitoring of the 
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progression of the reaction, as the concentration of NADPH is directly proportional to 
substrate depletion. Such a technique may be used to measure both the depletion of 
NADPH in reductive reactions and the depletion of NADP+ in oxidative reactions by 
measuring the decrease or increase in absorbance at 340 nm respectively. 
 
Figure 2.9: The oxidation of the enzyme cofactor NADPH to form NADP+. This 
oxidation can be detected spectophotometrically, as NADPH absorbs at 340 nm while 
NADP+ does not.  
All NADPH concentration assays were carried out in a GCB-DBUV spectrophotometer 
(Cintra10) in a quartz cuvette (1 mL). Reactions (1 mL) were carried out with the 
components outlined in Table 2.16. 
Table 2.18: Reaction components used in enzyme kinetic assays 
Component Volume Final concentration 
*NADPH/NADP+ 20 μL 0.2 mM 
Substrate (solubilised in 
ethanol) 
10 μL Increasing from 0.5 mM 
until saturation achieved 
Enzyme 100 μL 0 – 10 mg mL-1 





All reaction components excluding enzyme were mixed in a quartz cuvette (1 mL). 
Enzyme was then added to initiate the reaction, which was monitored at 370 nm over 
a time course of 3 – 15 min depending on reaction rate. Assuming the absorption 
coefficient of NADPH to be 2300 M-1 cm-1, the raw absorbances were converted to the 
concentration of NADPH at a given time point. Using the assumption that the change 
in concentration of NADPH is inversely proportional to change in substrate 
concentration for reductive reactions, or directly proportional for oxidative reactions, 
reaction velocities could be determined.  
 
2.7.4 Data analysis 
With the GraphPad Prism software suite, non-linear regression analysis was used to 
determine best fit values for the kinetic parameters KM, kcat and Ki for datasets of 
reaction rates vs. substrate concentration for given enzyme-substrate systems using 
either the Michaelis-Menten or substrate inhibition model.  
An F-test was performed to compare which model (Michaelis-Menten or substrate 
inhibition) most closely fit the data, where: 
H0 = Michaelis Menten model 
Ha = Substrate inhibition model 
Critical value = 0.05. 
2.8 Biotransformations 
2.8.1 Biotransformations by SkR-IRED 
Biotransformations using SkR-IRED were carried out to ascertain the selectivity and 
substrate scope of the enzyme. Reactions containing imines 1a – 8a (5 mM), NADPH 
(0.2 mM) and purified enzyme (0.8 mg mL-1) were incubated (20 h, 25 °C, 250 rpm).  
GITC derivatization procedure 
For analysis of biotransformations of 1a, functionalisation with the chiral derivatizing 
agent 2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate (GITC) was carried 




An aqueous sample (100 µL) of the 1a biotransformation was mixed with 
triethylamine (100 µL, 0.8% (w/v)) in acetonitrile and 2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosyl Isothiocyanate (GITC) (200 µL, 0.8% (w/v)). The mixture was 
incubated (37°C, 30 min). Insoluble fractions were removed by centrifugation and the 
supernatant analysed by HPLC. 
Extraction procedure 
For samples of biotransformations of 2a – 8a, extraction with t-butyl methyl ether 
(TBME) was carried out in preparation for analysis by HPLC. Reactions (1 mL) were 
extracted with an equal volume of TBME by vortexing. Samples were centrifuged 
(4,000 g, 10 min) and the TBME fraction decanted into a clean vial for HPLC analysis. 
Chromatography conditions 
For analysis of biotransformations of SkR-IRED towards 1a, reverse phase HPLC for 
samples of GITC-derivatised 1a and 1b was performed on an Agilent system equipped 
with a  Luna® C18(2) column (3 μm particle size) was used.  The typical injection 
volume was 10 µL and chromatograms of absorbance at 254 nm were recorded.  
For analysis of biotransformations with SkR-IRED towards imines 2a – 8a, normal 
phase chiral HPLC was performed on an Agilent system equipped with either a 
CHIRALPAK®IC Analytical (5 µm particle size) or CHIRALCEL®OD-H (5 µm particle 
size). The typical injection volume was 10 µL and chromatograms of absorbance at 
265 nm were recorded.  
Table 2.19: HPLC conditions used for the analysis of imines 









2a CHIRALPAK®IC[ Hexane:iPrOH:DEA 90:10:0.1 1 14.03 
3a CHIRALPAK®IC Hexane:iPrOH:DEA 90:10:0.1 1 5.21 
4a CHIRALPAK®IC Hexane:iPrOH:DEA 97:03:0.1 1 17.12 
5a CHIRALCEL®OD-H Hexane:iPrOH:DEA 90:10:0.1 1 8.75 
6a CHIRALPAK®IC Hexane:iPrOH:DEA 90:10:0.1 1 8.60 
7a CHIRALPAK®IC Hexane:iPrOH:DEA 80:20:0.1 1 7.22 





Table 2.20: HPLC conditions used for the analysis of amines 












1b-GITC Eclipse XDB-C18 KPB pH 2.5:MeOH 55:45 1 16.067 16.899 
2 CHIRALPAK®IC Hexane:iPrOH:DEA 90:10:0.1 1 10.777 (prochiral) 
3 CHIRALPAK®IC Hexane:iPrOH:DEA 90:10:0.1 1 6.571 (prochiral) 
4 CHIRALPAK®IC Hexane:iPrOH:DEA 97:03:0.1 1 9.829 10.699 
5 CHIRALCEL®OD-H Hexane:iPrOH:DEA 90:10:0.1 1 12.606 16.781 
6 CHIRALPAK®IC Hexane:iPrOH:DEA 90:10:0.1 1 10.056 11.154 
7 CHIRALPAK®IC Hexane:iPrOH:DEA 80:20:0.1 1 11.867 14.097 
8 CHIRALPAK®IC Hexane:iPrOH:DEA 95:05:0.1 1 5.976 5.372 
2.8.4 Biotransformations using mutants of SS-IRED and SR-IRED  
Biotransformations of 1a using mutants of SS-IRED and SR-IRED were carried out in 
order to assess the effect of mutations on enantioselectivity using chiral GC. 
Extraction and acetylation procedure 
Reactions containing 1a (5 mM), NADPH (20 mM) and purified enzyme (0.2 – 0.5 mg 
mL-1) were diluted to a volume of 500 μL with phosphate buffer (100 mM, pH 7.5) and 
incubated (25 °C, 250 rpm). Extract was transferred to a GC vial containing a 200 μL 
inlet. Imines and amines in the reaction mixture were functionalised with an acetyl 
group to improve resolution of separation in GC analysis.  Samples were acetylated by 
addition of acetic anhydride (15 μL) trimethylamine (30 μL).  
Chromatography conditions 
For analysis of biotransformations of 1a by mutants of SS-IRED and SR-IRED, samples 
containing acetylated 1a and the corresponding product 1b were analysed using an 
Agilent 6890 GC equipped with a chiral SGE Analytical Science BP20. A split ratio of 
5.0:1 and a flow rate of 9.7 mL min-1 was employed. Column conditions and analyte 




Table 2.21: Chromatography conditions employed in the chiral GC analysis of 
biotransformations of 1a by mutants of SS-IRED and SR-IRED 
Conditions Retention time (min) 




150 °C 22 min, 20 °C/min 
to 200 °C, 5 min at 200 °C  
16.3 20.1 18.7 
 
2.8.5 Biotransformations using mutants of Pp-IRED 
Biotransformations were carried out with substrates 11a – 13a (5 mM), NADP+ (for 
the oxidation of 11a and 13a) and NADPH (for the reduction of 12a) and purified 
enzyme (0.5 mg mL-1) diluted to a volume of 500 μL with phosphate buffer (100 mM, 
pH 7.5). Reactions were incubated (20 h, 25 °C, 250 rpm). 
Extraction procedure 
Reactions were extracted with TBME (250 μL) containing pentadecane (0.15 % v/v) 
as an internal standard. Extract was transferred to GC vials containing 200 μL inlets. 
Chromatography conditions 
Biotransformations of substrates 11a – 13a by Pp-IRED were analysed using an 
Agilent 6890 GC equipped with an HP-5 column. A split rate of 5.0:1 and a flow rate of 
26.7 mL min-1 were used. The analyte retention times and column conditions applied 




Table 2.22: Chromatography conditions employed in the chiral GC analysis of 
biotransformations of 11a – 13a by Pp-IRED 
Conditions Retention time (min) 
 11a 12a 13a 
160 °C, 10 min 5.6 8.4 9.3 
 
2.9 Site-directed mutagenesis (SDM) 
Site-directed mutagenesis is a molecular biological tool for introducing a specific and 
targeted mutation into a DNA sequence allowing the mutation of a chosen single 
amino acid residue to a chosen target residue. SDM is commonly used for investigating 
the importance of certain residues in enzymatic activity or to alter the properties of a 
protein in a targeted way. 
To carry out SDM, primers complementary to the target DNA sequence containing the 
desired mutation were designed. The primers anneal to the target DNA and copies 
containing the desired mutation are synthesised using PCR. The template DNA is 
digested by the restriction endonuclease DpnI, which exclusively digests methylated 
DNA. The genetic material is then only the unmethylated DNA synthesised during the 
PCR, which can then be used to transform a host organism for cloning. Selected 
colonies are cultured and the transformed is DNA isolated using a miniprep 
procedure. Isolated DNA is sequence to screen for the presence of the desired 




Figure 2.10: A schematic representation of the steps involved in site-directed 
mutagenesis (SDM). The template DNA is denatured at high temperatures, allowing 
the mutagenic primers to anneal. The plasmid is then amplified from the mutagenic 
primers. The template DNA is removed by digestion by DnpI, and E. coli is transformed 





PCR reaction components 
Table 2.23: PCR reaction components employed for site directed mutagenesis 
Component Stock concentration Volume/ µL 
Plasmid DNA template 100 ng µL-1 1 
Forward primer 20 pmol µL-1 1 
Reverse primer 20 pmol µL-1 1 
dNTPs 2 mM (each 
nucleotide) 
5 
Agilent Pfu Turbo DNA polymerase 
buffer 
10 x 5 
Agilent Pfu Turbo DNA polymerase 1.0 U µL-1 1 
Milli-Q water to 50 µL 
 
PCR cycling parameters 
Table 2.24: PCR cycling parameters for site directed mutagenesis 
Step Temperature/ °C Time 
Initial 
denature 
95 300 s 
Denature 95 60 s 
Annealing 55 60 s 
Extension 72 600 s 
Final extension 72 300  s 
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2.9.2 DpnI Digest 
To the PCR reaction, DpnI (2 units μL-1, 1.5 μL) is added to digest template DNA. The 
digest reaction is incubated (37 °C, 4.5 h). 
2.9.3 Transformation 
To a 1.5 mL Eppendorf, chemically competent E. coli XL10 Gold cells (50 µL) and SDM 
DNA product (5 μL) containing the desired mutation was added. The mixture was 
incubated on ice for 20 min followed by heat shock  (42 °C, 45 s) before returning to 
ice for 2 min. To the heat shocked cells, SOC medium was added (150 µL) and the 
resulting mixture incubated in an orbital shaker (37 °C, 60 min, 180 rpm). The cells 
were subsequently plated out onto LB+Kan plates and incubated (37 °C, 16 h). 
2.9.4 DNA isolation 
From each plate, two colonies were selected and cultured in LB-Kan medium (5 mL) 
and incubated in an orbital shaker (37 °C, 16 h, 180 rpm). Cells were harvested by 
centrifugation (13,000 rpm, 1 min), from which plasmid DNA was isolated using a 
Sigma miniprep kit according to manufacturer’s instructions. DNA was eluted in 50 
μL Milli-Q water. DNA concentration was measured using an Eppendorf 
biophotometer.  
2.9.5 DNA Sequencing 
Purified plasmids were diluted to 20 μL at 60 ng μL-1 and submitted to sequencing at 
GATC Biotech to verify the presence of the desired mutation. 
2.10 Sample preparation for electrospray mass spectrometry 
SkR-IRED was highly concentrated to 100 mg mL-1 and resuspended in ddH2O to 
remove Tris buffer which might interfere with mass spectrometry analysis.  The 
sample was ionized by electrospray ionisation (ESI) and analysed using FT-MS by the 
Technology Facility at the University of York. 
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3. Isolation, application, structure and mechanism of SkR-IRED, an 
(R)-selective NADPH-dependent imine reductase from Streptomyces 
kanamyceticus 
3.1 Introduction  
The asymmetric reduction of the prochiral C=N bond in imines by an enantioselective 
enzyme offers a convenient route for the synthesis of chiral amines, which offer a 
broad range of applications in the pharmaceutical, agrochemical and chemical 
industries. Prior to 2010, there existed few reports of imine-reducing enzymes 
(IREDs) suited for industrial biotechnological applications. 
In an effort to identify IREDs with applicability to biocatalysis, a broad ranging screen 
of organisms for activity towards imine 1a was carried out by Mitsukura and co-
workers, which led to the discovery of two organisms that catalysed the reduction of 
the imine to the corresponding amine 1b. The two strains produced 
enantiocomplementary amines; Streptomyces sp. GF3587 and Streptomyces sp. 
GF3546, which catalysed the formation of amines (R)-1b and (S)-1b with 99.2 % and 
92.3 % ee respectively.54 The enzymes responsible for these reactions, which will be 
referred to as SR-IRED and SS-IRED respectively, were isolated and their sequence 
was identified using N-terminal sequence acquisition. The enzymes were 
characterized and reported to be NADPH-dependent.53, 55 Knowledge of the sequence 
of SR-IRED and SS-IRED presented an opportunity to identify homologues which 
could be screened for additional imine reductase activities. Knowledge of the gene 
sequences of SR-IRED and SS-IRED facilitated the discovery of an additional (R)-
selective IRED in Streptomyces kanamyceticus, which has been termed SkR-IRED, 
which was also found to catalyse the reduction of 1a to form enantiomerically pure 





Figure 3.1: The NADPH-mediated reduction of imine 1a to form enantiomerically 
pure (R)-1b by SkR-IRED. 
 
Prior to the beginning of this project, no characterization of SkR-IRED had been 
reported, presenting the opportunity to study a novel IRED, which forms the basis of 
this chapter. This section describes the characterization of the structure, substrate 
scope, kinetic behaviour and mechanistic studies of SkR-IRED. 
This enzyme was the first enzyme that became the primary focus of this project not 
only because it was novel, but because it was readily crystallisable. Attempts to 
crystallise SR-IRED, which had been characterized by Mitsukura and coworkers, were 
not successful and therefore SkR-IRED was a more ideal target for mechanistic 
studies. 
3.2 Preliminary work 
Preceding this PhD project, preliminary work was carried out on SkR-IRED by M. 
Rodriguez-Mata. 
3.2.1 Crystallization and data collection 
Purified SkR-IRED was subjected to broad ranging crystallization screens. An initial 
hit was achieved in a 300 nL drop containing 1:1 v/v ratio of protein and precipant 
using a protein concentration of 20 mg mL-1 and tacsimate (pH 7.0, 35 % v/v) in a 96-
well sitting drop format in the commercially available INDEX screen (Hampton 
research). The crystallization scale was increased using 2 μL hanging drops 
containing a 1:1 v/v ratio of protein and precipitate. A selection of crystals was soaked 
in mother liquor containing NADPH (10 mM) in order to obtain a cofactor complex. 
Crystallographic data was collected at Diamond light source using the I03 and I04-1 
beamlines for apo and NADPH-complexed crystals respectively. Crystals of SkR-IRED 
diffracted to a resolution of 2.6 Å in its apo form and 2.7 Å in complex with NADPH.  
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3.2.2 Structure solution 
The structure of SkR-IRED was solved by molecular replacement using tartronic 
semialdehyde reductase from Salmonella typhymurium as a model (PDB accession 
code 1YB4), with which SkR-IRED shares 21.1 % identity and 54.6 % similarity. The 
unit cell contained four monomeric units arranged as two pairs of dimers. 
SkR-IRED monomer 
A monomeric subunit of SkR-IRED (Figure 3.2) consists of an N-terminal Rossman fold 
domain characteristic of NADPH-binding proteins (residues 1-181) and a C-terminal 
helical domain (residues 210 – 306) connected by a long inter-domain helix (residues 
182 – 209).60 
 
Figure 3.2: The crystal structure of a single monomeric subunit of SkR-IRED at a 
resolution of 2.6 Å. The monomer consists of an N-terminal Rossman fold motif 
(residues 1 – 181) and a C-terminal helical domain (residues 210 – 306) connected by 
a long inter-domain helix (Leu182 – Gly209). 60 
Dimer formation 
SkR-IRED exists as a dimer of two monomeric subunits (A and B) (Figure 3.3) 
participating in reciprocal domain sharing. Analysis using PISA demonstrated that the 
two subunits share a contact area of 3761 Å2. The surface of the inter-domain helix is 
largely hydrophobic, which assists in its binding into a hydrophobic channel of the 
opposite subunit in dimer formation. In the dimer, a cleft is formed between the N-
terminal subunit of monomer A and the C-terminal subunit of monomer B, with the 
interlocking C-terminal domains forming the central region of the dimeric complex 




Figure 3.3: The crystal structure of apo SkR-IRED at 2.6 Å resolution. The monomer 
consists of an N-terminal Rossman fold motif (1 – 181) and a C-terminal helical 
domain (210 – 306) connected by a long inter-domain helix (Leu182 – Gly209). Dimer 
formation is facilitated by the reciprocal domain sharing of the two monomeric 





NADPH binds in a cleft between the N-terminal domain of one subunit and the C-
terminal domain of the opposite subunit (Figure 3.4) at the consensus GXGXXG 
NADPH-binding motif, which in SkR-IRED is GLGMLG 26-31.  
 
Figure 3.4: SkR-IRED in complex with NADPH cofactor at 2.7 Å resolution. The 
positioning of NADPH indicates that the active site is formed in a cleft between the N-
terminal domain of one subunit and the C-terminal domain of the opposite subunit. 
NADPH is illustrated by ball and stick representation.60 
3.3 Aims 
The crystal structure of SkR-IRED will be used as a basis to study the mechanism of 
the enzyme and to investigate its physiological role. Additionally, the substrate scope 
and catalytic properties of SkR-IRED will be characterized.  Ultimately, this structural, 
mechanism and activity data may be used as a basis for the rational engineering of the 
enzyme towards improved catalytic properties. 
3.4 Results and discussion 
3.4.1 Large scale expression and purification 
SkR-IRED was expressed in the pET-YSBLIC3C vector in E. coli BL21 (DE3) cells in 2 L 
LB-Kan medium at the previously established optimal expression conditions (16 °C, 
180 rpm, 20 h).60 Protein was purified from lysed, resuspended cells using nickel 
affinity chromatography, and protein samples were analysed by SDS-PAGE to assess 




Figure 3.5: SDS-PAGE gel analysis of purification of SkR-IRED by nickel affinity 
chromatography. Lane 1: Bio-Rad low range molecular weight marker, lane 2: 
unbound flow-through collected during loading of nickel column, lanes 3 – 14: 
fractions containing purified protein eluted during increasing imidazole gradient. 
Purified SkR-IRED is observed to be approximately 32 kDa by SDS-PAGE. 
SkR-IRED was further purified by size exclusion chromatography (figure 3.6) using a 
Superdex® HiLoad 75 gel filtration column to remove remaining host proteins and 
SkR-IRED in different oligomeric states. Fractions which exhibited absorbance at 280 





Figure 3.6: Chromatogram of the purification of SkR-IRED by size exclusion 
chromatography. The presence of protein is detected using absorbance 
measurements at 280 nm, which is indicated by the blue trace. 
SkR-IRED was eluted in a large, shouldered peak with 55 – 65 mL buffer, indicating 
that the protein existed in only one oligomeric state. The noise visible at the highest 
points in the peak may be due to the absorbance value exceeding the detector limit, 
and the shoulder at a higher elution volume may be due to the presence of impurities 
in the sample. Using a calibration curve provided by GE Healthcare, the elution volume 
was used to estimate a protein molecular weight of approximately 60 kDa. The 
molecular weight of a monomer of 6His-tagged SkR-IRED is approximately 33 kDa, 
indicating that SkR-IRED was most likely to be present as a dimer in solution. Protein-
containing fractions were analysed by SDS-PAGE (Figure 3.7). The protein was of high 
homogeneity, with very minor quantities of E. coli host proteins present relative to 



































Figure 3.7: SDS-PAGE gel analysis of purification of SkR-IRED by size exclusion 
chromatography. Lane 1: Bio-Rad low range molecular weight marker, lanes 2 – 9: 
fractions containing purified protein eluted between 55 and 65 mL buffer. Purified 
SkR-IRED is observed to be approximately 32 kDa by SDS-PAGE. 
3.4.2 Kinetic analysis and pH behaviour of SkR-IRED 
A kinetic assay was carried out with increasing concentrations of substrate 1a to 
determine the kcat and KM of the enzyme in the imine reduction reaction as described 
in section 2.5.3. 
Visual inspection of the data indicated that the system exhibits significant levels of 
substrate inhibition with reaction velocities beginning to decrease at substrate 
concentrations greater than approximately 7.5 mM.  
In an extra sum of squares F test, the substrate inhibition model was convincingly 
favoured over the Michaelis-Menten model (F = 19.82, P = 0.0005). Curve fitting was 
therefore carried out using non-linear regression analysis with the substrate 
inhibition model (Figure 3.8).  
When non-linear regression was carried out using the substrate inhibition model 
without constraints on parameter values, an unreasonably high value of KM was 
calculated (47.7 mM). Therefore, KM was artificially constrained to be equal to the 
literature value of 8.21 mM in the calculation of best-fit values for kcat and Ki.60 The 
best fit values for kinetic parameters calculated during non-linear regression are 
outlined in Table 3.1. 
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Figure 3.8: Michaelis-Menten plot for the reduction of 1a by SkR-IRED.  
 
Table 3.1: Kinetic parameters determined during non-linear regression analysis of 
experimental data of the reduction of 1a by SkR-IRED at varying substrate 
concentrations using the substrate inhibition model 
 Value Standard error 
kcat 0.0264 s-1 ±0.0018 s-1 
KM 8.21 mM N/A* 
Ki 9.05 mM 1.74 mM 
   
*No standard error may be calculated for KM as this value has been artificially 
constrained, not calculated 
The relatively small standard errors for the values of kcat and Ki indictate that the 
calculated values are likely to be reliable and that 8.21 mM was a reasonable estimate 
of KM. The kcat value of 0.0264 s-1 is low, indicating poor catalytic efficiency of SkR-
IRED towards 1a. The high KM value also suggests that SkR-IRED exhibits low affinity 
towards substrate 1a. These findings suggest that 1a is not likely to be a natural 
substrate for SkR-IRED. 
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3.4.3 Biotransformations using SkR-IRED 
A range of imines (Figure 3.9) were investigated as substrates for SkR-IRED in the 
presence of NADPH. The reactions were analysed using HPLC. For substrate 1a, the 
reaction was carried out on a larger scale with the use of a glucose-6-phosphate 
dehydrogenase-based NADPH recycling system.  
 
Figure 3.9: The range of imines tested as substrates for SkR-IRED 
 
The outcome of the biotransformation experiments is outlined in Table 3.1. Reactions 
for which conversion is observed are outlined in Figure 3.10. 
Table 3.2: Summary of data obtained from HPLC analysis of biotransformations of 









1a 22.6 100 R 
3a 15.7 25 R 










Figure 3.10: A summary of substrates accepted by SkR-IRED in biotransformation 
experiments. High ee values are observed for the conversion of 1a and 8a. For the 
biotransformation of 1a, an NADPH recycling system was used where *G6P is glucose-
6-phosphate, **6PGL is 6-phosphoglucanolactone, and ***G6PDH is glucose-6-
phosphate dehydrogenase. 
 
IRED activity of SkR-IRED was found to be confined mostly to substrate 1a and 8a, 
suggesting a possible preference of SkR-IRED for substituted 5- and 6-membered 
cyclic imines. SkR-IRED displayed either modest or limited activity towards fused ring 
systems 2a – 5a, and no activity towards β-carboline imines 6a and 7a. 
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For substrates 1a and 8a, SkR-IRED displayed a strong preference for the formation 
of the corresponding (R)- and (S)-amine respectively. This apparent reversal of 
stereoselectivity for substrate 8a is an artefact of Cahn-Ingold-Prelog nomenclature 
rules as opposed to any fundamental changes in enantioselectivity. 
3.4.5 Mechanism proposal for SkR-IRED 
Structurally related enzymes 
Structurally similar enzymes were sought in order to provide insight into the 
previously uncharacterised mechanism of SkR-IRED. A DALI structural alignment 
showed that SkR-IRED shares the most similarity with members of the gamma-
hydroxybutyrate dehydrogenase (GHBDH) and β-hydroxyisobutyrate dehydrogenase 
(HIBDH) families. HIBDH from Thermus thermophilus HB8 was used as an illustrative 
example.67 
2CVZ and SkR-IRED were structurally aligned (Figure 3.11). Their superimposition 
highlights the structural similarity of the two enzymes, where the structure of the N-
terminal helical domain is almost totally conserved. While the C-terminal helical 
domain also shares a high degree of structural similarity, their orientations are 





Figure 3.11: The superimposition of the structures of SkR-IRED (red) and HIBDH 
(blue). The overlay demonstrates very high structural similarity between the two 
enzymes, where there is almost complete conservation between the two N-terminal 
Rossman fold subdomains (right). There is also significant conservation between the 
two C-terminal helical domains. However, in HIBDH a sharp β-turn occurs at residue 
Ser204, thereby turning C-terminal domain back towards the N-terminal domain. 
Such a feature is not observed in SkR-IRED, causing the N-terminal domain to 
protrude from the C-terminal domain.67 
The differences in the orientation of the C-terminal helical domain of SkR-IRED and 
2CVZ explain why the unusual reciprocal domain sharing phenomenon is possible in 
SkR-IRED, but not in structurally related enzymes such as HIBDH. 
Mechanistic information from 2CVZ 
In other NADPH-dependent oxidoreductases such as HIBDH, a protic amino acid 
residue in the vicinity of the nicotinamide ring of the NADPH cofactor and the region 
occupied by the substrate is required in order to provide a proton to the hydroxyl 
group of the substrate in the reductive direction. In HIBDH, this role is fulfilled by 
Lys165, which donates a proton to β-hydroxyisobutyrate to form the corresponding 




Figure 3.12: The mechanism for the reduction of 2-methyl-3-oxopropoanoate by β-
hydroxyisobutyrate dehydrogenase from Thermus thermophilus (HIBDH). Residue 
Lys165, which is proximal to both the NADPH cofactor and β-hydroxyisobutyrate 
substrate behaves as a proton donor to facilitate the formation of the corresponding 
alcohol.67 
The superimposition of the active sites of HIBDH and SkR-IRED showed that the 
catalytically active Lys165 residue of 2CVZ is substituted by residue Asp178 in the 





Figure 3.13: The superimposition of the active sites of 2CVZ (purple) and SkR-IRED 
(red) shows that residue Asp187 occurs in the equivalent position in SkR-IRED to the 
catalytically active Lys165 residue of 2CVZ. 
Based on the similarities of the overall structures and active site topology of SkR-IRED 
and 2CVZ, it was proposed that the mechanism of SkR-IRED could proceed in a similar 
manner, where residue Asp187 of SkR-IRED could be catalytically active in the 
reduction of imines such as 1a, as opposed to residue Lys165 of HIBDH in the 
reduction of β-hydroxyisobutyrate (Figure 3.14). The proposed mechanism is 




Figure 3.14: The mechanism proposed for the reduction of imines (such as 1a) by 
SkR-IRED. A proton is donated to 1a by catalytic residue Asp187, resulting in the 
formation of an activated iminium ion. Hydride is then delivered to the iminium ion 
by NADPH to form the corresponding (R)-amine. 
3.4.6 Investigations towards the proposed mechanism of SkR-IRED 
The SkR-IRED mutant Asp187Ala was generated for use in imine reduction assays to 
assess whether the Asp187 residue is necessary for catalysis. The Ala sidechain is 
aprotic, and incapable of carrying out the proposed protonation for the reduction of 
imines as shown in the mechanism in figure 3.14. Therefore, if the resultant mutant 
does not possess imine reduction activity, this would support the suggestion that 
residue Asp187 is required for catalysis.  
Site-directed mutagenesis 
The wild-type gene was used as a template for the generation of mutant Asp187Ala 
by site-directed mutagenesis (SDM). The SDM reaction was digested with DpnI to 
remove template DNA and used to transform E. coli cells. DNA was isolated from a 
resultant colony using a miniprep kit, and submitted for sequencing at GATC Biotech. 
The gene in the isolated DNA was found to have 100 % sequence identity to the target 
Asp187Ala mutated gene.  
Expression and purification of SkR-IRED mutant 
SkR-IRED was expressed in the pET-YSBLIC3C vector in E. coli BL21 (DE3) cells in 2 L 
LB-Kan medium at the optimal expression temperature for the wild-type protein of 
16 °C.  Protein was initially purified from lysed, resuspended cells by nickel affinity 
chromatography. 
SkR-IRED Asp187Ala was subsequently purified by size exclusion chromatography 
(Figure 3.15) using a Superdex® HiLoad 75 gel filtration column. Protein-containing 





Figure 3.15: Chromatogram of the purification of SkR-IRED Asp187Ala by size 
exclusion chromatography. The presence of protein is detected using absorbance 
measurements at 280 nm, which is indicated by the blue trace.  
The chromatogram from SEC purification contained a cluster of peaks with an elution 
volume of 55 – 67 mL. There is a shoulder main peak at 50 – 55 mL elution volume 
which may be due to impurities. Using a calibration curve provided by GE Healthcare, 
the elution volume could be used to estimate a protein molecular weight of 
approximately 60 kDa that the dimeric structure of the wild-type protein had been 
preserved.  
Protein-containing fractions from both the main peak and shouldering peak were 
analysed by SDS-PAGE (figure 3.14). All fractions appeared to contain pure SkR-IRED. 
Proteins eluted in the shoulder peak may have corresponded to heavier oligomers of 
SkR-IRED Asp187Ala and were therefore discarded. Only minor quantities of E. coli 































Figure 3.16: SDS-PAGE gel analysis of purification of SkR-IRED Asp187Ala by size 
exclusion chromatography. Lane 1: Bio-Rad low range molecular weight marker, lane 
2: crude cell lysate, lane 3: sample of protein pooled following nickel-affinity 
chromatograpy, lanes 3-15: fractions containing purified protein eluted between 49 
and 66 mL buffer. Purified SkR-IRED Asp187Ala is observed to be approximately 32 
kDa by SDS-PAGE. 
Kinetic assays using SkR-IRED mutant 
A spectrophotometric-based NADPH-depletion assay was used to assess the kinetic 
parameters of SkR-IRED Asp187Ala towards the standard substrate 1a under the 
same conditions used for the wild-type protein. No NADPH-depletion was observed 
for 1a concentrations between 1 and 30 mM. The results suggested that residue 
Asp187 is necessary for catalysis.  
Asp187 as a catalytic residue 
The generation of mutant Asp187Ala resulted in an enzyme that was devoid of activity 
according to a spectrophotometric-based NADPH-depletion assay, which supports 
that this residue may be necessary for catalysis. However, the bond distance between 
the Asp187 residue and the C4 atom of the nicotinamide ring of the NADPH cofactor 
is 7.86 Å (Figure 3.17). In HIBDH, the distance between the catalytic Lys165 residue 
and the C4 of NADPH is 4.4 Å, which facilitates Lys165 to act as a direct proton 
donor67. This suggests that Asp187 may protonate 1a directly, unless a large domain 
shift occurs upon binding of the imine substrate. It may be the case that mutation of 
Asp187 renders the mutant inactive due to a change in the physical properties of the 
enzyme. Alternatively, it is possible that Asp187 may protonate 1a via an activated 
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water molecule. Further investigation would be required in order to ascertain the 
precise role of Asp187 in catalysis. 
 
Figure 3.17: The active site of SkR-IRED. The dashed line illustrates the bond distance 
of 7.9 Å between the C4 atom of NADPH (from which hydride is delivered to the 
substrate) and the potentially catalytic residue Asp187, further than the 4.4 Å Lys165-
NADPH C4 distance observed in the homologue HIBDH, where direct protonation 
from the protic Lys165 to the substrate occurs. 
3.4.7 Investigation of physiological role of SkR-IRED 
The limited catalytic efficiency of SkR-IRED towards 1a described in the kinetic 
analysis of this reaction in section 3.4.2 indicates that this is not likely to be a natural 
substrate of SkR-IRED. The physiological function of SkR-IRED is therefore currently 
unknown. If a natural substrate is determined, this will provide information on the 
type of substrate that is most readily accepted by SkR-IRED, and provide insight 
towards substrates which may be efficiently converted by the enzyme. 
In the structural solution for SkR-IRED, an unassigned region of electron density is 
observed in the active site (Figure 3.18). It was proposed that this may provide insight 





Figure 3.18: A region of unassigned electron density in the active site of SkR-IRED in 
the vicinity of the putative catalytic residue Asp187. 
Screening for activity towards dihydrofolate and methotrexate 
It was suggested that the unassigned electron density in the active site of SkR-IRED 
could be attributed to a folate derivative such as dihydrofolate (Figure 3.19), as this 
is a known substrate for the naturally occurring imine reductase dihydrofolate 
reductase (DHFR).  
 
Figure 3.19: The chemical structure of dihydrofolate, a known substrate for the imine 
reductase DHFR. 
A UV-Vis spectrophotometric-based NADPH depletion assay was used to assess 
whether dihydrofolate behaved as a substrate for SkR-IRED. Additionally, it was 
assessed whether the presence of DHFR inhibited the activity of SkR-IRED towards a 
known substrate 1a, as this would also indicate active site binding. However, no 




The dihydrofolate mimic methotrexate (Figure 3.20) was also investigated for both 
substrate and inhibitor behaviour towards SkR-IRED, as this is a known inhibitor of 
the imine reductase DHFR. However, no substrate activity was observed, and the 
presence of methotrexate had no effect on the activity of SkR-IRED towards 1a. 
 
Figure 3.20: The chemical structure of methotrexate, a known inhibitor for the imine 
reductase DHFR. 
Mass spectrometry investigations 
In an effort to identify the unassigned electron density in the active site of SkR-IRED, 





Figure 3.21: Mass spectrum of purified SkR-IRED using electrospray ionisation. Two 
intense peaks are observed in a feasible mass region for potential substrates which 
may explain the unassigned density in the enzyme active site. The accurate masses of 
the peaks suggest a molecular formula of C27H33N5O5 and C22H21N3O5 for m/z = 
507.24806 and 408.15574 respectively. 
The two most intense peaks in the lower mass region of the mass spectrum 
correspond to molecular formulae of C27H33N5O5 and C22H21N3O5 according to their 
accurate masses. Both ions were resistant to further fragmentation with increasing 
amounts of collision energy, which would not be expected with an imine, as 
fragmentation should occur readily across the carbon-nitrogen double bond. No 
matches were found for the  E. coli metabolome database (ECMB) for the masses of 
formulae corresponding to the two intense peaks. 
This prevented any chemical structures being proposed from the molecular formulae.  
Screening for reductive amination activity 
Opine dehydrogenases (OpDHs) are NAD(P)H-dependent enzymes that catalyse the 
reductive condensation of L-amino acids with α-keto acids. The primary function of 
OpDHs is to oxidise glycolytically generated NAD(P)H to form NADP+, which sustains 
the glycolytic cycle which generates ATP under anaerobic conditions during short, 
intense periods of muscular activity in invertebrates.68 In such reactions, an imine is 
m/z = 507.24806 
m/z = 408.15574 
92 
 
formed in-situ by the condesnation of L-amino acid and α-keto acid, which is 
subsequently reduced by OpDH and NADPH (Figure 3.22).  
It was proposed that the density observed in the active site could represent a 
conjugated L-amino acid and α-keto acid, which would indicate that the natural 
function of SkR-IRED was that of an OpDH. 
 
Figure 3.22: The condensation and reduction of an L-amino acid and α-keto acid by 
an opine dehydrogenase (OpDH) and NADPH to form a product containing a newly 
formed amine moiety. 
In order to investigate the presence of OpDH activity in SkR-IRED, activities towards 
several combinations of L-amino acids and α-keto acids outlined in Table 3.3 were 
measured. Amino acids were selected to include a broad range of side chain 
properties, including; positively charged (arginine and histidine), hydrophobic 
(leucine), aromatic (phenylalanine), negatively charged (glutamic acid), and compact 
(alanine) acids. 
One mL reactions containing SkR-IRED (0.44 mg mL-1), NADPH (0.2 mM), L-Amino 
acid (10 mM) and α-keto acid (10 mM) in Tris.HCl buffer (pH 7.5, 50 mM) were 




Table 3.3: Combinations of α-keto acids and L-amino acids used in opine 
dehydrogenase activity tests with SkR-IRED 
  α-Keto acid 










Arginine  No activity No activity No activity 
Isoleucine  No activity No activity No activity 
Phenylalanine  No activity No activity No activity 
Glutamic acid No activity No activity No activity 
Histidine No activity No activity No activity 
Alanine No activity No activity No activity 
 
No NADPH depletion was detected in the assay for any combinations of α-keto acid 
and L-amino acid, indicating that SkR-IRED does not display opine dehydrogenase 
activity for the substrates tested. Therefore, this is unlikely to be the physiological 
role of SkR-IRED. 
Possible role of SkR-IRED in typtophan dimer formation 
Tryptophan dimers (TDs) are formed by the oxidation and subsequent dimerization 
of tryptophan, and are precursors to a diverse collection of bacterial natural products. 
TDs are frequently associated with biological activity, such as antibacterial and 
antifungal properties, which suggests that these may be a useful scaffold for bioactive 
natural products.69, 70 
Brady and co-workers reported the characterization of the pathway towards the TD 
reductasporine (Figure 3.23), which acts as a biosynthetic precursor for a natural 
product possessing antifungal bioactivity. This gene cluster was identified during 




Figure 3.23: The chemical structure for reductasporine; a tryptophan dimer (TD) 
with antifungal properties.70 
The pathway involves an imine reduction step, performed by an IRED which is termed 
RedE (Figure 3.24).70 
 
Figure 3.24: An imine reduction step performed by IRED RedE in the biosynthetic 
pathway of reductasporine, a tryptophan dimer (TD) with antifungal properties.70 
The closest relative of RedE was found to be SkR-IRED. The role of RedE in the 
reduction of the pyrrole ring in the synthesis of reductasporine is consistent with the 
ability of SkR-IRED to reduce the similar pyrroline 1a. It is possible that the natural 
function of SkR-IRED is in TD formation in a biosynthetic pathway similar to that 
which is catalysed by RedE. 
 





During this study, SkR-IRED has been recombinantly expressed and purified. Purified 
protein has been used in assays to assess the substrate scope and kinetic parameters 
for the enzyme. Biotransformations with a number of imines demonstrated that SkR-
IRED is able to convert substituted 5-membered pyrrolines and 6-membered 
piperideines to the corresponding (R)-amines (or (S)-amines in instances where 
nomenclature is reversed according to Cahn-Ingold-Prelog rules).  
For the conversion of 1a to the corresponding amine 1b, the KM was 8.21 mM and the 
kcat 0.0264 s-1, indicating a relatively low catalytic efficiency that suggests that 1a is 
not a natural substrate for the enzyme. SkR-IRED converted imines 1a and 8a to the 
corresponding (R)- and (S)-amine with 100 % ee.60 
Structural observations indicated that Asp187 may provide a role in catalysis, which 
was reinforced by the fact that the mutant Asp187Ala lost activity towards 1a. 
However, bond distances between the Asp187 hydroxyl and the C4 carbon of NADPH, 
from which hydride is delivered, were too large to suggest direct protonation from 
Asp187Ala. Further investigation would be required to determine the exact role of 
Asp187 in catalysis.60 
Despite investigations into the physiological role of SkR-IRED by screening for activity 
towards or inhibitory effects from dihydrofolate and methotrexate, screening for 
opine dehydrogenase activity and investigations of active site density using mass 
spectrometry, no native substrates were identified for SkR-IRED from experimental 
work. However, research work was published subsequently by Brady and co-workers 
revealed a close homologue to SkR-IRED which plays a role in the formation of 
reductasporine, a tryptophan dimer (TD) with antifungal properties, which might 
suggest that SkR-IRED plays a similar biosynthetic role.70 
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4. Isolation, application, structure and mechanism of SS-IRED, an (S)-
selective NADPH-dependent imine reductase from Streptomyces sp. 
GF3546  
4.1 Introduction 
The characterization of an (R)-selective imine reductase (IRED) has been described 
in section 3. At the start of this project, there were no known 3D-structures of an (S)-
selective IRED. This will outline a a collaborative effort with colleagues at the 
Manchester Institute of Biotechnology to thoroughly characterise an (S)-selective 
imine reductase. As described in section 3, a broad ranging screen of organisms for 
activity towards imine 1a lead to the discovery of two organisms that catalysed the 
reduction of this substrate to the corresponding amine 1b; Streptomyces sp. GF3587 
and Streptomyces sp. GF3546, which catalysed the formation of (R)-1a and (S)-1b with 
99.2 % and 92.3 % ee respectively.54 The two enzymes associated with the reactions 
were termed SR-IRED and SS-IRED. As at the start of this project, SS-IRED was the only 
imine reductase with confirmed (S)-selective activity towards substrate 1a, this 
enzyme will be used as model for the study for (S)-selective imine reductases. 
4.2 Aims 
The primary aim of this project will be to characterise the structure of SS-IRED using 
X-ray crystallography, which may be used to inform the mechanism of (S)-selective 
imine reductases, rationalise the differences in selectivity to (R)-selective imine 
reductases and serve as a basis for rational engineering towards increased substrate 
scope and improved catalytic properties. This will be carried out as complementary 
work to collaborators at the Manchester Institute of Biotechnology, who will focus 
mainly on the chemical applications of the enzyme. 
The gene will be subcloned into the house expression vector pET-YSBLIC3C, 
recombinantly expressed in E. coli and purified. Crystallization conditions will then 
be established, and any crystals formed will be used in X-ray diffraction experiments 
to determine the enzyme structure.  
Enzyme kinetic behaviour will be compared with SkR-IRED, the (R)-selective IRED 
described in Chapter 3. The two enzyme structures will be compared to rationalise 
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these differences as well as differences in enantioselectivity, which will contribute 
towards an overall understanding of NADPH-dependent IREDs as an enzyme family. 
4.3 Results 
4.3.1 Amplification of target genes 
Primers with LIC extensions were used for the amplification of the gene coding for SS-
IRED. A synthetic gene with coding for SS-IRED with codon optimisation for 
expression in E. coli was used as a template for PCR amplification. The PCR reaction 
product was visualised by agarose gel electrophoresis (Figure 4.1). 
 
Figure 4.1: Agarose gel visualising the amplification of the gene coding for SS-IRED 
by PCR. Lane 1: NEB 1 kB ladder, lane 2: PCR product of gene coding for SS-IRED 
A bright band at the expected length of approximately 900 bp is observed in the 
analysis of the amplification of SS-IRED. The band was excised and purified.  
4.3.2 Subcloning into pET-YSBLIC3C expression vector 
The purified SS-IRED gene was treated with T4 DNA polymerase and annealed to 
linearized T4 DNA polymerase-treated pET-YSBLIC3C vector. E. coli was transformed 
with the annealed plasmid and DNA isolated. A diagnostic restriction digest was 
carried out on the purified plasmid to assess for the presence of an appropriately 




Figure 4.2: Agarose gel visualising restriction digest of gene coding for SS-IRED 
subcloned into the pET-YSBLIC3C expression vector. Lane 1: NEB 1 kB ladder. Lane 
2: pET-YSBLIC3C plasmid containing S-IRED gene, digested with NcoI and NdeI. Two 
bands are observed in lane 2; the pET-YSBLIC3C vector backbone (~5.5 kB) and the 
SS-IRED gene (~900 bp) 
The restriction digest showed an appropriately sized insert of approximately 900 bp 
arising from the gene coding for SS-IRED. The agarose gel indicated that the cloning 
experiment had been successful, and the corresponding plasmid was submitted for 
sequencing analysis. 
DNA sequencing 
The DNA sample corresponding to lane 2 in figure 4.1 was submitted for sequencing 
at GATC Biotech. DNA sequencing confirmed that the gene present in the sample had 
100 % sequence identity with the target sequence. 
4.3.3 Large scale expression and purification 
SS-IRED was expressed in the pET-YSBLIC3C vector in E. coli BL21 (DE3) cells in 2 L 
LB-Kan medium at the previously established optimal expression temperature of 16 
°C.  Protein was initially purified from lysed, resuspended cells by nickel affinity 
chromatography, and protein samples were analysed by SDS-PAGE to assess protein 




Figure 4.3: SDS-PAGE gel analysis of purification of SS-IRED by nickel affinity 
chromatography. Lane 1: Bio-Rad low range molecular weight marker, lane 2: 
unbound flow-through collected during loading of nickel column, lanes 3 – 14: 
fractions containing purified protein eluted during increasing imidazole gradient. 
Purified SS-IRED is observed to be approximately 32 kDa by SDS-PAGE. 
SS-IRED was subsequently purified by size exclusion chromatography (Figure 4.4) 
using a Superdex® HiLoad 75 gel filtration column. Fractions which showed 





Figure 4.4: Chromatogram of the purification of SS-IRED by size exclusion 
chromatography. The presence of protein is detected using absorbance 
measurements at 280 nm, which is indicated by the blue trace. 
 
SS-IRED was eluted in a large peak between 40 – 67 mL buffer.  The peak was broader 
due to shoulders at both sides, possibly due to high protein volumes loaded onto the 
column. The elution volume of the protein corresponded to a molecular weight of 
approximately 60 kDa in a calibration curve provided by GE healthcare, indicating 
that SS-IRED was present as a dimer in solution, similarly to SkR-IRED (Chapter 3). 
































Figure 4.5: SDS-PAGE gel analysis of purification of SS-IRED by size exclusion 
chromatography. Lane 1: Bio-Rad low range molecular weight marker, lanes 2 – 9: 
fractions containing purified protein. Purified SS-IRED is observed to be 
approximately 32 kDa by SDS-PAGE. 
SDS-PAGE analysis indicated that purified SS-IRED was highly homogeneous and free 
of contaminant host proteins from E. coli. 
4.3.4 Cleavage of 6His tag 
For use in crystallization trials, SS-IRED with its N-terminal 6His tag removed was 
prepared for use in addition to the N-terminally tagged construct, as the presence or 
absence of this tag can have a strong influence on the crystallization behaviour of a 
protein. After purification by nickel-affinity chromatography, an aliquot of SS-IRED 
was removed. The imidazole from the protein buffers was removed by dialysis 
overnight. SS-IRED was then incubated with HRV3C protease. Uncleaved SS-IRED and 
HRV3C protease, which are both 6His-tagged, were separated from SS-IRED using a 
second round of nickel-affinity chromatography. Cleaved SS-IRED was found in the 
flowthrough fractions, as its lack of 6His tag prevented binding to the column.  
Cleaved SS-IRED was then purified by size exclusion chromatography using a 
Superdex® HiLoad 75 gel filtration column (Figure 4.6). Protein-containing fractions 




Figure 4.6: Chromatogram of the purification of SS-IRED, after cleavage of its 6His 
tag, by size exclusion chromatography. The presence of protein is detected using 
absorbance measurements at 280 nm, which is indicated by the blue trace. 
SS-IRED was eluted in a narrow peak with 57 – 63 mL buffer.  Protein-containing 
fractions were analysed by SDS-PAGE (Figure 4.7). Distortion is visible at the tip of 
the peak due to the absorbance value exceeding the capacity of the UV detector. The 
protein appeared to be homogeneous, and had lost the expected molecular weight of 






























Figure 4.7: SDS-PAGE gel analysis of purification of SS-IRED by size exclusion 
chromatography. Lane 1: Bio-Rad low range molecular weight marker, lanes 2 – 9: 
fractions containing purified protein. Purified SS-IRED is observed to be 
approximately 30 kDa by SDS-PAGE. 
4.4.5 Structure determination 
The structure of SS-IRED was investigated using X-ray crystallography in order to 
rationalise differences in substrate specificity and selectivity compared to (R)-
selective IDEDs such as SkR-IRED (Chapter 3) and (S)-selective IREDs. The ultimate 
aim is to provide a sufficient understanding of SS-IRED to serve as a basis for the 
rational engineering of the enzyme  
Crystallization of SS-IRED 
SS-IRED both with and without its N-terminal 6His tag was subjected to a broad range 
of commercially available crystallization screens in a 96-well sitting drop format; 
PACT, INDEX, CSS 1 and 2, Hampton 1 and 2, the PEG ion screen and the MPD screen. 
Screens were dispensed with 300 nL drops consisting of a 1:1 v/v ratio of purified 
protein and precipitate. Crystals for SS-IRED were obtained with 6His-cleaved protein 
at a concentration of 120 mg mL-1 in DL-malic acid (2.1 M, pH 7.0) and sodium citrate 
tribasic dihydrate (1.4 M) (Figure 4.8).  As crystals could not be reproduced at 
increased scale, data collection was carried out on crystals obtained directly from the 




Figure 4.8: Crystals of SS-IRED cleaved of N-terminal 6His tag obtained with protein 
at 120 mg ml-1  in 2.1 M DL-malic acid pH 7.0 (left) and 0.1 M HEPES pH 7.5, 1.4 M 
sodium citrate tribasic dehydrate (right). 
Data collection 
Crystals could not be reproduced in a 24-well hanging drop format. Therefore, the 
original crystals in the 96-well sitting drop crystallization screen pictured in Figure 
4.8 were used for X-ray diffraction experiments at Diamond synchrotron using the I-
04 beamline. The crystals obtained in 2.1 M DL-malic acid pH 7.0 diffracted to 3.2 Å 
resolution.  
Structural solution 
The structure was solved using a molecular replacement strategy based on the 
structure of SkR-IRED.  
The alignment of the protein sequences of SS-IRED and SkR-IRED (Figure 4.9) shows 
that the two IREDs share 68.9 % sequence similarity and 38.2 % sequence identity. 
The GXGXXG motif is conserved between the two enzymes as GLGPMG in SS-IRED and 
GLGLMG in SkR-IRED. In place of the ‘catalytic’ SkR-IRED-Asp187 residue in the 





SS-IRED       ----------------MSKQSVTVIGLGPMGQAMVNTFLDNGHEVTVWNRTASKAEALVA 44 
SkR-IRED      MPDNPSTKGRMMRNQQAEHTPVTVIGLGLMGQALAGAFLGAGHPTTVWNRTAAKAEPLVA 60 
                               .:  ******* ****:..:**. ** .*******:*** *** 
 
SS-IRED       RGAVLAPTVEDALSANELIVLSLTDYDAVYAILEPVTGS-LSGKVIANLSSDTPDKAREA 103 
SkR-IRED      RGAKSAGSVAEAVAASPLVVVCVSDYDAVHALLDPLDGTALQGRTLVNLTSGTSAQARER 120 
              ***  * :* :*::*. *:*:.::*****:*:*:*: *: *.*:.:.**:*.*  :***  
 
SS-IRED       AKWAAKHGAKHLTGGVQVPPPLIGKPESSTYYSGPKDVFDAHEDTLKVL-TNADYRGEDA 162 
SkR-IRED      AAWADGRGADYLDGAILAGPAAIGTADAVVLLSGPRSAFDPHASALGGLGAGTTYLGADH 180 
              * **  :**.:* *.: . *  **. :: .  ***:..** * .:*  * :.: * * *  
 
SS-IRED       GLAAMYYQAQMTIFWTTMLSYYQTLALGQANGVSAKELLPYATMMTSMMPHFLELYAQHV 222 
SkR-IRED      GLASLYDAAGLVMMWSILNGFLQGAALLGTAGVDATTFAPFITQGIGTVADWLPGYARQI 240 
              ***::*  * :.::*: : .: *  **  : **.*. : *: *   . : .:*  **::: 
 
SS-IRED       DSADYPGDVDRLAMGAASVDHVLHTHQDAGVSTVLPAAVAEIFKAGMEKGFAENSFSSLI 282 
SkR-IRED      DDGAYPADDAAIDTHLATMEHLIHESEFLGVNAELPRFIKALADRAVADGHGGSGYPALI 300 
              *.. **.*   :    *:::*::*  :  **.: **  :  : . .: .*.. ..: :** 
 
SS-IRED       EVLKKPAV- 290 
SkR-IRED      EQFRTHSGK 309 
              * ::. :  
 
Figure 4.9: Protein sequence alignment of SS-IRED (top) and SkR-IRED (bottom). The 
GXGXXG NADPH-binding motif which is conserved between the two sequences is 
highlighted in blue. The ‘catalytic’ Asp187 residue of SkR-IRED aligns with Tyr169 in 




The unit cell contained four monomers (A – D) arranged as two pairs of homodimers 
(A-B and C-D). A monomer of SS-IRED, represented by subunit A in Figure 4.10, shares 
many of its structural features with SkR-IRED; an N-terminal Rossman fold motif 
charactistic of NADPH binding proteins (Met1 - Gly163) and a C-terminal helical 
domain (Gly194 – Val290), connected by a long inter-domain helix (Leu164 - Asn193). 









Wavelength (Å) 0.97626 
Resolution (Å) 73.80-3.19 (3.27-3.19) 
Space Group P212121 
Unit cell (Å) a = 85.9, b = 87.7; c = 136.7 
 =  =  = 90° 
No. of molecules in the asymmetric unit 4 
Unique reflections 17782 (1292) 
Completeness (%) 99.9 (99.9) 
Rmerge (%) 0.13 (0.89) 
Rp.i.m. 0.08 (0.56) 
Multiplicity 6.5 (6.4) 
<I/(I)> 12.9 (2.4) 
CC1/2 1.00 (0.72) 
Overall B factor from Wilson plot (Å2) 58 
Rcryst/ Rfree (%) 25.4/32.7 
r.m.s.d 1-2 bonds (Å)  0.012 
r.m.s.d 1-3 angles (o) 1.56 
Avge  main chain B (Å2) 61 






Figure 4.10: Graphical representation of the 2D-structural description of SS-IRED. β-
helices are represented by blue arrows and α-helices are represented by red barrels. 
The SS-IRED monomer consists of twelve alpha helices: α1 (residues Pro13-Asn20), 
α2 (Val53-Ser58), α3 (Tyr70-Leu77), α4 (Pro97-Lys109), α5 (Pro123-Leu125), α6 
(Val141-Ala144), α7 (Glu146-Leu149), α8 (Ala164-Ala192), α9 (Ala197-Ser224), α10 
(Leu234-Gln248) α11 (Val256-Glu170) and α12 (Ile282-Leu285) and seven beta 
sheets: β1 (Val6-Ile9), β2 (Val29-Val31), β3 (Leu62-Val64), β4 (Val87-Asn90), β5 
(Lys113-Val119), β6 (Ser132-Ser136) and β7 (Asn154-Asp156). This information is 
also outlined graphically in Figure 4.11, which emphasises that the N-terminal 
Rossman fold domain includes a mixture of α-helices and β-sheets, while the C-




Figure 4.11: Graphical representation of the 2D-structural description of SS-IRED. β-
helices are represented by blue arrows and α-helices are represented by red 
barrels.71-74 
The active form of the enzyme is a dimer which is represented in Figure 4.12 by 
subunits A and B. As is the case for SkR-IRED, the SS-IRED dimer exhibits a domain 
swapping arrangement where the inter-domain helix of each subunit interlocks with 
the helical domain of the opposite subunit. Analysis by the EBI PISA tool showed that 
the surface area of the interface between chains A and B is 3867 Å2, indicating 
substantial contact between the two subunits of comparable magnitude to the 3761 





Figure 4.12: The crystal structure of SS-IRED in its apo form at 3.2 Å resolution. The 
monomer consists of an N-terminal Rossman fold motif and a C-terminal helical 
domain connected by a long interdomain helix (Ala164-Ala192). Dimer formation is 
facilitated by the reciprocal domain sharing of the two monomeric subunits A (green) 
and B (blue). 
A structural overlay of SS-IRED and SkR-IRED is pictures in Figure 4.13. The overlay 
highlights that SS-IRED-Tyr169, which aligns with SkR-IRED-Asp187 in the sequence 
alignment in Figure 4.9, also aligns structurally. In chapter 3, it was concluded that 
Asp187 may have some importance in enzyme mechanism. It is a possibility that 
Tyr169 may be of catalytic importance in SS-IRED in place of Asp187 in SkR-IRED. 






Figure 4.13: Structural overlay of the putative active sites of SkR-IRED and SS-IRED. 
The image shows that the possible catalytic residue Asp187 of SkR-IRED is replaced 
by Tyr169 in SS-IRED. 
A structural similarity search on the structure of SS-IRED using the DALI search 
yielded that, aside from structures of other IREDs that have recently been solved, SS-
IRED shares the most structural similarity with the protein with PDB accession 
number 316D, a putative oxidoreductase from Pseudomonas putida KT2440. 
Interestingly, 316D shares the unusual domain-swapping arrangements exhibited in 
IREDs, but as yet its function is unknown. 
Knowledge of the apo structure of SS-IRED has confirmed that its 3D structure is very 
similar to that of SkR-IRED. It would now be useful to obtain a complex of the enzyme 
with NADPH and its imine substrates, as this would assist in indicating 
mechanistically important amino acids, as well as the configuration of the imine in the 
active site to help rationalise the selectivity of the enzyme.  
However, attempts to reproduce crystals of SS-IRED with the wild-type protein in the 
original crystallization conditions were unsuccessful. Further techniques, including 
macro-seeding of lower quality crystals of SS-IRED, manipulation of protein and 
precipitant volume ratios, total drop volumes, crystal growth temperatures and the 
use of larger scale hanging drops also failed to produce more SS-IRED crystals. 




In an effort to remedy this, modified constructs of SS-IRED were therefore designed 
in an effort to obtain complexed crystals. 
4.4.6 SS-IRED+, a modified protein for the crystallization of SS-IRED 
Gene design 
SkR-IRED (Chapter 3) could be crystallized readily. However, the crystallization of SS-
IRED was notably more challenging. Therefore, features of SkR-IRED which differed 
heavily from SS-IRED which may contribute towards the relative ease of 
crystallization for this enzyme were sought. 
An alignment of the genes coding for SkR-IRED and SS-IRED showed that SkR-IRED 
has a much longer N-terminus upstream to the consensus sequence (21 amino acids, 
highlighted in blue in Figure 4.14) than SS-IRED (5 amino acids, highlighted in grey in 
Figure 4.14). 
 
Figure 4.14: A sequence alignment of SkR-IRED and SS-IRED. The comparison shows 
that SkR-IRED has a significantly longer N-terminus (highlighted in blue). The N-
terminus of SS-IRED, by contrast, consisted of only 5 amino acids (highlighted in grey).  
In the crystal packing of SkR-IRED, this lengthy N-terminus forms protein-protein 
crystal- contacts with its neighbouring crystallographic subunits, possibly facilitating 
crystallization. A modified construct of SS-IRED with the N-terminus of SkR-IRED was 
SkR-IRED  MPDNPSTKGRMMRNQQAEHTPVTVIGLGLMGQALAGAFLGAGHPTTVWNRTAAKAEPLVA 60 
SS-IRED   -----------MSKQ-----SVTVIGLGPMGQAMVNTFLDNGHEVTVWNRTASKAEALVA 44 
                     * :*     .******* ****:..:**. ** .*******:***.*** 
 
SkR-IRED  RGAKSAGSVAEAVAASPLVVVCVSDYDAVHALLDPLDGTALQGRTLVNLTSGTSAQARER 120 
SS-IRED   RGAVLAPTVEDALSANELIVLSLTDYDAVYAILEPVTG-SLSGKVIANLSSDTPDKAREA 103 
          ***  * :* :*::*. *:*:.::*****:*:*:*: * :*.*:.:.**:*.*. :***  
 
SkR-IRED  AAWADGRGADYLDGAILAGPAAIGTADAVVLLSGPRSAFDPHASALGGLGAGTTYLGADH 180 
SS-IRED   AKWAAKHGAKHLTGGVQVPPPLIGKPESSTYYSGPKDVFDAHEDTLKVLTN-ADYRGEDA 162 
          * **  :**.:* *.: . *. **..:: .  ***:..**.* .:*  *   : * * *  
 
SkR-IRED  GLASLYDAAGLVMMWSILNGFLQGAALLGTAGVDATTFAPFITQGIGTVADWLPGYARQI 240 
SS-IRED   GLAAMYYQAQMTIFWTTMLSYYQTLALGQANGVSAKELLPYATMMTSMMPHFLELYAQHV 222 
          ***::*  * :.::*: : .: *  **  : **.*. : *: *   . :..:*  **::: 
 
SkR-IRED  DDGAYPADDAAIDTHLATMEHLIHESEFLGVNAELPRFIKALADRAVADGHGGSGYPALI 300 
SS-IRED   DSADYPGDVDRLAMGAASVDHVLHTHQDAGVSTVLPAAVAEIFKAGMEKGFAENSFSSLI 282 
          *.. **.*   :    *:::*::*  :  **.: **  :  : . .: .*.. ..:.:** 
 
SkR-IRED  EQFRTHSGK 309 
SS-IRED   EVLKKPAV- 290 
          * ::. :   
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therefore designed in an effort to produce a more readily crystallisable analogue of 
SS-IRED. 
The sequence of SS-IRED was truncated to the consensus sequence of the two proteins 
by removal of its original N-terminus (highlighted grey in Figure 4.14). The N-
terminus of SkR-IRED (highlighted blue in Figure 4.14) was then added to the N-
terminus of SS-IRED. The resultant construct was termed SS-IRED+ (Figure 4.15). 
 
Figure 4.15: The sequence of SS-IRED+ (middle), a modified version of the SS-IRED 
enzyme, in alignment with the original SS-IRED sequence (top) and the sequence of 
SkR-IRED (bottom). The N-terminus of SS-IRED has been truncated to the consensus 
sequence of the two wild-type enzymes SS-IRED and SkR-IRED, and the N-terminus of 
SkR-IRED has been inserted in its place (highlighted in blue). 
The gene coding for SS-IRED+ was codon-optimised for expression in E. coli and 
commercially synthesised.  
Amplification of target gene 
Primers with LIC extensions were designed and commercially synthesised for the 
amplification of the gene coding for SS-IRED+. The synthetic gene coding for SS-IRED 
SS-IRED    -----------MSKQ-----SVTVIGLGPMGQAMVNTFLDNGHEVTVWNRTASKAEALVA 44 
SS-IRED+   MPDNPSTKGRMMRNQQAEHTPVTVIGLGPMGQAMVNTFLDNGHEVTVWNRTASKAEALVA 60 
SkR-IRED   MPDNPSTKGRMMRNQQAEHTPVTVIGLGLMGQALAGAFLGAGHPTTVWNRTAAKAEPLVA 60 
                      * :*     .******* ****:..:**. ** .*******:***.*** 
 
SS-IRED    RGAVLAPTVEDALSANELIVLSLTDYDAVYAILEPVTG-SLSGKVIANLSSDTPDKAREA 103 
SS-IRED+   RGAVLAPTVEDALSANELIVLSLTDYDAVYAILEPVTG-SLSGKVIANLSSDTPDKAREA 119 
SkR-IRED   RGAKSAGSVAEAVAASPLVVVCVSDYDAVHALLDPLDGTALQGRTLVNLTSGTSAQARER 120 
           ***  * :* :*::*. *:*:.::*****:*:*:*: * :*.*:.:.**:*.*. :***  
 
SS-IRED    AKWAAKHGAKHLTGGVQVPPPLIGKPESSTYYSGPKDVFDAHEDTLKVLTN-ADYRGEDA 162 
SS-IRED+   AKWAAKHGAKHLTGGVQVPPPLIGKPESSTYYSGPKDVFDAHEDTLKVLTN-ADYRGEDA 178 
SkR-IRED   AAWADGRGADYLDGAILAGPAAIGTADAVVLLSGPRSAFDPHASALGGLGAGTTYLGADH 180 
           * **  :**.:* *.: . *. **..:: .  ***:..**.* .:*  *   : * * *  
 
SS-IRED    GLAAMYYQAQMTIFWTTMLSYYQTLALGQANGVSAKELLPYATMMTSMMPHFLELYAQHV 222 
SS-IRED+   GLAAMYYQAQMTIFWTTMLSYYQTLALGQANGVSAKELLPYATMMTSMMPHFLELYAQHV 238 
SkR-IRED   GLASLYDAAGLVMMWSILNGFLQGAALLGTAGVDATTFAPFITQGIGTVADWLPGYARQI 240 
           ***::*  * :.::*: : .: *  **  : **.*. : *: *   . :..:*  **::: 
 
SS-IRED    DSADYPGDVDRLAMGAASVDHVLHTHQDAGVSTVLPAAVAEIFKAGMEKGFAENSFSSLI 282 
SS-IRED+   DSADYPGDVDRLAMGAASVDHVLHTHQDAGVSTVLPAAVAEIFKAGMEKGFAENSFSSLI 298 
SkR-IRED   DDGAYPADDAAIDTHLATMEHLIHESEFLGVNAELPRFIKALADRAVADGHGGSGYPALI 300 
           *.. **.*   :    *:::*::*  :  **.: **  :  : . .: .*.. ..:.:** 
 
SS-IRED    EVLKKPAV- 290 
SS-IRED+   EVLKKPAV- 306 
SkR-IRED   EQFRTHSGK 309 
           * ::. :   
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with codon optimisation for expression in E. coli was used as a template for PCR 
amplification. The PCR reaction product was visualised by agarose gel electrophoresis 
(Figure 4.16). 
 
Figure 4.16: Agarose gel visualising the amplification of the gene coding for SS-IRED+ 
by PCR. Lane 1: NEB 1 kB ladder, lane 2: PCR product of gene coding for SS-IRED+. 
A bright band at the expected length of approximately 900 bp is visible in the analysis 
of PCR amplification of the SS-IRED+ gene, which was then excised and purified.  
Subcloning into pET-YSBLIC3C expression vector 
The purified SS-IRED+ gene was treated with T4 DNA polymerase and annealed with 
linearised T4 DNA polymerase-treated pET-YSBLIC3C vector. E. coli was transformed 
with the annealed plasmid. DNA was isolated and a diagnostic restriction digest 






Figure 4.17: Agarose gel visualising restriction digest of gene coding for SS-IRED+ 
subcloned into the pET-YSBLIC3C expression vector. Lane 1: NEB 1 kB ladder. Lane 
2: pET-YSBLIC3C plasmid containing SS-IRED+ gene, digested with NcoI and NdeI. 
Two bands are observed in lane 2; the pET-YSBLIC3C vector backbone (~5.5 kB) and 
the SS-IRED+ gene (~1000 bp) 
The restriction digest showed an appropriately sized insert of approximately 1000 bp 
arising from the gene coding for SS-IRED+. The agarose gel indicated that the cloning 
experiment had been successful, and the corresponding plasmid was submitted for 
sequencing analysis. 
DNA sequencing 
The DNA sample corresponding to lane 2 in Figure 4.14 was submitted for sequencing 
at GATC Biotech. DNA sequencing confirmed that the gene present in the sample had 
100 % sequence identity with the target SS-IRED+ sequence. 
Small-scale expression testing 
As SS-IRED+ was a novel construct, expression was tested in 10 mL scale in order to 
determine the optimum growth temperature for the production of soluble 
recombinant protein. Samples were incubated (37 °C, 180 rpm) until an OD600 of 0.8 
was reached. Cultures were induced with IPTG and incubated (180 rpm, 20 h) at 
multiple growth temperatures; 16, 30 and 37 °C. Samples from both soluble and 





Figure 4.18: SDS-PAGE analysis of small scale expression test for the production of 
SS-IRED+. Lane 1: BioRad low range molecular weight marker. Lane 2: Insoluble 
fraction for uninduced control cells. Lanes 3 – 5: Insoluble fractions for expression at 
16, 30 and 37 °C respectively. Lane 6: Soluble fraction for uninduced control cells. 
Lanes 7 – 9: Soluble fractions for expression at 16, 30 and 37 °C respectively. The 
target protein is present in both soluble and insoluble fractions for all induced 
samples.  
The expression tests demonstrated that soluble expression was present at all growth 
temperatures. The highest levels of soluble expression were achieved at a growth 
temperature of 16 °C (lane 7). This condition was therefore employed for large scale 
expression of SS-IRED+. 
Large scale expression and purification 
SS-IRED+ was expressed in the pET-YSBLIC3C vector in E. coli BL21 (DE3) cells in 2 L 
LB-Kan medium at the previously established optimal expression temperature of 16 
°C.  Protein was initially purified from lysed, resuspended cells by nickel affinity 
chromatography, and protein samples were analysed by SDS-PAGE to assess protein 




Figure 4.19: SDS-PAGE gel analysis of purification of SS-IRED+ by nickel affinity 
chromatography. Lane 1: Bio-Rad low range molecular weight marker, lane 2: crude 
cell lysate, lane 3: unbound flow-through fraction collected during loading of nickel 
column, lanes 4 – 14: fractions containing purified protein eluted during increasing 
imidazole gradient. Purified SS-IRED+ is observed to be approximately 32 kDa by SDS-
PAGE. 
SS-IRED+ was subsequently purified by size exclusion chromatography (Figure 4.20) 
using a Superdex® HiLoad 75 gel filtration column. Protein-containing fractions were 





Figure 4.20: Chromatogram of the purification of SS-IRED+ by size exclusion 
chromatography. The presence of protein is detected using absorbance 
measurements at 280 nm, which is indicated by the blue trace. 
 
SS-IRED was eluted in a single sharp peak at 58 - 66 mL buffer. Using a calibration 
curve provided by GE Healthcare, the elution volume could be used to estimate a 
protein molecular weight of approximately 60 kDa, indicating that the dimeric 
structure of SS-IRED had not been disrupted by the modification of the N-terminus. 
Protein-containing fractions were analysed by SDS-PAGE (figure 4.18). The protein 































Figure 4.21: SDS-PAGE gel analysis of purification of SS-IRED+ by size exclusion 
chromatography. Lane 1: Bio-Rad low range molecular weight marker, lanes 2 – 9: 
fractions containing purified. Purified SS-IRED is observed to be approximately 32 
kDa by SDS-PAGE. 
Purified protein corresponding to fractions 2-9 was pooled and used for 
crystallization trials. 
Protein crystallization 
Purified protein both with and without the N-terminal 6His tag was subjected to a 
broad range of crystallization screens; PACT, INDEX, CSS 1 and 2, Hampton 1 and 2, 
the PEG ion screen and the MPD screen in a 96-well sitting drop format. A range of 
protein concentrations (20 – 120 mg ml-1) were employed. No crystals were obtained 
in any of the attempted conditions.  
Alternative methods for the crystallization of SS-IRED were therefore attempted. 
4.4.7 Kinetic analysis and pH behaviour of SS-IRED 
The kinetic analysis of SS-IRED towards the standard substrate 1a was carried out 
using an spectrophotometric NADPH-depletion assay as described in section 2.5.3 to 
determine kcat and Km. The outcomes of the experiment are outlined in Figures 4.22 
and Table 4.2. 
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Figure 4.22: Michaelis-Menten kinetic plot of SS-IRED towards substrate 1a. 
Table 4.2:  Kinetic parameters of SS-IRED towards substrate 1a.  
 Value Standard Error 
kcat (s-1) 0.0236 ±0.0011 
Km (mM) 3.24 ±0.60 
 
The kinetic parameters calculated by curve fitting using non-linear regression 
analysis returned reasonable standard errors relative to their values, suggesting that 
the data can be treated with confidence. The relatively low kcat and high KM suggest 
that the catalytic efficiency and affinity of SS-IRED towards 1a is poor, and it is 
therefore unlikely to be a natural substrate for the enzyme. 
4.4.8 Proposing a mechanism of SS-IRED 
The mechanism of an (R)-selective IRED has been studied in section 3.4.6. However, 
the mechanism of an (S)-selective NADPH-dependent IRED has so far not been 
reported. Therefore, SS-IRED was used as a model for mechanistic studies of (S)-
selective NADPH-dependent imine reductases. 
A sequence alignment of the genes coding for SkR-IRED and SS-IRED showed that in 
place of the putative catalytic residue Asp187 of SkR-IRED, SS-IRED possesses a 




Figure 4.23: Sequence alignment of genes coding for SkR-IRED (top) and SS-IRED 
(bottom). The two genes are 36 % sequence similar. The putative catalytic Asp187 
residue of SkR-IRED is replaced by residue Tyr169 in SS-IRED (highlighted blue).  
 
An alignment of the 3D structures of SkR-IRED (section 3.1) and SS-IRED (section 
4.4.5) could be used to investigate the relative positions of Asp178 (SkR-IRED) and 
Tyr169 (SS-IRED). The structural overlay was examined in the active site region of 
SkR-IRED (Figure 4.24). 
  
SkR-IRED  MPDNPSTKGRMMRNQQAEHTPVTVIGLGLMGQALAGAFLGAGHPTTVWNRTAAKAEPLVA 60 
SS-IRED   -----------MSKQ-----SVTVIGLGPMGQAMVNTFLDNGHEVTVWNRTASKAEALVA 44 
                     * :*     .******* ****:..:**. ** .*******:***.*** 
 
SkR-IRED  RGAKSAGSVAEAVAASPLVVVCVSDYDAVHALLDPLDGTALQGRTLVNLTSGTSAQARER 120 
SS-IRED   RGAVLAPTVEDALSANELIVLSLTDYDAVYAILEPVTG-SLSGKVIANLSSDTPDKAREA 103 
          ***  * :* :*::*. *:*:.::*****:*:*:*: * :*.*:.:.**:*.*. :***  
 
SkR-IRED  AAWADGRGADYLDGAILAGPAAIGTADAVVLLSGPRSAFDPHASALGGLGAGTTYLGADH 180 
SS-IRED   AKWAAKHGAKHLTGGVQVPPPLIGKPESSTYYSGPKDVFDAHEDTLKVLTN-ADYRGEDA 162 
          * **  :**.:* *.: . *. **..:: .  ***:..**.* .:*  *   : * * *  
 
SkR-IRED  GLASLYDAAGLVMMWSILNGFLQGAALLGTAGVDATTFAPFITQGIGTVADWLPGYARQI 240 
SS-IRED   GLAAMYYQAQMTIFWTTMLSYYQTLALGQANGVSAKELLPYATMMTSMMPHFLELYAQHV 222 
          ***::*  * :.::*: : .: *  **  : **.*. : *: *   . :..:*  **::: 
 
SkR-IRED  DDGAYPADDAAIDTHLATMEHLIHESEFLGVNAELPRFIKALADRAVADGHGGSGYPALI 300 
SS-IRED   DSADYPGDVDRLAMGAASVDHVLHTHQDAGVSTVLPAAVAEIFKAGMEKGFAENSFSSLI 282 
          *.. **.*   :    *:::*::*  :  **.: **  :  : . .: .*.. ..:.:** 
 
SkR-IRED  EQFRTHSGK 309 
SS-IRED   EVLKKPAV- 290 




Figure 4.24: A structural overlay between the active site region of SkR-IRED (in 
complex with NADPH) and the equivalent position in SS-IRED in the active site region 
of SkR-IRED. The figure demonstrates that Asp187 (SkR-IRED) and Tyr169 (SS-IRED) 
occur in the same position.  
 
The alignment demonstrates that residues Asp187 (SkR-IRED) and Tyr169 (SS-IRED) 
align structurally. It is possible, therefore, that the two residues perform a similar 
mechanistic role, where Tyr169 behaves as a proton donor in the reduction of imines, 
a mechanism for which is outlined in Figure 4.25.  
 
Figure 4.25: The mechanism proposed for the reduction of imines (such as 1a) by SS-
IRED. A proton is donated to 1a by catalytic residue Tyr169, resulting in the formation 
of an activated iminium ion. Hydride is then delivered to the iminium ion by NADPH 
to form the corresponding (S)-amine. 
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The behaviour of tyrosine as a proton donor in the reduction of imines has precedent 
in the naturally occurring imine reductase pteridine reductase (PTR1) (Figure 4.26). 
 
Figure 4.26: The mechanism of the imine reductase PTR1 in the first step in the 
NADPH-assisted reduction of an oxidised pterin to the active tetrahydro-form. 
Here, residue Tyr194 hydrogen bonds to the nucleophilic centre of the pterin 
substrate and provides a proton for the reduction of its imine moiety. A neighbouring 
residue Lys198 was suggested to lower the pKa of Tyr194 due to its positively charged 
side chain which would stabilise the intermediary tyrosinate ion, thus favouring its 
formation. It was proposed that Asp181 may also help stabilise the charged tyrosinate 
intermediate while providing a role in proton relay. 
In light of the PTR1 mechanism, the active site of SS-IRED was therefore more closely 
in order to investigate whether, like PTR1, the active site of SS-IRED contains residues 
that could assist Tyr169 in the transfer of a proton to its imine substrate. 
Active site of SS-IRED 
The neighbouring residues of Tyr169 were examined in the putative active site region 
of SS-IRED. It was noted that residues Ser94 and His243 are found in the vicinity of 
Tyr169, which could behave as analogues to PTR1-Asp181 and PTR1-Lys198 




Figure 4.27: The putative active site region of SS-IRED. Residue Tyr169, which may 
have a role as a proton donor in the reduction of imines, is neighboured by residues 
His243 and Ser94 which may assist Tyr169 in catalysis. 
Serine and histidine residues have a precedent of playing important roles in catalytic 
triads.77 SS-IRED-Tyr169 may behave as a proton donor in the reduction of imines. 
This residue may be assisted by Ser94 and His243 similarly to residues Asp181 and 
Lys198 in PTR1. Positively charged His243 may lower the pKa of Tyr169 by stabilising 
the intermediary tyrosinate ion by electrostatic interactions. Ser94 may play a role in 
proton relay as well as in the stabilisation of Tyr169.   
4.4.9 Mutational studies towards the mechanism of SS-IRED 
In order to assess whether residue Tyr169 could be a catalytically active residue, the 
wild-type gene was used as a template for the generation of the mutant Tyr169Phe. 
The Phe sidechain is sterically similar to that of Tyr, but lacks the hydroxyl functional 
group and is therefore aprotic and incapable of carrying out the proposed protonation 
step in the reduction of imines as shown in the mechanism in Figure 4.13. Therefore, 
if the resultant mutant does not possess imine reduction activity, this would support 
the suggestion that residue Tyr169 may behave as a proton donor.  Mutants Ser94Ala 
and His243Ala were also generated in order to assess whether these may play a role 




The wild-type gene was used as a template for the generation of mutants Tyr169Phe, 
Ser94Ala and His243Ala by site-directed mutagenesis (SDM). The SDM reaction was 
digested with DpnI and used to transform E. coli cells. DNA was isolated from resultant 
colonies for each mutant using a miniprep kit, and submitted for sequencing at GATC 
Biotech. The genes in the isolated DNA were found to have 100 % sequence identity 
to the target SS-IRED Tyr169Phe, Ser94Ala and His243Ala mutated genes.  
Expression and purification of SS-IRED mutants 
SS-IRED Tyr169Phe, Ser94Ala and His243Ala were expressed in the pET-YSBLIC3C 
vector in E. coli BL21 (DE3) cells in 2 L LB-Kan medium at the optimal expression 
temperature for the wild-type protein of 16 °C.  Protein was initially purified from 
lysed, resuspended cells by nickel affinity chromatography. Protein-containing 
fractions were analysed by SDS-PAGE (Figures 4.28 – 4.30) 
 
Figure 4.28: SDS-PAGE gel analysis of purification of SS-IRED Tyr169Phe by nickel 
affinity chromatography. Lane 1: Bio-Rad low range molecular weight marker, lane 2: 
crude cell lysate, lane 3: Unbound flow-through fractions on column binding, lanes 4 





Figure 4.29: SDS-PAGE gel corresponding to the purification of SS-IRED Ser94Ala by 
nickel affinity chromatography. Lane 16: Bio-Rad low range molecular weight marker, 
lane 17: crude cell lysate, lane 18: Unbound flow-through fractions on column binding, 
lanes 19-28: fractions containing purified protein, 
 
 
Figure 4.30: SDS-PAGE gel corresponding to the purification of SS-IRED His243Ala 
by nickel affinity chromatography. Lane 29: Bio-Rad low range molecular weight 
marker, lane 30: crude cell lysate, lane 31: Unbound flow-through fraction on column 
binding, lanes 32-43: fractions containing purified protein. 
SS-IRED Tyr169Phe, Ser94Ala and His243Ala were subsequently purified by size 
exclusion chromatography (Figures 4.31 - 33) using a Superdex® HiLoad 75 gel 





Figure 4.31: Chromatogram of the purification of SS-IRED Tyr169Phe by size 
exclusion chromatography. The presence of protein is detected using absorbance 
measurements at 280 nm, which is indicated by the blue trace. 
 
 
Figure 4.32: Chromatogram of the purification of SS-IRED Ser94Ala by size exclusion 
chromatography. The presence of protein is detected using absorbance 
















































Figure 4.33: Chromatogram of the purification of SS-IRED His243Ala by size 
exclusion chromatography. The presence of protein is detected using absorbance 
































Figure 4.34: SDS-PAGE gel analysis of purification of mutants of SS-IRED by size 
exclusion chromatography. Top: SDS-PAGE gel corresponding to SS-IRED Tyr169Phe. 
Lane 1: Bio-Rad low range molecular weight marker, lanes 2-10: fractions containing 
purified protein, Bottom left: SDS-PAGE gel corresponding to SS-IRED Ser94Ala. Lane 
11: Bio-Rad low range molecular weight marker, lanes 11 - 16: fractions containing 
purified protein, Bottom right: SDS-PAGE gel corresponding to SS-IRED His243Ala. 
Lane 17: Bio-Rad low range molecular weight marker, lanes 18 - 24: fractions 
containing purified protein, 
All SS-IRED mutants were eluted in a single peak with maxima at 57, 62 and 63 mL for 
Tyr169Phe, Ser94Ala and His243Ala respectively. Using a calibration curve provided 
by GE Healthcare, the elution volume could be used to estimate a protein molecular 
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weight of approximately 60 kDa for mutants Ser94Ala and His243Ala, indicating that 
the dimeric structure of SS-IRED had not been preserved during point mutations. 
However, the earlier elution volume for SS-IRED Tyr169Phe suggested a lower 
molecular weight, which could correspond to a protein monomer. This would suggest 
that dimerization had been disrupted by the mutation. This is investigated further in 
section 4.4.8. 
For subsequent use, Protein corresponding to fractions 2-10, 12-15 and 18-23 was 
pooled. Fractions containing considerable levels of non-target proteins were 
discarded. 
Kinetic assays using SkR-IRED mutant 
A spectrophotometric-based NADPH depletion assay was used to assess the kinetic 
parameters of SS-IRED Tyr169Phe, Ser94Ala and His243Ala towards the standard 
substrate 1a under the same conditions used for the wild-type protein. No NADPH-
depletion was observed for 1a concentrations between 1 and 30 mM. The results 
suggested that these residues may have importance for catalysis. However, further 
investigation will be required to confirm a precise role that they play for imine 
reductase activity, as the elimination of activity may have arisen for other reasons.  
4.4.10 Conclusion 
An (S)-selective NADPH-dependent imine reductase from Streptomyces sp. GF3546 
has been sub-cloned, recombinantly expressed in E. coli, purified to homogeneity and 
crystallized. A 3.2 Å resolution structure was obtained of SS-IRED in the apo form.  
A probable active site region of SS-IRED was identified using a structural alignment 
with the previously characterised (R)-selective imine reductase SkR-IRED (chapter 3). 
A tyrosine residue, Tyr169, is observed in the active site in place of the putative 
catalytic residue of SkR-IRED. It was suggested that this may act as a proton donor in 
imine reduction in a similar manner to the naturally occurring imine reductase PTR1, 
which reduces oxidised pteridines. The PTR1 mechanism involves assistance from 
neighbouring aspartate and lysine residues. Tyr169 of SS-IRED is neighboured by 
residues Ser94 and His243 in the active site cavity, which could assist the tyrosine 
residue in catalysis in a similar manner to Asp and Lys in PTR1. 
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In order to assess whether this proposed mechanism is feasible, SS-IRED mutants 
Tyr169Phe, Ser94Ala and His243Ala were generated. Samples of mutants were 
loaded onto an analytical gel filtration column to assess their homogeneity and 
molecular weight, to test whether the dimeric structure had been preserved. The 
mutants were screened for activity towards imine 1a. A spectrophotometric-based 
NADPH depletion assay showed that none of the mutants displayed activity towards 
the imine substrate.  
This supports the hypothesis that Tyr169 may have a role as a proton donor with 
assistance from Ser94 and His243. However, more data is required in order to confirm 
whether this is the case, as elimination of activity could occur for any number of 
reasons, such as disruptions in the 3D structure of the protein which may inhibit 
binding of the substrate. 
To investigate the mechanism and selectivity of SS-IRED further, it is important to 
obtain a structure of the enzyme in complex with NADPH and an imine substrate, as 
this will provide conclusive evidence towards the residues that are necessary for 
catalysis, as well as helping to rationalise the selectivity of the enzyme by observing 
the orientation adopted by the substrate in the active site. As SS-IRED is difficult to 
crystallize, it has so far not been possible to obtain such a complex. 
Therefore, modifications and homologues of SS-IRED have been explored in an effort 
to obtain an improved structure of an (S)-selective imine reductase. So far, 
crystallization has not been achieved in this project using this method. This goal is 




5. Investigating the basis for enantioselectivity of NADPH-
dependent IREDs 
5.1 Introduction 
Many IREDs that have been characterized display a high degree of enantioselectivity. 
Examples include SkR-IRED from Streptomyces kanamyceticus and SR-IRED from 
Streptomyces sp. GF3587, which both catalyse the formation of (R)-1b with greater 
than 98 % enantiomeric excess,53, 54, 59, 60 and SS-IRED from Streptomyces sp. GF3546 
and BcS-IRED from Bacillus cereus which catalyse the formation of (S)-2b also with at 
least 98 % optical purity.54, 57, 78 However, despite high levels of enantioselectivity 
commonly displayed by IREDs, the reasons for this selectivity have not yet been 
determined.  
Gaining an understanding of their enantioselectivity would provide an insight into the 
nature of substrate binding in IREDs, which has thus far been difficult to characterize, 
in part due to the typically large active sites and high degrees of dynamicity belonging 
to these enzymes, as well as generally low affinities of IREDs for imine substrates 
which have thus far been identified, which makes it challenging to obtain complexes 
of IREDs with their substrates.59, 60, 78 Additionally, knowledge of the residues 
responsible for directing enantioselectivity could provide a basis for customising 
IREDs by rational mutagenesis in terms of which amine enantiomer they produce and 
improving the optical purity of products formed. 
5.2 Aims 
This chapter will describe investigations into the differences between (R)- and (S)-
selective IREDs using two approaches. Firstly, the substrate binding pocket of (R)- and 
(S)-selective IREDs will be examined to determine structural differences in the 
substrate binding region between these two groups of IREDs that may direct 
enantioselectivity. Secondly, an analysis by Wetzl and coworkers (Wetzl) on the 
bacterial protein-sequence space of imine reductases will be reviewed and examined 
for sequence differences between (R)- and (S)-selective IREDs.65 
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5.2 Comparison of the active site of an (R)- and (S)-selective IRED 
Identifying residues that direct enantioselectivity in IREDs 
The structure of an IRED from Amycolatopsis orientalis (AoIRED) was recently 
reported in complex with an amine product, (R)-1-methyl-1,2,3,4-
tetrahydroisoquinoline (4b). This structure revealed the location of the previously 
unknown binding site of substrates and products to the enzyme active site. 
 
 
Figure 5.1: The active site position in the crystal structure of AoIRED in complex 
with (R)-1-methyl-1,2,3,4-tetrahydroisoquinoline ((R)-4b). The figure demonstrates 
the nature of imine substrate binding in AoIRED.  The amine product (R)-4b is 
bound in a cleft between the C-terminal domain of subunit A (green) and the N-
terminal domain of subunit B (purple). 
The enantioselectivity of AoIRED is substrate-dependent. While it displays 
predominantly (S)-selectivity, there are a number of substrates, including 4a, for 
which it shows selectivity for the formation of the (R)-enantiomer. This enzyme 
therefore does not provide a clear subject for the study of enantioselectivity in IREDs. 
Instead, two more uniformly selective IREDs will be used as models in this study; SS-
IRED and SR-IRED from Streptomyces sp. GF3546 and 3587 respectively. SR-IRED has 
been selected for this study because of its superior activity towards imine substrates 
in comparison with SkR-IRED.59 An overlay of the putative substrate binding sites of 
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SS-IRED and SR-IRED is pictured in figure 5.2. The location of the active site has been 
proposed on the assumption that it lays in the equivalent region of the protein to that 
of AoIRED. Inspection of the binding sites of each enzyme reveals five positions at 
which residues differ between the two IREDs; L176, M179, L183, H242 and Y283 in 
SR-IRED which structurally overlay with M173, F176, M180, G237 and F278 in SS-
IRED. 
 
Figure 5.2: Active site overlay of SR-IRED and SS-IRED at the putative amine binding 
site, based on the location of imine binding in AoIRED. The figure details the positions 
at which residues are not conserved between enzymes. 
Preparation of reciprocal mutants of SR-IRED and SS-IRED 
Mutagenesis experiments were performed to assess whether these five residues 
direct enantioselectivity in either enzyme. For each enzyme at each of the five 
positions, reciprocal mutants were generated (SR-IRED L176M, M179F, L183M, 
H242G and Y283F and SS-IRED M173L, F176M, M180L, G237H and F278Y) by site-
directed mutagenesis. Each mutant will be used in biotransformations of model imine 
1a, and the resultant enantioselectivity measured by chiral GC analysis. This will 
demonstrate whether enantioselectivity has been changed as a result of mutation to 
the residue found in the IRED with opposite enantioselectivity. 
Heterologous expression tests were carried out in E. coli BL21(DE3) and presence of 






Figure 5.3. SDS-PAGE analysis of expression of mutants A1 - B5. Samples 1 and 7 
correspond to a low range molecular weight marker supplied by NEB. Samples 2 – 6 
and 8 - 12 correspond to the soluble and insoluble fractions for expression of SR-IRED 
mutants A1 – 5 in E. coli BL21(DE3) respectively. Soluble expression is seen for 
mutants A2, A3 and A5. No clear soluble expression is seen for mutant A4, and no 






Figure 5.4. SDS-PAGE analysis of expression of mutants B1-B5. Samples 1 and 7 
correspond to a low range molecular weight marker supplied by NEB. Samples 2 – 6 
and 8 - 12 correspond to the soluble and insoluble fractions for expression of SS-IRED 
mutants B1 – 5 in E. coli BL21(DE3) respectively. Soluble expression is seen for 
mutants B2, B3 and B5. Only insoluble expression is seen for mutant B4, and no 
expression at all is seen for mutant B1. 
Expression tests revealed that seven out of ten mutants expressed soluble protein, 
with particularly high levels of soluble expression for mutants SS-IRED B2 and B3 and 
SR-IRED A2 and A3. Mutants SR-IRED A1 and B1 did not express at all, and mutant A4 
expressed only insolubly. 
Mutants which expressed solubly during expression tests (SR-IRED A2, A3 and A5, 
and SS-IRED B2, B3 and B5) were expressed on 1 L scale and purified using Ni-affinity 
chromatography.  
GC analysis of biotransformations with mutants of SR-IRED and SS-IRED 
Purified mutants were used in biotransformations of 1a and reaction products were 
analysed by chiral-GC after 24 h reaction time. The retention times of imine 1a and 
the corresponding products (R)-1b and (S)-1b were identified by analysing the GC 
traces recorded from commercially prepared 1a, 1b and (R)-1b (Figures 5.5, 5.6 and 
5.7). Biotransformations of 1a performed using mutants of SR-IRED and SS-IRED 
were analysed under the same conditions as the substrate and product standards 




Figure 5.5: Chiral GC analysis of 1a (5 mM) in EtOAc. The figure demonstrates that 
imine 1a has a retention time of 16.37 min. 
 
Figure 5.6: Chiral GC analysis of (R)-1b (5 mM) in EtOAc. The figure demonstrates 



































RT = 16.37 
min 





Figure 5.7: Chiral GC analysis of racemic 1b (5 mM) in EtOAc. The figure 
demonstrates that the optically pure amine (S)-1b has a retention time of 18.72 min, 
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Table 5.1: The results of GC analysis of biotransformations of imine 1a with mutants 
SR-IRED A1 – A5 and SS-IRED B1 – B5. The analysis demonstrates the 
enantioselectivity of each mutant by demonstrating the stereochemistry of the amine 
products formed in each reaction. Mutant reactions were performed in duplicate, and 
have been referred to as repeat 1 and repeat 2. 
Enzyme  Peak area 
of imine 1a 
Peak area of 
amine (R)-1b 
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Chiral GC data for the conversion of 1a shows that no mutations resulted in reduced 
enantioselectivity. This may indicate that none of these residues are responsible for 
directing enantioselectivity. However, this could indicate that more than a single 
mutation is necessary in order to alter the enantiospecificity of an IRED, particularly 
if broader structural differences are implicated.  
5.3 Analysis of bacterial protein-sequence space of imine reductases for 
the basis of enantioselectivity 
The availability of IRED protein sequences whose activity has been confirmed in a 
laboratory setting have been used as a reference in BLAST searches that have 
facilitated the discovery of a large number of sequences of putative IREDs in addition 
to those already characterised in the literature. Most notably, such investigations 
were used by Hauer and coworkers to construct an invaluable database of over 350 
protein sequences, termed the Imine Reductase Engineering Database (IBD), which 
putatively possess imine reducing activity.62 
However, although many potential imine reductase genes had been identified, the 
number of imine reductases that had been experimentally isolated and characterized 
remained low. In an effort to increase the number of characterized imine reductases, 
Wetzl and coworkers selected a total of an additional 23 putative IRED genes to 
express, purify and characterize in terms of their substrate scope and 
enantioselectivity.65 
Because protein sequences that were selected were highly diverse and sourced from 
multiple different organisms, and involved practical characterizations of each 
enzyme, this study gave rise to an unprecedented opportunity to allow investigators 
to make links between sequence properties and the catalytic properties of an IRED.  
In the scope of this chapter, the focus will be on the relation of (R)- and (S)-selectivity 
to sequence motifs and individual residues within the enzyme active site. In the study 
by Wetzl and coworkers, it was hypothesised that residues occurring in the C-
terminal domain would be more important in influencing the catalytic properties of 
an IRED than the N-terminal Rossman fold domain, whose purpose is NADPH-binding 
and is more highly conserved between IREDs.  
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In this study, a profile Hidden Markov Model (HMM) was built using the sequence-
alignment of a group of six IREDs previously characterized in the literature. The HMM 
was used to find protein sequences with residues conserved at the most statistically 
important positions, which led to the identification of 702 protein sequences. 
Sequences were allocated to clusters based on their homology, with the majority of 
these protein sequences being organised into 85 clusters, only 15 of which contained 
3 or more IREDs. Genes were selected across multiple clusters and organisms of origin 
to maximise sequence diversity. 
All proteins were heterologously expressed and purified and biotransformations 
were carried out in a range of substrates, displayed in Figure 5.8. Biotransformations 
were analysed by chiral HPLC in order to determine level of conversion and 
enantiomeric purity of enzymatically-formed products. 
For some enzymes enantioselectivity was substrate-dependent, where they displayed 
strong (R)-selectivity toward some substrates and strong (S)-selectivity for other 
substrates. In order to carry out a clearer analysis on the sequence basis of 
enantioselectivity for the purposes of this study, only enzymes which were 
consistently (R)- or (S)-selective across the entire range of tested substrates have 
included. All enzymes that fit these criteria are listed in Table 5.2. The table includes 
both reaction data from the study by Wetzl and coworkers, as well as data from SkR-
IRED from the results section of chapter 3 in this thesis, BcS-IRED as described by Man 




Table 5.2:  Names and source organisms of enzymes included in analysis of sequence 
basis for enantioselective in IREDs. 
IRED Name Organism of Origin IRED Name Organism of Origin 
IRED_1 Streptomyces sp. Mg1 IRED_11 Frankia sp. QA3 
IRED_2 Streptomyces fulvissimus IRED_12 Verrucosispora maris 
IRED_3 Bacillales IRED_13 Streptomyces sp. CNBO91 




IRED_5 Streptomyces aurantiacus IRED_15 Paenibacillus ehimensis 
IRED_6 Mycobacterium 
smegmatis 
IRED_16 Streptomyces sp. CNH287 
IRED_7 Saccharopolyspora SS-IRED Streptomyces sp. GF3546 
IRED_8 Actinomadura rifamycini SR-IRED Streptomyces sp. GF3587 
IRED_9 Mycobacterium vaccae BcS-IRED Bacillus cereus 
IRED_10 Mycobacterium sp. JLS SkR-IRED Streptomyces 
kanamyceticus 
A range of cyclic imine substrates were selected for this screen, including 5-, 6- and 7-
membered rings and number of quinoline derivatives. Chosen substrates are outlined 





Figure 5.8: Substrates selected for IRED biotransformations in study selected by 
Wetzl and coworkers. 
Enantiopurity of products produced from IREDs from substrates 1a, 4a and 9-12a 
are recorded in Table 5.3. Some enzymes displayed substrate-dependent 
enantioselectivity, where the stereochemistry of the enantiomer formed is reversed 
for given substrates relative to the usual selectivity of the enzyme. For clarity reasons, 




Table 5.3: Enantioselectivity of selected IREDs towards six varying imine substrates. 
Enantioselectivity values for formation of (S)-amines are highlighted in blue and 
listed with positive values, enantioselectivity values for formation of (R)-amines are 
highlighted in red and listed with negative values 
Substrate: 1a 17a 18a 4a 19a 20a 
IRED_1 99 98 99 99 96 99 
IRED_2 n.d. 99 n.d. n.d. 11 69 
IRED_3 n.d. n.d. n.d. 86 37 93 
IRED_4 95 85 97 99 98 99 
IRED_5 99 99 96 99 97 99 
IRED_6 97 98 95 99 98 94 
IRED_7 44 97 98 68 90 79 
IRED_8 99 99 99 99 18 17 
IRED_9 98 99 97 97 97 92 
IRED_10 98 99 93 99 98 99 
SS-IRED 99 99 96 92 91 98 
BcS-IRED* 99 99 n.d. n.d. 81 n.d. 
IRED_11 -95 -90 -99 -99 -98 -92 
IRED_12 -98 -69 -88 -88 -21 -6 
IRED_13 -97 -81 -73 -85 -33 -56 
IRED_14 -80 -82 -25 -89 -98 -90 
IRED_15 n.d. -99 -99 n.d. -97 -97 
IRED_16 -93 -92 -99 -96 -76 -72 
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Substrate: 1a 17a 18a 4a 19a 20a 
SkR-IRED** -99 n.d. n.d. n.d. n.d. n.d. 
SR-IRED*** -99 -99 n.d. -99 n.d. n.d. 
n.d. = not determined. This is stated where conversion is low (>25 %) or data are not available 
(where reaction data was obtained from sources external to Wetzl publication). 
* Reaction data obtained from Man and coworkers78 
**Reaction data obtained from results outlined in chapter 3 
***Reaction data obtained from Hussain and coworkers59 
Some enzymes displayed substrate-dependent enantioselectivity, where the 
preference for the formation of the opposite enantiomers can be formed dependent 
on substrate. Based on these results, only enzymes which displayed consistent 
enantioselectivity were included any subsequence analysis of sequence basis for 
enantioselectivity (Table 5.4).  
Table 5.4: List of IREDs which consistently display >80 % enantioselectivity for the 
formation of only (R)- or only (S)-amine for all substrates tested. Enzymes with <80 
% enantioselectivity for any substrate, or displayed mixed enantioselectivity 
(formation of different enantiomers depending on substrate) were omitted. 











Sequences of all IREDs were listed and separated according to (R)- or (S)-selectivity, 
where sequences highlighted in blue are (S)-selective and sequences highlighted in 
red are (R)-selective (figure 5.3). Sequences of IREDs that displayed consistently at 
least 80 % ee of products formed from all substrates are listed in black font. Sequences 
of IREDs that displayed consistently (R)- or (S)-selectivity but less than 80 % ee for 
one or more products are listed in grey italics. 
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  27      34 81     87 108     116 134       143 184         195 222     228     231,232     247                  265 
>1         LGPMGQAM LSLTDYR NLSSDTPDR GGVMVPAPMV QLMYQAQLAVFL LLSSAD-AIG-----A-ILRAG GDLSTVTMMGATADHIVET  
>2         LGPMGRAM ISLTDYA NLTSATPEE GGVNSPPSGI ALLYQIGVGMFW ADDTAN-SLT-----Q-FFAFY GDVDRLAMGMASVEHVLRT  
>3         LGPMGKAI LSLTDYR NLSSDTPEK GGVLASPPGI MLYYQLQIDVFW VSDILS-TMP-----K-LLEFY GDVEKLAMGLASVEHVVQT  
>4         LGPMGQAM LSLTDYQ NLSSDTPDR GGVMIPAPMV QLMYQAQLDVFL LIGMLR-TVP-----A-MLEAG GDLSTITMMGATADHIVGA  
>7         LGPMGQAM LSLIDYD NLSSDTPEK GGVLSPPPGI ALMYQLNMVVFW VSENFA-GMG-----Q-FIDFY GDVDRLSMGVASMEHVVHT  
>8(GF3546) LGPMGQAM LSLTDYD NLSSDTPDK GGVQVPPPLI AMYYQAQMTIFW ATMMTS-MMP-----H-FLELY GDVDRLAMGAASVDHVLHT  
>10        LGPMGQAL VNVVDHD GLSSDTPDR GAIMTPIDTI AAFDMALLDLFW AHGIVG-ILS-----P-IFTEV DASASVSSVASSVRHLIAA  
>13        LGPMGYAL VCVADYA NLCSGTPQE GAIMVPVEVI VLHNTALLGLMW AVDWFLPSVT-----GEILRAE GDGGTLAMCLTAIEHIVRT 
>15        LGPMGKAM ISQTDYK NLSSGSPDE GGVMVPPPGI NLYYQAQLYLFW ATETVT-SLGVDGPMG-FLRIL GGENSMLMMAVGADHMVEA 
>17        LGPMGRAL INVVDHD GLSSDTPDR GAIMTPTDVV AAYDMALLDVFW AVGIAA-ILP-----P-VFSEV DANATVSSAAASLSHLVAT  
>18        QGPMGQAL VNVVDQA GLASDTPDT GAIMTPTDTI AAFDMALLDLFW AQGIVG-ILP-----P-IVDEL DSRAQVASVAASVRHLIAA  
>Bcer  LGPMGQAM LSLTDYN NLSSDTPEK GGVQVPPSGI MLYYQIQMDIFW ASAMMS-SLP-----K-FVEFY GDVDRLAMGLASVEHVVHT 
 
>9         LGAMGTAL VCLLDDA NLTTGSPAQ GGIMAVPPMV ALHDVALLSAMT LVEWLR-AMA-----T-SASAT GVMSNLAMQVAGNATLLRT 
>11        LGAMGSAL ICVLDYR NLTSGTPGD GAIMATPSMI SLYDVALLGLMW AQAWFEYVIS-----P-EVPNL DNDSTLGMQTVAIEHLVEA 
>12        LGAMGSAL TCLTTYE TLNSGSPAG GAIKNVPPAV ALYEMAVGGTLL SEQWLQ-MIA-----S-VLPVL EPLSSVNVFVAGAAHDAEL 
>19        LGAMGRAL AVLLDHA NLVTTTPEE GGIMAVPGMI PLYDLGLLAGMY AAPWIA-AMT-----A-ELAGY GGPGQQSLEFSDLSDMVRA  
>21        LGMMGSAL VCVLDYE NLTNGKPEQ GGIMAVPQMI ALYDLALLTTAY VIPWLQ-AMI-----A-SLPSQ TDVSSLNINKVGFVNLIEA  
>23        TGAMGSAL ACLLDDD NLTTGTPGQ GGIMAVPPMI ALHDVALLSAMY LVSWLT-AMA-----P-AALES DVVSNLAMQVAGIPTFLRT 
>Skan      LGLMGQAL VCVSDYD NLTSGTSAQ GAILAGPAAI SLYDAAGLVMMW ITQGIG-TVA-----D-WLPGY ADDAAIDTHLATMEHLIHE  
>SPGF3587  LGLMGQAL VCLSTYD NLTSGSSDQ GAIMITPPGI ALYDVSLLGLMW AHMWLE-AIK-----M-FTADY ANDATLETHLAALKHLVHE 
Figure 5.9: List of sequences which display consistent (R)- or (S)-enantiopurity of products formed by tested imine substrates, where 
strongly selective (>80 % ee for all products) IREDs are listed in black and more weakly selective IREDs (<80 % ee for one or more 
products) are listed in grey italics. Residues are numbered according to SkR-IRED sequence positions. 
148 
 
An analysis was carried out on the differences between sequences of (R)- and (S)-
selective IREDs. For the purposes of this analysis, only IREDs which were deemed to 
be strongly selective (>80 % ee for all products) were included. For each group of 
IREDs ((R)- and (S)-selective), the extent to which each residue is conserved was 
assessed manually. Amino acid residues treated as similar are listed in Table 5.5. 
Groupings were made based on hydrophobicity, size, charge and aromaticity of amino 
acid side chains, as these are believed to affect substrate binding. All other residues 
(H, C, G, and P) were deemed not to have unique properties which meant they are not 
sufficiently similar to other residues to be placed in any group, and were treated 
individually. 
Table 5.5: Groups of amino acids treated as similar in sequence similarity analysis of 
enantioselective IREDs. Amino acid side chains are grouped according to 
hydrophobicity, size, charge and aromaticity. 
Amino acid type Amico acids in group 
Amino acids with aromatic side 
chains 
F, Y, W 
Amino acids with hydrophobic, 
aliphatic side chains 
V, I, L, A 
Amino acids with large polarised, 
uncharged side chains 
N, Q, M 
Amino acids with small, polarised, 
uncharged side chains 
S, T 
Amino acids with positively 
charged side chains 
K, R 
Amino acids with negatively 
charged side chains 
D, E 
 
In each sequence alignment, level of conservation for each position was calculated 
and highlighted according to the colour code in Table 5.6. Similar amino acid residues 
were regarded as conserved, and the percentage conservation was calculated as the 
number of amino acids identical or similar to the most abundant amino acid. 
Using this analysis, a consensus sequence for both (R)- and (S)-selective IREDs was 
constructed using the most abundant amino acid for each position between 
sequences. Where more than one amino acids were equally highly abundant, the least 
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functionalised amino acid was used in the consensus sequence (for example, Ala 
would be used in the consensus sequence instead of Val, if the two were equally the 
most abundant). 
Table 5.6: Key describing degree of conservation correlating to colour used to 




0 – 19 %  
20 – 39 %  
40 – 59 %  
60 – 79 %  
80 – 99 %  
100 %  
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    27      34 81     87 108     116 134       143 184         195 222     228     231,232     247                  265 
>1           LGPMGQAM LSLTDYR NLSSDTPDR GGVMVPAPMV QLMYQAQLAVFL LLSSAD-AIG-----A-ILRAG GDLSTVTMMGATADHIVET  
>4           LGPMGQAM LSLTDYQ NLSSDTPDR GGVMIPAPMV QLMYQAQLDVFL LIGMLR-TVP-----A-MLEAG GDLSTITMMGATADHIVGA  
>7           LGPMGQAM LSLIDYD NLSSDTPEK GGVLSPPPGI ALMYQLNMVVFW VSENFA-GMG-----Q-FIDFY GDVDRLSMGVASMEHVVHT  
>8(GF3546)   LGPMGQAM LSLTDYD NLSSDTPDK GGVQVPPPLI AMYYQAQMTIFW ATMMTS-MMP-----H-FLELY GDVDRLAMGAASVDHVLHT  
>10          LGPMGQAL VNVVDHD GLSSDTPDR GAIMTPIDTI AAFDMALLDLFW AHGIVG-ILS-----P-IFTEV DASASVSSVASSVRHLIAA  
>17          LGPMGRAL INVVDHD GLSSDTPDR GAIMTPTDVV AAYDMALLDVFW AVGIAA-ILP-----P-VFSEV DANATVSSAAASLSHLVAT  
>18          QGPMGQAL VNVVDQA GLASDTPDT GAIMTPTDTI AAFDMALLDLFW AQGIVG-ILP-----P-IVDEL DSRAQVASVAASVRHLIAA  
>Bcer    LGPMGQAM LSLTDYN NLSSDTPEK GGVQVPPSGI MLYYQIQMDIFW ASAMMS-SLP-----K-FVEFY GDVDRLAMGLASVEHVVHT 
 
>S Consensus LGPMGQAM LSLTDYD NLSSDTPDR GGVMTPPPMV ALYYQAQLDVFW ASGMVA-ILP-----P-VLEEY GDVDTVSMGAASVDHLVAT                                                                                      
 
>9           LGAMGTAL VCLLDDA NLTTGSPAQ GGIMAVPPMV ALHDVALLSAMT LVEWLR-AMA-----T-SASAT GVMSNLAMQVAGNATLLRT 
>21          LGMMGSAL VCVLDYE NLTNGKPEQ GGIMAVPQMI ALYDLALLTTAY VIPWLQ-AMI-----A-SLPSQ TDVSSLNINKVGFVNLIEA  
>Skan        LGLMGQAL VCVSDYD NLTSGTSAQ GAILAGPAAI SLYDAAGLVMMW ITQGIG-TVA-----D-WLPGY ADDAAIDTHLATMEHLIHE  
>SPGF3587    LGLMGQAL VCLSTYD NLTSGSSDQ GAIMITPPGI ALYDVSLLGLMW AHMWLE-AIK-----M-FTADY ANDATLETHLAALKHLVHE  
 
>R Consensus LGLMGQAL VCVLDYD NLTSGSPAQ GGIMAVPPMI ALYDVALLSnMW AVnWLn-AMA-----n-SLPnY ADDASLDTHLAGnnHLIHE 
 
Figure 5.10: An alignment of sequences of strongly (S)-selective (blue) and (R)-selective (red) IREDs with amino acid residues colour coded 
according to level of conservation between equivalent positions in similarly selective IREDs according to the key in Table 5.5. The most highly 




(R)- and (S)-selective consensus sequences were inspected for differences. Attention 
was drawn to residues that were highly conserved within one group, but were 
different or non-conserved in the opposite group. The most notable differences occur 
at amino acids Pro29, Asp112, Lys116 and Phe194 which are strongly conserved in 
(S)-selective IREDs but not present in (R)-selective IREDs, and residues Cys82, Gly112 
and Gln116 which are strongly conserved in (R)-selective IREDs but not (S)-selective 
IREDs. Some of these strongly conserved residues are reciprocal (positions 112 and 
116), where each group of IREDs had strong conservation of different residues at 
these positions. Other residues were strongly conserved in one group of IREDs but 
had no particular consensus amino acid at the equivalent position in the other group. 
The results of these findings are outlined in Table 5.7. 




Amino acid present in (R)-seletive 
IREDs 
(amino acid, percentage conservation) 
Amino acid present in (S)-selective 
IREDs 
(amino acid, level of conservation) 
29 No strong conservation Pro, 100 % 
82 Cys, 100 % No strong conservation 
112 Gly, 100 % Asp, 100 % 
116 Arg, 88 %* Gln, 100 % 






As there are known sequences for more weakly selective IREDs with (R)- and (S)-
selectivity (<80 % product ee formed for one or more substrates, sequences in grey 
italics in figure 5.4), it is possible to provisionally inspect whether the absence of these 
conserved residues make affect enantioselectivity.  
At position 29, there are no strongly or weakly (S)-selective sequences that do not 
have the conserved Pro residue. Equally, Cys82 is conserved among all (R)-selective 
IREDs. This could perhaps be because these residues are essential for (S)- and (R)-
selectivity, respectively, or these could simply be artefacts of evolution within (R)- 
and (S)-selective IREDs. 
At other positions, however, residues that were highly conserved in strongly selective 
IREDs were not always conserved in weakly selective IREDs. At position 112, strongly 
(S)-selective IREDs possess a highly conserved Asp residue, whereas strongly (R)-
selective IREDs have a strongly conserved Gly residue. Out of the four more weakly 
(S)-selective IREDs, three do not have the conserved Asp112 residue (IRED2, IRED13 
and IRED15), but instead either a Gly or Ala residue. Conversely, one of four weakly 
(R)-selective IREDs possessed a Thr residue in place of the Gly present in strongly (R)-
selective IREDs. 
At position 116, all strongly (S)-selective IREDs have a highly conserved Arg (or 
similar Lys) residue. In the four weakly (S)-selective IREDs, three instead have a Glu 
residue (IRED2, IRED7 and IRED8). 
At position 194, strongly (S)-selective IREDs have a highly conserved Phe residue. In 
one of the four weakly (S)-selective IREDs (IRED13), this is replaced by a Met residue. 
A Met residue at this position is found in 75 % of the strongly (R)-selective IREDs, 
suggesting that mutation of this residue to Met could result in weakened (S)-
selectivity. 
These observations suggest that Gly112, Arg (or Lys)116 and Phe194 may play a role 
in directing (R)-selectivity, as there are examples of IREDs without these residues 
whose enantioselectivity is compromised. Residues Asp112 and Gln116 may assist in 
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directing (S)-selectivity, as some IREDs where these residues were not conserved also 
displayed weakened enantiopreference. 
However, while IREDs without these residues sometimes displayed weakened 
enantioselectivity, this may not indicate that these residues are directly responsible 
for this effect. Evidence would be required from mutagenesis experiments that, for 
more strongly selective IREDs, removal of these residues results in weakened 
enantioselectivity. The opportunity to conduct these mutagenesis experiments is 
prohibited by time limitations in this project, but would be a valuable future 
experiment. 
Finally, it is important to make note that, aside from IRED7, all (R)- and (S)-selective 
IREDs studied in this section exhibited consistently high enantioselectivity towards 
substrate 1a. Only the larger substrates 10a, 11a and 12a exposed the weakened 
enantioselectivity of the less selective IREDs. This could suggest that it is the steric 
bulk surrounding the imine moiety interacting with the enzyme active sites in such a 





IREDs are commonly highly enantioselective enzymes, yet the reason for this is not 
currently known. This chapter outlines investigations into the basis for the 
enantiospecificity of IREDs.  
Firstly, comparison of the amine binding sites of (R)-selective SR-IRED and (S)-
selective SS-IRED revealed five residues which were not conserved between the two 
enzymes. In order to assess whether these residue differences were responsible for 
the opposing enantioselectivities of these IREDs, reciprocal mutants were made for 
both enzymes at each site (SR-IRED L176M, M179F, L183M, H242G and Y283F and 
SS-IRED M173L, F176M, M180L, G237H and F278Y). Soluble expression was achieved 
for seven out of ten of these mutants (all except SR-IRED L176M and SS-IRED M173L 
and M180L). Soluble mutants were expressed and purified and used in 
biotransformations of imine 1a. The enantiomeric configuration of amine products 
were assessed using chiral GC. The findings demonstrated that these point mutations 
did not alter enantioselectivity relative to the wild-type enzymes. This suggests that 
these residues do not individually direct enantioselectivity. This could mean that 
other residues are instead responsible, or that more broad structural changes are 
necessary to alter enantioselectivity.  
Secondly, a publication reporting the sequences of 19 (R)- or (S)-selective IREDs was 
analysed for further sequence-based differences between IREDs with opposite 
enantioselectivities. A consensus sequence of IREDs which formed amines with 
consistently >80 % ee across the full range of substrates tested in this study was 
constructed. The consensus sequence of (R)- and (S)-selective IREDs was compared 
and a number of sequence differences were observed. Cys82, Gly112, Arg116 and 
Phe194 was strongly conserved in (R)-selective IREDs but not present in selective 
IREDs. Conversely, Pro29, Asp112 and Gln116 were strongly conserved in (S)-
selective IREDs but not in (R)-selective IREDs. By observing sequences of IREDs which 
were still consistently (R)- or (S)-selective, but whose enantiopreferences were not as 
strong as those used in the construction of the consensus sequences, it was possible 
to see that the absence of Gly112, Arg116 and Phe194 in (R)-selective IREDs and 
Asp112 and Gln116 in (S)-selective IREDs could result in reduced enantiopreference, 
155 
 





6. Characterization of an PpIRED: an Imine Reductase from 
Physcomitrella patens 
6.1 Introduction 
This chapter outlines the results from an industrial collaboration with 
GlaxoSmithKline (GSK). 
A broad screen of novel IREDs towards a range of substrates was carried out by 
collaborators at GSK. The screen involved activity tests towards both imine and amine 
substrates in the reductive and oxidative directions respectively. During this 
screening effort, an IRED from Physcomitrella patens (PpIRED) displayed markedly 
different substrate selectivity to other IREDs. It was active towards substrates 
towards which no other IREDs had been reported to work, either during this 
screening effort or previously in literature. 
The distinctly different substrate scope of PpIRED means that it is complementary to 
existing IREDs which catalyse the transformation of other substrates. It would 
therefore be of interest to characterize this enzyme further. 
This chapter outlines the characterization of PpIRED in terms of its substrate scope 
and 3D structure as determined using X-ray Crystallography. This provides the first 
opportunity to characterize an IRED deriving from a plant organism as well as an IRED 
which so far operates exclusively on a unique set of substrates. 
6.2 Aims 
Following interesting preliminary results suggesting a unique substrate scope for 
PpIRED, a fuller characterization of this IRED will be carried out. The crystal structure 
will be determined, including a cofactor complex, in order to gain a mechanistic 
understanding of the enzyme. Furthermore, the reactivity profile of PpIRED will be 
carried out and detailed kinetic analysis will be performed for each reaction in order 
to ascertain the potential applications of the enzyme. GC analysis will be used to 





6.3.1 Expression and purification of PpIRED 
PpIRED was expressed at 2 L scale in LB medium in shake flasks and purified by 
nickel-affinity chromatography and size exclusion. Further purification was carried 
out by size exclusion chromatography (Figure 6.1). After each purification step, 
fractions were analysed by SDS-PAGE (Figures 6.2 and 6.3). 
 
Figure 6.1: Chromatogram recorded during size exclusion chromatography 
purification of PpIRED. PpIRED is eluted in a broad peak between approximately 45 – 
59 mL elution volume. The peak exhibits some shoulders which may have arisen due 



































Figure 6.2: SDS-PAGE analysis of fractions collected during nickel-affinity 
chromatography purification of PpIRED.  
 
Figure 6.3: SDS-PAGE analysis of fractions collected during size exclusion 
chromatography purification of PpIRED. 
 
Pure protein was pooled and concentrated to 50 mg ml-1 prior to being flash frozen 
and stored at -20 °C for subsequent use. 
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6.4 Crystal structure of PpIRED in apo form 
Crystallization 
Purified PpIRED was subjected to the commercial crystallization screens INDEX 
(Hampton Research) and CSS (Molecular Dimensions) in a 96 well sitting drop format. 
The protein was readily crystallized, with a large number of crystals forming in a 
range of conditions in the INDEX and CSS screens within 24 hours. The highest quality 
crystals were obtained in the INDEX screen condition 0.2 M NaCl, 0.1 M BIS-TRIS pH 
6.5, 25 % w/v PEG 3350 (Figure 6.4).   
 
Figure 6.4: A single cystal of PpIRED in its apo form in the INDEX screen in 0.2 M NaCl, 
0.1 M BIS-TRIS pH 6.5, 25 % w/v PEG 3350. 
 
The condition was repeated in 48- and 96-well scale without success. Therefore, 
crystals from the initial 96-well crystallization screen were used for diffraction 
experiments. 
Structural solution 
The structure of PpIRED was solved using a molecular replacement strategy using the 
glyoxylate reductase 1 (GLYR1) enzyme from Arabidopsis thaliana, which was the 
protein for which PpIRED shared the highest level of protein sequence similarity of 
all proteins whose structures had been deposited in the PDB. 
GLYR1 from Arabidopsis thaliana, which will hereon be referred to by its PDB 
accession code, 3DOJ, shares 68.0 % protein sequence identity and 88.7 % protein 
sequence similarity with PpIRED, suggesting a very closely related enzyme. 
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GLYR1 type enzymes such as 3DOJ are one of two possible isoforms of GLYR in plants 
(GYLR1 or GLYR1).79 GLYR enzymes are found in a plant’s cytoplasm and catalyse the 
NADH- or NADPH-dependent reduction of glyoxylate, a photorespiration metabolite, 
to glycolate. High levels of glyoxylate in plants is an indication of stress and glyoxylate 
can cause damage in the plant by reacting with DNA, cell membrane lipids and plant 
proteins as well as by increasing transcription of stress-related genes.80 This 
highlights the importance of 3DOJ and other GLYR1s as detoxifying enzymes in their 
removal of harmful excesses of glyoxylate.  
PpIRED      MGSDGMDIGFLGLGIMGIAMARNLLKKGFNVTVWNRSPGKCEELAKEGASIGSSPADVVK 
3DOJ        ----MMEVGFLGLGIMGKAMSMNLLKNGFKVTVWNRTLSKCDELVEHGASVCESPAEVIK 
                 *::********* **: ****:**:******: .**:**.:.***: .***:*:* 
 
PpIRED      KCSITIAMLADPSVAISVALGPGGVVEGITPGKGYVDMSTVDSATSSQIAKAIEAKGGDF 
3DOJ        KCKYTIAMLSDPCAALSVVFDKGGVLEQICEGKGYIDMSTVDAETSLKINEAITGKGGRF 
            **. *****:**..*:**.:. ***:* *  ****:******: ** :* :** .*** * 
 
PpIRED      LEAPVSGSKQPAEAGTLIILAAGSESLFAKVKPAFDAMGKKSFFLNDVGSGAKMKLVVNM 
3DOJ        VEGPVSGSKKPAEDGQLIILAAGDKALFEESIPAFDVLGKRSFYLGQVGNGAKMKLIVNM 
            :*.******:*** * *******.::** :  ****.:**:**:*.:**.******:*** 
 
PpIRED      IMGSMMTAFSEGLALADKAGLSQQTLLEVLELGAIGNPMFKLKGPSMISGKCPTAFPLKH 
3DOJ        IMGSMMNAFSEGLVLADKSGLSSDTLLDILDLGAMTNPMFKGKGPSMNKSSYPPAFPLKH 
            ******.******.****:***.:***::*:***: ***** ***** ... * ****** 
 
PpIRED      QQKDMRLALALGDEVGQSMPVAAAANEIYKKARSLGLGEQDFSSVHQALTQEAANASDSA 
3DOJ        QQKDMRLALALGDENAVSMPVAAAANEAFKKARSLGLGDLDFSAVIEAVKFSRE------ 
            ************** . ********** :*********: ***:* :*:. .         
 
PpIRED      KAAA 
3DOJ        ---- 
Figure 6.5: Protein sequence alignment of PpIRED and 3DOJ (glyoxylate reductase 
from Arabidopsis thaliana).  
Both enzymes possess the GxGxxG binding motif, which presents as GLGIMG in both 
PpIRED and 3DOJ.  
The unit cell of PpIRED determined using a molecular replacement strategy with 3DOJ 
contained two monomers (A and B) arranged as a single homodimer. A monomer of 
PpIRED is represented by subunit A in Figure 6.6. 
The monomer of PpIRED possesses several structural features which are consistent 
with other IREDs including SS-IRED and SkR-IRED;60, 61, 78 PpIRED consists of an N-
terminal Rossman fold domain (Met1 – Val165) and a C-terminal helical domain 
(Gly200 – Ala304) connected by a long interdomain helix (Gly169 – Ala199). This is 
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described visually by a secondary structure sequence annotation in Figure 6.7. The 









Wavelength (Å) 0.96856 
Resolution (Å) 50.06-2.53 (2.64-2.53) 
Space Group I222 
Unit cell (Å) a = 82.5, b = 87.2; c = 182.3 
 =  =  = 90° 
No. of molecules in the asymmetric unit 2 
Unique reflections 22294 (2665) 
Completeness (%) 99.9 (100.0) 
Rmerge (%) 0.16 (0.73) 
Rp.i.m. 0.09 (0.42) 
Multiplicity 7.3 (7.3) 
<I/(I)> 10.0 (3.2) 
CC1/2 0.99 (0.85) 
Overall B factor from Wilson plot (Å2) 22 
Rcryst/ Rfree (%) 19.5/2396 
r.m.s.d 1-2 bonds (Å)  0.015 
r.m.s.d 1-3 angles (o) 1.91 
Avge  main chain B (Å2) 37 
Avge  side chain B (Å2) 38 






Figure 6.6: Crystal structure of a single monomeric subunit of PpIRED, consisting of 
an N-terminal Rossman fold motif and a C-terminal helical domain 
 
Figure 6.7: Secondary structure sequence annotation for PpIRED. The figure depicts 
that the structure consists of an N-terminal Rossman fold motif, C-terminal helical 





However, PpIRED differs structurally to other IREDs in the orientation of its N- and C-
terminal domains. While in previously studied IREDs such as SkR-IRED and SS-IRED, 
the C-terminal helical domain protrudes outwards from the inter-domain helix, in 
PpIRED this C-terminal domain reverts backwards towards the N-terminal domain of 
the same monomeric subunit. 
This has a strong impact in the nature of dimer formation. In IREDs such as SkR-IRED 
and SS-IRED, the protrusion of the C-terminal domain away from the N-terminal 
domain and inter-domain helix causes the formation of a large cleft through which the 
opposite subunit binds during dimer formation. This phenomenon is responsible for 
the characteristic reciprocal domain sharing observed in many IREDs.60, 61, 78 
However, in PpIRED the closer proximity of the N- and C-terminal domains of the 
same subunit means this phenomenon is not observed, and dimer formation occurs 
through the association of two monomers without interlocking of domains (Figure 
6.8). The nature of dimer formation exhibited by PpIRED is common in enzymes such 
as 3DOJ and HIBDH (Chapter 2) which catalyse the reversible reduction of carbonyls. 
 
Figure 6.9: A dimer of PpIRED formed by the association of two monomeric subunits 
A and B. The dimer does not exhibit any domain sharing effects which are observed 




An analysis of the structure using the EBI PISA tool revealed that the contact surface 
area of the interface between subunits A and B was 2681 Å2.75, 76 This is significantly 
lower than the ~3800 Å2 interface areas exhibited by other IREDs such as SkR-IRED 
and SS-IRED and reflects the less intimate nature of domain sharing in PpIRED relative 
to other IREDs.  
The structure of subunit A of the PpIRED monomer was submitted to the DALI server 
to search for the most structurally similar protein. The protein with the highest level 
of structural homology was 3PDU; the NADP+ bound form of GLYR1 from Arabidopsis 
thaliana, which had a rmsd of 0.7 Å relative to PpIRED. This result is unsurprising 
given the very high level of sequence homology between the two enzymes, and also 
strongly suggests that the two enzymes share similar physiological roles. 
6.5 Crystal structure of PpIRED in complex with NADP+ 
Crystallization 
In order to gain an insight into the active site mechanism of PpIRED, a structure of the 
enzyme in complex with its putative cofactor, NADPH, was sought. Pure, concentrated 
Pp-IRED protein was incubated with either NADPH or NADP+ with final cofactor 
concentrations ranging from 0.5 – 10 mM and subjected to a range of commercially 
available 96-well crystallization screens in the sitting drop format. 
Crystals were obtained in numerous crystallization conditions with all cofactor 
concentrations but diffraction experiments at Diamond synchrotron demonstrated 
that a complex was only formed with crystals grown in 0.2 M L-proline with Pp-IRED 
incubated with 10 mM NADP+ in the Hampton INDEX screen (Figure 6.10). All other 
crystallization conditions, including those with NADPH and lower concentrations of 






Figure 6.10: Crystals of Pp-IRED in complex with NADP+ formed using Pp-IRED 
incubated with 10 mM NADP+ in 0.2 M L-proline in the Hampton INDEX screen in a 
96-well sitting drop format. 
Crystal structure 
The crystal structure of Pp-IRED in complex with NADP+ was solved with a molecular 
replacement strategy using the apo structure of Pp-IRED. The unit cell contained 20 
subunits (A – J) arranged as 10 dimers, each containing the NADP+ cofactor. The 
structure is represented by subunits A and B in Figure 6.11. The data collection and 










Wavelength (Å) 0.97949 
Resolution (Å) 65.49-2.50 (2.56-2.50) 
Space Group P21 
Unit cell (Å) a = 106.2, b = 143.3; c = 215.5 
 =  = 90°;  = 104°; 
No. of molecules in the asymmetric unit 20 
Unique reflections 213205 (15837) 
Completeness (%) 98.6 (99.0) 
Rmerge (%) 0.16 (0.81) 
Rp.i.m. 0.14 (0.70) 
Multiplicity 2.0 (2.2) 
<I/(I)> 6.7 (1.5) 
CC1/2 0.980 (0.55) 
Overall B factor from Wilson plot (Å2) 42 
Rcryst/ Rfree (%) 24.6/27.4 
r.m.s.d 1-2 bonds (Å)  0.012 
r.m.s.d 1-3 angles (o) 1.88 
Avge  B (Å2) 56 
Avge  water B (Å2) 39 
Avge  ligand B (Å2) 56 
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The structure shows that, similarly to other IREDs, NADPH binds in a cleft formed 
between the N- and C-terminal domains. However, unlike in other IREDs where 
NADP+ binds between domains of opposite subunits, in PpIRED the cofactor binds 
between domains of the same subunit. This is as a result of the lack of reciprocal 
domain sharing in PpIRED which is observed in other IREDs. 
 
Figure 6.11: The crystal structure of PpIRED in complex with NADP+. The cofactor 
binds in a cleft formed between the N- and C-terminal domains of a single subunit. 
6.6 Kinetic analysis of PpIRED activity towards amines, ketones and 
alcohols 
During a screen of NADPH concentration assays to test for oxidation activity towards 
a range of imine and amine substrates.  
PpIRED was shown to be uniquely active towards amines 11a and 12a during an 
activity screen carried out by GlaxoSmithKline (Figure 6.12).  
       
       11a             12a 
Figure 6.12: Amine substrates which are oxidised to the corresponding imine by 
PpIRED with the cofactor NADP+. These were identified as substrates for PpIRED 
during NADP+ depletion assays carried out by GlaxoSmithKline. 
To fully characterize the reactivity profile of PpIRED, the enzyme was tested on a 
range of substrates using a UV-vis based NADPH concentration assay to test for the 
presence of activity and to determine values for kinetic parameters.  
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Initially, the activity of PpIRED towards the amines 11a and 12a (Figure 6.12). As 
PpIRED shares high levels of sequence identity with 3DOJ, a glyoxylate reductase 
which catalyses the reversible reduction of C=O bonds, PpIRED was also tested 
towards several carbonyl-and hydroxyl-containing substrates; 13a and 14a (the 
aldehyde and alcohol analogues of 11a), 15a (hydroxyisobutyrate) and 16a 
(glyoxylate – the substrate for the most closely related enzyme to PpIRED, 3DOJ). 
Kinetic parameters were determined by measuring the activity towards each 
substrate at increasing substrate concentrations. Parameters were calculated by 
fitting the data using non-linear regression to the Michaelis-Menten model or, where 
substrate inhibition is present, the substrate inhibition model. 
The outcome of kinetic analyses towards substrates 11a – 16a is pictured below in 
Figures 6.13 – 6.17. The values for kinetic parameters KM, kcat/KM and, where substrate 
































Figure 6.13: Non-linear regression analysis of activity levels of PpIRED towards 
increasing concentrations of 11a fitted using the substrate inhibition model. The 
presence of substrate inhibition is visible from the marked decrease in reaction 
velocity at the highest substrate concentration (60 mM). This conclusion is confirmed 





























Figure 6.14: Non-linear regression analysis of reaction velocity of PpIRED towards 
increasing concentrations of substrate 13a using the Michaelis-Menten model. 





























Figure 6.15: Non-linear regression analysis of reaction velocity of PpIRED towards 
































Figure 6.16: Non-linear regression analysis of reaction velocity of PpIRED towards 
increasing concentrations of substrate 15a using the Michaelis-Menten model. 
 























Figure 6.17: Non-linear regression analysis of reaction velocity of PpIRED towards 





Table 6.3: Values for kinetic parameters calculated from activity of PpIRED towards 








1.577 × 10-2   
± 0.484 × 10-
2 
18.44 ± 8.04 
 






0.464 ± 0.012 4.22 ± 0.41 -† 0.110 
14a 
 
8.30 × 10-3  
± 1.94 × 10-3 
9.83 ± 0.90 -† 4.23 × 10-3 
15a 
 
4.53 × 10-3  
± 0.63 × 10-3 
163.1 ± 43.5 -† 2.78 × 10-5 
16a 
 
306.8 ± 32.3 2.46 ± 0.63 -† 124.72 
 
* No activity was recorded for substrate 12a due to limited substrate availability 
† KI not calculated unless substrate inhibition model used 
Activity was observable for PpIRED in the oxidation of amine 11a with a modest kcat. 
The high KM of 18.44 mM suggests that, while 11a is a substrate for PpIRED, the 
affinity of the enzyme towards 11a is weak. The KI of 32.92 mM also indictates strong 
levels of substrate inhibition, so the maximum reaction velocity reported by the kcat is 
not realised under real reaction conditions. 
No activity was detectable towards amine 12a. However, as very limited quantities of 
substrate were available, it was neither possible to test at higher substrate 
concentrations (> 10 mM) nor to retest at higher enzyme concentrations. It is possible 
that activity may be observed if these experiments are later performed. 
174 
 
PpIRED is strongly active towards 13a with a kcat of 0.464 s-1. The reductive, rather 
than oxidative nature of this reaction may contribute towards this increased activity, 
as reductions generally proceed faster than oxidations in IREDs. 
PpIRED also displays modest levels of activity towards alcohol 14a. Because this is 
also an oxidation reaction, kinetic parameters for this reaction may be directly 
compared to the oxidation of 11a.  Interestingly, PpIRED displays a higher catalytic 
turnover number for 11a than 14a which initially suggests a preference for amines 
over hydroxyls. However, the presence of substrate inhibition in reactions with 11a 
makes this comparison difficult, as the theoretical maximum turnover number is 
never achieved due to decreasing reaction velocities at higher substrate 
concentrations. Additionally, the KM of PpIRED is approximately twofold higher for 
11a than 14a, indicating a tighter binding preference for the alcohol- rather than the 
amine-containing substrate. 
Finally, PpIRED displays activity towards 16a which is many magnitudes greater than 
for any other substrate tested. This result can be expected as the closest homologue 
to PpIRED in both sequence and structure is the glyoxylate reductase 3DOJ, for which 
16a is a natural substrate. 
In summary, PpIRED does display modest activity in the oxidation of amine 11a which 
supports the identification of PpIRED as an IRED. However, the equivalent imine is 
not available for testing. PpIRED displays the greatest activity in the reduction of 




6.7 GC analysis of biotransformations of quinoline derivatives by PpIRED 
To quality control findings from Section 6.6 that PpIRED displays oxidative activity 
towards amine 11a, a GC assay was carried out. This was to measure the strength of 
the evidence that PpIRED acts as an IRED. While imine 11b is not commercially 
available and therefore directly testing imine reduction is not possible, the 
assumption was made that if PpIRED successfully oxidises an amine with NADP+, then 
the reverse reaction (imine reduction using NADPH) would also be possible. As 11a 
was the only amine substrate for which activity was confirmed using an NADPH-
formation assay, and the corresponding imine is not commercially available, GC 
analysis was used to verify these findings. 
Samples of reactions containing PpIRED, 11a (5 mM) and NADP+ were collected 
periodically and analysed by GC.  
GC chromatograms of standards containing the substrate 11a and the internal 
standard pentadecane were recorded to determine their retention times (8.03 min 
and 4.33 min respectively) (Figure 6.18 and 6.19). This allowed the substrate and 
internal standard peaks to be identified in subsequent chromatograms of reactions 
using PpIRED. No standard could be recorded for the imine product, 11b, as this 





Figure 6.18: Chromatogram recorded from GC analysis of sample containing 
commercially prepared 11a  (5 mM) in EtOAc 
 
 
Figure 6.19: Chromatogram recorded from GC analysis of sample containing 
commercially prepared pentadecane (5 mM) in EtOAc. Pentadecane acts as an 
internal standard in the analysis. 
Samples drawn from the reaction at time points (0 min, 20 min, 40 min, 1 h, 2h, 4h 
and 24h) were analysed by GC. Analysis demonstrated that, after 24 h of reaction 
time, there was no change in relative peak area for substrate 11a (Figure 6.20). The 

































Rt = 4.33 min 
Rt = 8.03 min 
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However, again there was no reduction in peak area for substrate 11a and no 
formation of any apparent product peaks (Figure 6.21). 
 
Figure 6.20: Chromatogram recorded from GC analysis of samples drawn from a 
reaction of 11a with 0.2 mg mL-1 PpIRED and NADP+ at 0 min (top) and 24 h (bottom). 
























Figure 6.21: Chromatogram recorded from GC analysis of samples drawn from a 
reaction of 11a with 5 mg mL-1 PpIRED and NADP+ at 0 min (top) and 24 h (bottom). 
There is, again, no evidence of the depletion of the peak corresponding to 11a after 
24 h reaction time despite an increased enzyme concentration. 
 
The lack of change in chromatograms between 0 min and 24 h reaction time for 
oxidation of 11a with PpIRED and NADP+ is inconsistent with the findings of the 
NADPH-formation kinetic assay carried out in Section 6.6, the results of which 
suggested that PpIRED does indeed oxidise 11a to the corresponding imine 11b. 
There are multiple possibilities as to why this is not seen during GC analysis. Firstly, 
a UV-Vis based NADPH formation assay is far more sensitive than a GC assay, and it is 
possible to detect only very minute levels of substrate conversion. It is possible that 
the levels of conversion are insufficient to be detected using GC. Additionally, because 
there is no commercially available standard for the product of the reaction, imine 11b, 
it is impossible to assess where the product peak should appear. There is a small 
possibility that the substrate and product peaks co-elute very closely and are 






















A novel IRED from Physcomitrella patens, a plant often used as a model organism in 
studies of plants. was identified during a UV-Vis based NADPH-concentration screen 
carried out by GSK towards a broad range of amine and imine substrates. PpIRED was 
uniquely active towards two amine substrates; 11a and 12a. Its unique reactivity 
profile made it interesting as a target for further study.  
The structure of PpIRED was solved both in its apo form and in complex with its 
cofactor, NADP+. PpIRED shares most similarity, both in terms of its sequence and 
structure, with a Glyoxylate reductase from Arabidopsis thaliana (PDB accession 
number 3DOJ); also a plant plant-based organism. Like other IREDs, PpIRED 
possesses an N-terminal Rossman fold motif and a C-terminal domain. However, 
unlike other IREDs, PpIRED does not form a dimer with a reciprocal domain sharing 
arrangement. The cofactor NADP+ binds in a cleft formed between the N- and C-terms 
domains of the same subunit unlike in other IREDs, where this cleft is formed between 
domains of opposite subunits. 
The reactivity profile of PpIRED was characterised further using UV-Vis based 
NADPH-concentration assays. Activity was tested not only towards amines 11a and 
12a but also carbonyl- and hydroxyl-containing compounds 13a – 16a. Analysis 
showed that PpIRED indeed catalyses the oxidation of amine 11a, but displays 
preferential activity towards the equivalent alcohol 14a. PpIRED displayed 
particularly strong activity towards the reduction of aldehydes the quinoline 
derivative 13a and glyoxylate, 16a. The levels of activity of PpIRED towards 16a were 
several orders of magnitude higher than for any other substrate, suggesting that this 
may be a natural substrate for the enzyme. This result is expected due to the high 
levels of sequence identity and structural similarity of PpIRED with 3DOJ. 
GC analysis was used to verify the fact that PpIRED can indeed oxidise amines, as the 
ability to convert both amines (and therefore imines) and aldehydes/alcohols was 
unprecedented in any other IRED. However, GC analysis remains inconclusive as 





Imine reductases (IREDs) are enzymes of the oxidoreductase group that catalyse the 
asymmetric reduction of imines to form chiral amines. They offer a convenient, 
sustainable method for the synthesis of chiral amines, compounds which are widely 
applied in the chemical, agrochemical and pharmaceutical industries.  
During the course of this project, NADPH-dependent IREDs SkR-IRED from 
Streptomyces kanamyceticus and and SS-IRED from Streptomyces sp. GF3546 were 
expressed and purified. These IREDs catalyse the reduction of the model imine 
substrate 2-methylpyrroline to form the corresponding (R)- and (S)-amine 
respectively. 
The structure of SkR-IRED was used as a basis to study the mechanism of NADPH-
dependent IREDs. It was proposed that residue Asp187 may play a role in the 
protonation step of imine reduction during catalysis. It was found that mutants in 
which Asp187 had been reduced to Ala or Asn were devoid of activity, which suggests 
that Asp187 is important for catalysis. However, due to the large interatomic distance 
between the C4 carbon of NADPH and the Asp187 residue (approximately 8 
Ångstrom), the exact of involvement of this residue in catalysis remains unclear, 
particularly in the absence of a structure in which SkR-IRED is complexed with an 
imine. The substrate scope of SkR-IRED was also investigated, and it was found to be 
active towards 6-membered rings as well as quinoline-based imines.60 
The structure of SS-IRED was solved in its apo form to a resolution of 3.2 Å, and 
permitted  a comparison of the structure of an (R)- and (S)-selective IRED. SS-IRED 
was proposed to be dependent on a catalytic Tyr169 residue, and indeed the mutant 
Tyr169Phe was found to be devoid of activity. The direct involvement of Tyr169 was 
considered to be more feasible, as there is precedent for tyrosine as a proton donor 
in  in other reductase mechanisms.81 Furthermore the interatomic distance between 
the protic Tyr169 hydrogen and the C4 carbon of NADPH is considerably shorter 
(approximately 5 Ångstrom), in SS-IRED than in SkR-IRED 
The prior study of both an (R)- and (S)-selective IREDs prompted an investigation into 
factors that may influence the selectivity of IREDs. Reciprocal mutants of an (R)- and 
(S)-selective IRED were generated in what is believed to be the substrate binding site 
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by sequence comparison with other IREDs.82 None of these point mutations 
influenced selectivity, suggesting that the factors which might direct selectivity may 
involve more complex factors  such as protein dynamics, or be affected by residues 
elsewhere in the protein. 
Last, a novel IRED, PpIRED from the moss Physcomitrella patens, which displayed 
activity towards a unique panel of substrates, was studied. While it appears that 
PpIRED is active towards amines, producing certain imines in the oxidative direction, 
it was found to display greater activity towards carbonyl and hydroxyl substrates. The 
substrate towards which PpIRED was most active was glyoxylate, and the homology 
of PpIRED to known glyoxylate reductases suggests that PpIRED is a glyoxylate 
reductase with promiscuous imine-reducing capabilities. The structure of PpIRED 
was solved in both its apo form and in complex with NADPH, and demonstrated that 
it is structurally somewhat different to other IREDs. Most noticeably, it does not share 
the reciprocal domain sharing arrangement upon dimer formation that is usually 
characteristic of IREDs. 
This work has contributed towards the understanding of IREDs as an enzyme class, a 
field which was in its infancy at the beginning of this project. The work reported in 
this thesis provided some of the first structural and mechanistic insights of IREDs.  
In conclusion, IREDs have shown great promise as a class of enzymes for industrial 
application in the production of chiral imines. Wild-type IREDs are often active 
towards a structurally diverse selection of cyclic imine substrates, including 
substituted pyrrolines, substituted piperideines, isoquinoline derivatives and beta-
carboline imines as well as a small number of acyclic imines with high 
enantioselectivity.59-61, 78 
Furthermore, a subsection of this class of enzymes known as RedAms has evolved to 
catalyse the direct reductive amination of carbonyl-containing substrates. This 
reaction involves the in situ formation of an imine from the conjugation of an imine 
and ketone substrate, and removes the need for the separate formation of an imine 
intermediate.61,83 This reaction is even more direct than that which is offered by 
traditional IREDs, and offers the potential for a highly efficient synthesis of chiral 
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Primer sequences 
Table 8.1:  Primer sequences used for all sub-cloning experiments 
Enzyme Primer Purpose Primer Sequence 
SS-IRED Sub-cloning into pET-YSBL-LIC3C 
vector, forward primer 
CCAGGGACCAGCAATGAGCAAACAGTCA 
GTTACGGTGATTGGTCTG 
SS-IRED Sub-cloning into pET-YSBL-LIC3C 




Table 8.2:  Primer sequences used for all site-directed mutagenesis experiments 
Enzyme Mutation and Primer 
Direction 
Primer Sequence 
SkR-IRED D178A, forward primer CAAGCCTGTATGCGGCCGCAGGTCTGG 
SkR-IRED D178A, reverse primer CCAGACCTGCGGCCGCATACAGGCTTG 
SkR-IRED D178N, forward primer GGCAAGCCTGTATAATGCCGCAGGTCTGGTC 
SkR-IRED D178N, reverse primer GACCTGCGGCATTATACAGGCTTGCC 
SS-IRED Y169F, forward primer CTGGCCGCAATGTATTTTCAGGCGCAAATGACC 
SS-IRED Y169F, reverse primer GGTCATTTGCGCCTGAAAATACATTGCGGCCAG 
184 
 
SS-IRED M179F, forward primer CGTGTCACTGCTGGGTCTGTTTTGGGGCAC 
GCTGAACTCG 
SS-IRED M179F, reverse primer CGAGTTCAGCGTGCCCCAAAACAGACCCAG 
CAGTCACACG 
SS-IRED L176M, forward primer CTACGACGTGTCACTGATGGGTCTGATGTGGG 
SS-IRED L176M, reverse primer CCCACATCAGACCCATCAGTGACACGTCGTAC 
SS-IRED Y283F, forward primer CACGCTAAAAACAGCTTTGCGGCAGTCCTGAAAG 
SS-IRED Y283F, reverse primer CTTTCAGGACTGCCGCAAAGCTGTTTTTAGCGTG 
SS-IRED H242G, forward primer CGCTACGCTGGAAACCGGCCTGGCGGCCCTGAAAC 
SS-IRED H242G, reverse primer GTTTTCAGGGCCGCCAGGCCGGTTTCCAGCGTAGG 
SR-IRED L183M forward primer CTGATGTGGGGCACGATGAACTCGTTTCTGC 
SR-IRED L183M reverse primer GCAGAAACGAGTTCATCGTGCCCCACATCAG 
SS-IRED F176M forward primer CCAGGCGCAAATGACCATTATGTGGACCACGATC 
TGAGC 
SS-IRED F176M reverse primer GCTCAGCATCGTGGTCCACATAATGGTCATTTGCC 
CTGG 
SS-IRED M173L forward primer GTATTACCAGGCGCAACTGACCATTTTCTGGACC 
SS-IRED M173L reverse primer GGTCCAGAAAATGGTCAGTTGCGCCTGGTAATAC 
SS-IRED F278Y forward primer GCTTTGCTGAAAATTCGTATTCCTCTCTGATTGA
A 
GTCC 
SS-IRED F278Y reverse primer GGACTTCAATCAGAGAGGAATACGAATTTTCAGC
A 
AAGC 
SS-IRED G237H forward primer GTGGACCGTCTGGCGATGCATGCAGCTTCAGTCG
AT 
CACG 
SS-IRED G237H reverse primer CGTGATCGACTGAAGCTGCATGCATCGCCAGACG
GT 
CCAC 
SS-IRED M180L reverse primer CATTTTCTGGACCACGCTGCTGAGCTATTACC 







Glossary of Abbreviations and Symbols 
Abbreviation Denotation 
ADH Alcohol dehydrogenase 
AmDH Amine dehydrogenase 
bp Base pairs 
DHFR Dihydrofolate reductase 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide 
EDTA Ethylenediaminetetraacetic acid 
g grams 
HIBDH Hydroxyisobutyrate dehydrogenase 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IRED Imine reductase 
L Litre 
LB Lysogeny broth 
LB-Amp LB supplemented with 100 μg mL-1 ampicillin 
LB-Kan LB supplemented with 30 μg mL-1 kanamycin 
M Molar 
m/z Mass charge ratio 







NADP+ Nicotinamide adenine dinucleotide phosphate 
NADPH Nicotinamide adenine dinucleotide phosphate (reduced form) 
OD600 Optical density at 600 nm 
PCR Polymerase chain reaction 
PTR1 Pteridine reductase 
SDS Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate protein agarose gel electrophoresis 
SkR-IRED (R)-selective imine reductase from Streptomyces kanamyceticus 
SOC Super optimal broth with catabolite repression 
SR-IRED (R)-selective imine reductase from Streptomyces sp GF3587 
SS-IRED (S)-selective imine reductase from Streptomyces sp GF3546 
TEMED Tetramethylethylenediamine 
U Units (of enzyme activity) 
v/v Volume per volume 
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